SEARCH:      Monitor Keywords |  Custom RSS

Drug, bio-affecting and body treating compositions May archived listing by USPTO class 05/07

20070122341 - Benzylideneaniline derivatives and their radioisotope labeled compounds for binding and imaging of beta-amyloid plaques: wherein R1-R5 are independently selected from hydrogen, C1-C4 alkyl and F (at least one of them is F) and each R6-R10 are independently selected from hydrogen, C1-C4 alkyl, OH, OCH3, NH2, NHCH3 and N(CH3)2 (at least one of them is OH, OCH3, NH2, NHCH3 or N(CH3)2) are disclosed. Benzylideneaniline derivatives... Agent: Heslin Rothenberg Farley & Mesiti PC

20070122342 - Ethylenedicysteine (ec)-drug conjugates compositions and methods for tissue specific disease imaging: The invention provides, in a general sense, a new labeling strategy employing 99mTc chelated with ethylenedicysteine (EC). EC is conjugated with a variety of ligands and chelated to 99mTc for use as an imaging agent for tissue-specific diseases. The drug conjugates of the invention may also be used as a... Agent: Fulbright & Jaworski L.L.P.

20070122340 - Necrosis avid tracer agent: The present invention concerns to the use of phenanthro[1,10,9,8-opqra]perylene-7,14-dione derivatives, and more specifically hypericin or its derivatives, as necrosis or infarct specific agents. The phenanthro[1,10,9,8-opqra]perylene-7,14-dione derivatives can be labeled with a radionuclide, a radiopaque material or a material enhancing the effects magnetic resonance imaging.... Agent: Clark & Elbing LLP

20070122343 - Non-invasive assay for the assessment of functioning and/or structure of the gut: The present invention relates to a diagnostic method for assessing the functioning and/or structural integrity of the gut in animal subjects. The method of the present invention is predicated on assessing the absorption and/or metabolism of one or more test sugars or functional equivalents such as phosphorylated sugars, oligopeptides or... Agent: The Mccallum Law Firm, P. C.

20070122346 - Conjugated macromolecules: A method of conjugating a carboxylate-containing molecule to an amine-containing macromolecule to form a substituted macromolecule is provided. The method includes (a) forming a first solution by dissolving a substance comprising at least one macromolecule having free amine groups in an aqueous basic solution; (b) forming a second solution by... Agent: General Electric Company Global Research

20070122347 - Method and system for automated supervised data analysis: The invention relates to a method for automatically analyzing data and constructing data classification models based on the data. In an embodiment of the method, the method includes selecting a best combination of methods from a plurality of classification, predictor selection, and data preparatory methods; and determining a best model... Agent: Miles & Stockbridge PC

20070122344 - Intraoperative determination of nerve location: The invention provides methods for intraoperatively determining the location of nerves by use of fluorescent dyes. The methods are particularly useful for locating the cavernous nerves innervating the penis.... Agent: Townsend And Townsend And Crew, LLP

20070122345 - Intraoperative determination of nerve location: The invention provides methods for intraoperatively determining the location of nerves by use of fluorescent dyes. The methods are particularly useful for locating the cavernous nerves innervating the penis.... Agent: Townsend And Townsend And Crew, LLP

20070122348 - Opioid agonist/antagonist combinations: The invention is directed in part to oral dosage forms comprising a combination of an orally analgesically effective amount of an opioid agonist and an orally active opioid antagonist, the opioid antagonist being included in a ratio to the opioid agonist to provide a combination product which is analgesically effective... Agent: Davidson, Davidson & Kappel, LLC

20070122351 - Inhalation drug combinations: A method for treating respiratory disorders by administrating by inhalation an effective amount of a β2-receptor agonist, an acceptable amount of a corticosteriod, and HFA 134a, to a patient in need thereof, is disclosed. Preferably, the β2-receptor agonist is salmeterol or a physiologically acceptable salt thereof, and the corticosteriod is... Agent: Glaxosmithkline Corporate Intellectual Property, Mai B475

20070122352 - Inhalation drug combinations: A method for treating respiratory disorders by administrating by inhalation an effective amount of a β2-receptor agonist, an acceptable amount of a corticosteroid, and HFA 134a, to a patient in need thereof, is disclosed. Preferably, the β2-receptor agonist is salmeterol or a physiologically acceptable salt thereof, and the corticosteroid is... Agent: Glaxosmithkline Corporate Intellectual Property, Mai B475

20070122349 - Measuring particle size distribution in pharmaceutical aerosols: Disclosed herein are methods for measuring the particle size distribution of a pharmaceutical aerosol, including methods utilizing laser diffraction.... Agent: Michael P. Morris Boehringer Ingelheim Corporation

20070122350 - Safe and effective methods of administering therapeutic agents: In one embodiment, the invention relates to a kit for administering a lipid-based platinum compound formulation via inhalation comprising: an inhalation device comprising a lipid-based platinum compound formulation, a demistifier tent of sufficient size to at least cover a patient's head and the inhalation device, and instructions for use thereof.... Agent: Foley Hoag, LLP Patent Group, World Trade Center West

20070122353 - Drug condensation aerosols and kits: The present invention provides novel condensation aerosols for the treatment of disease and/or intermittent or acute conditions. These condensation aerosols have little or no pyrolysis degradation products and are characterized by having an MMAD of between 1-3 microns. These aerosols are made by rapidly heating a substrate coated with a... Agent: Swanson & Bratschun, L.l.c

20070122354 - Storage stable powder compositions of interleukin-4 receptor: The present invention provides storage stable dry powder compositions of IL-4R. The powder compositions demonstrate superior chemical and physical stability over their solution counterparts, particularly upon storage under varying conditions of temperature and humidity. Moreover, the powders, as prepared, possess good aerosol properties, which are maintained upon storage.... Agent: Nektar Therapeutics

20070122355 - Rapidly absorbing oral formulations of pde 5 inhibitors: e

20070122356 - Glass compositions as an antimicrobial additive for dental materials: The invention relates to a use of glass compositions having an antimicrobial and/or disinfectant effect in materials used for restoring teeth, excluding implants.... Agent: Baker & Daniels LLP 111 E. Wayne Street

20070122357 - Dentifrice composition: Dentifrice compositions which provide chemical cleaning of the oral surfaces with a combination of surfactant, chelant, and pH; further this dentifrice composition can minimize the use of abrasives to provide a gentle cleaning of the oral surfaces.... Agent: The Procter & Gamble Company Intellectual Property Division

20070122359 - Dentifrice composition comprising binder system comprising hydrophilic clay material: A dentifrice composition which provides a viscosity of from about 10,000 Pas to about 450,000 Pas comprising; (a) a binder system comprising a hydrophilic clay material, a modified cellulose polymer, a carboxyvinyl polymer and a natural gum derived anionic polymer, (b) an effective amount of an oral care active, and... Agent: The Procter & Gamble Company Intellectual Property Division

20070122358 - Dentifrice composition free of abrasive material: A dentifrice composition comprising, (a) a hydrophilic clay material, (b) a phytic acid compound, (c) an effective amount of an oral care active, and (d) a polar solvent carrier; wherein the composition is substantially free of abrasive material.... Agent: The Procter & Gamble Company Intellectual Property Division

20070122362 - Hydrogel sheets and shapes for oral care: A hydrogel for use in oral care. The hydrogel is ion beam cross-linked, the hydrogel is adapted to be disposed in the oral cavity and may be adapted to provide a denture fixative or may be loaded with a whitening agent for use in whitening one or more teeth and... Agent: Berenbaum, Weinshienk & Eason, P.c

20070122360 - Nonaqueous gel composition for tooth whitening and tooth whitening set: A nonaqueous gel composition for tooth whitening, comprising: (A) tooth whitening ingredient having a relative permittivity of 17.0 to 43.0 (at 25° C.) and a vapor pressure of 0 to 7000 kPa (at 25° C.), (B) substance that is soluble in the tooth whitening ingredient and is precipitated by an... Agent: Birch Stewart Kolasch & Birch

20070122361 - Tooth colorant and whitener, method of manufacture, and method of use thereof: A polymerizable tooth colorant composition, comprising: a polymerizable resin composition; an additive composition comprising a colorant, a whitener, or both; and a curing system. The composition allows easy coloring and/or whitening of teeth.... Agent: Cantor Colburn, LLP

20070122363 - Corporeal delivery of carotenoids: A method for delivery of a phytochemical supplement to a corporeal body. The method of delivery comprises providing a phytochemical supplement in an orally acceptable composition and applying the orally acceptable composition including the phytochemical supplement in contact with a feature of the oral cavity of a corporeal body. An... Agent: Berenbaum, Weinshienk & Eason, P.c

20070122364 - Self-tanning facial product having anti-wrinkle/anti-aging properties: A sunless facial self-tanning composition having anti-wrinkle/anti-aging properties. The composition contains safe effective amounts of sunless or self-tanning agents and peptides having anti-wrinkle/anti-aging properties. A method for preparing such composition is disclosed.... Agent: Dunlap, Codding & Rogers P.C.

20070122365 - Skin-tightening preparations containing gliadin: The present invention is concerned with preparations for application to human skin including a cream or lotion base together with a quantity of a skin-tightening agent consisting essentially of gliadin. Products such as creams, lotions, facial masks and sunscreens can be prepared which exhibit desirable skin-tightening or anti-wrinkle effects.... Agent: Hovey Williams LLP

20070122366 - Preparations for the care nails that contain terbinafine hydrochloride: There are provided topical preparations for the care of fingernails and toenails. The preparation is in the form of a varnish solution that contains Terbinafine Hydrochloride as an active ingredient and a vehicle formulated with all or some of the following components: ethyl alcohol, poly (methyl vinyl ether alt maleic... Agent: Charles N.j. Ruggiero Ohlandt, Greeley, Ruggiero & Perle, L.L.P.

20070122367 - Resorcinol derivatives: The present invention relates to certain resorcinol derivatives and their use as skin lightening agents.... Agent: Warner-lambert Company

20070122368 - Preparation, in particular cosmetic preparation, and the production and use thereof: A preparation, in particular a cosmetic preparation, preferably in liquid or pasty form, for use on keratinic materials, in particular for decorating, coloring, improving the appearance of and caring for the skin and the skin appendages. The preparation is water-free and contains at least one wax with a dropping point... Agent: Bachman & Lapointe, P.C.

20070122369 - Cosmetic hair composition: The hair cosmetic composition contains a solvent-containing silicone emulsion (A) which is prepared by emulsifying a mixture of high-molecular-weight polyorganosiloxane (a) obtained by emulsion polymerization and a volatile solvent (b), a surfactant (B) and water (C). The component solvent-containing silicone emulsion (A) is contained at a ratio of 0.1-10 wt... Agent: Foley And Lardner LLP Suite 500

20070122372 - Amino-functional silicone waxes: The present invention relates to silicone waxes having plural tertiary or quaternary amino groups, their preparation and their use as softeners in the textile industry. These waxes can be processed into stable aqueous dispersions and lead to products having a pleasant, soft hand.... Agent: Clariant Corporation Intellectual Property Department

20070122370 - Compositions comprising oligoglycosides: Compositions containing an alkyl or alkenyl oligoglycoside and mixtures thereof, and a hydroxycarboxylic acid partial ester of an alkoxylated alcohol are provided.... Agent: Cognis Corporation Patent Department

20070122371 - Cleansing composition: There is provided a cleansing composition which has creamy foaming and excellent cleansing power, provides no stretched feeling of skin after rinsing and a refreshed feeling of skin, is excellent in storage stability and exhibits no reduction in physical properties, formation of precipitates and yellowing during a long-term storage period... Agent: Staas & Halsey LLP

20070122373 - Air freshener: Air freshener products and methods for freshening air are disclosed. In some embodiments, the air freshening product may include a container for storing an air freshening composition that may contain a perfume composition or may contain a perfume composition in conjunction with a malodor counteractant. The container may contain a... Agent: The Procter & Gamble Company Intellectual Property Division

20070122374 - Waterless urinal formulations: The present invention relates to A composition for use in urinals, comprising: (a) one or more aliphatic alcohols, the aliphatic alcohols comprising 11 carbon atoms or less; (b) one or more esters selected from molecules of formula R1—C(O)—O—R2 and triglycerides of formula CH2COOR6—CHCOOR7—CH2—COOR8, R1 comprising 6 to 24 carbon atoms,... Agent: Sonnenschein Nath & Rosenthal LLP

20070122375 - Bile acid sequestrant and process for preparation thereof: The present invention describes a copolymer comprising multiple unsaturations, which are obtained by polymerization of dimethyl β-cyclodextrin inclusion complex of monomer containing multiple vinyl unsaturation and amine functional monomer. These water soluble copolymers containing unsaturation sites, crosslinked in the presence of bile acid template. This novel sequential polymerization and crosslinked... Agent: Ladas & Parry

20070122376 - Pheromones and method of preventing infestation of contarinia nasturtii: The present invention relates to pheromone mixture comprising 2,9 diacetoxyundecane, 2,10-diacetoxyundecane and 2-acetoxyundecane, as a racemate or, biologically active stereoisomers thereof, as well as a method for monitoring and/or mating disruption of swede midge, Contarinia nasturtii, in Brassica vegetables, in particular Brussels sprouts, cauliflower and broccoli.... Agent: Gauthier & Connors LLP

20070122380 - Chimeric cytokine of il-7 and beta-chain of hgf and methods of use: The present invention relates to a single-chain or chimeric polypeptide comprising a cytokine and a growth factor linked by at least one amino acid residue, and wherein the chimeric polypeptide enhances the proliferation and/or differentiation of hematopoietic precursor cells. In particular the invention relates to, a chimeric polypeptide comprising the... Agent: Mccarter & English LLP Cityplace I

20070122379 - Combined tumor suppressor gene therapy and chemotherapy in the treatment of neoplasms: In one embodiment, this invention provides methods of treating mammalian cancer or hyperproliferative cells, said method comprising contacting said cells with a tumor suppressor protein or tumor suppressor nucleic acid and also contacting said cell with at least one adjunctive anti-cancer agent. The invention also provides for a pharmacological composition... Agent: Townsend And Townsend And Crew, LLP

20070122377 - Compositions and methods of treatment: A method of inducing tolerance to a therapeutic cell in a patient who is to be administered subsequently a therapeutic amount of the said therapeutic cell or a precursor thereof, the method comprising administering to the patient (a) a tolerising cell sharing the same antigenic characteristics as the therapeutic cell,... Agent: Nixon Peabody LLP - Patent Group

20070122381 - Method for regulating neuron development and maintenance: The present invention relates to a method for regulating neuron development/maintenance and/or regeneration in a nervous system of a mammal and to pharmaceutical compositions comprising leukaemia inhibitory factor useful for same.... Agent: Scully Scott Murphy & Presser, PC

20070122378 - Methods and compositions for the treatment of persistent infections: The present invention provides methods and compositions for the treatment, prevention, or reduction of persistent infections, such as chronic infections, latent infections, and slow infections and cancer. The methods and compositions of the invention are also useful for the alleviation of one or more symptoms associated with such infections and... Agent: Mintz, Levin, Cohn, Ferris, Glovsky And Popeo, P.C.

20070122383 - Interleukin-10 compositions for the treatment of adenocarcinomas: The present invention is directed to methods for the treatment of adenocarcinomas that are characterized by the overexpression of a particular oncogene, Pim-1. The procedure involves administering a therapeutically effective amount of interleukin-10 that has been coupled to a carrier that increases its circulating plasma half-life.... Agent: Law Office Of Michael A. Sanzo, LLC

20070122382 - Methods of treating cancer using il-21 and monoclonal antibody therapy: Methods for treating cancer by co-administering a therapeutic monoclonal antibody with IL-21 are described. Exemplary monoclonal antibodies that can be used are rituximab, trastuzumab and anti-CTLA-4 antibodies. The enhanced antitumor of the combination therapy is particularly useful for patient populations that are recalcitrant to monoclonal therapy, relapse after treatment with... Agent: Zymogenetics, Inc. Intellectual Property Department

20070122384 - Method for treating inflammatory bowel disease: A method for treating inflammatory bowel disease by administering interferon beta in conjunction with factor XIII to a mammal afflicted with the disease. The IBD may either be ulcerative colitis or Crohn's disease. The factor XIII used may be recombinant or nonrecombinant. The interferon beta used can be naturally occurring... Agent: Novo Nordisk, Inc. Patent Department

20070122385 - Replication competent viruses capable of silencing virus inhibitory factor expression: Described is a replication-competent virus capable of replication and having lytic capacity in target cells. The virus comprises in the genome thereof, at least one DNA sequence coding for a silencing factor functional in reducing expression of a target gene in the target cells, operably linked to one or more... Agent: Trask Britt

20070122394 - Compositions and methods for liver growth and liver protection: The present invention provides pharmaceutical compositions and methods for liver proliferation and protection. Specifically useful are VEGFR modulating agents capable of promoting liver growth. Disclosed compositions and methods may be useful for promoting proliferation or treating pathological conditions in other organs of significant biological functions.... Agent: Genentech, Inc.

20070122391 - Compositions and methods for non-targeted activation of endogenous genes: The present invention is directed generally to activating gene expression or causing over-expression of a gene by recombination methods in situ. The invention also is directed generally to methods for expressing an endogenous gene in a cell at levels higher than those normally found in the cell. In one embodiment... Agent: Lahive & Cockfield, LLP

20070122395 - Genetic and pharmacological regulation of antidepressant-sensitive biogenic amine transporters through pkg/p38 map kinase: The invention relates to the observation that the p38 mitogen-activated protein kinase pathway is an important regulator of biogenic amine transporter (BAT) function. By using modulator of p38 MAPK, one can alter BAT function in a specific manner. This recognition of the pathway and its interaction with the serotonin transporter... Agent: Fulbright & Jaworski L.L.P.

20070122393 - Immunophenotype and immunogenicity of human adipose derived cells: The present invention encompasses methods and compositions for generating an isolated adipose tissue-derived stromal cell exhibiting a low level of immunogenicity. The present invention encompasses methods and compositions for reducing an immune response associated with transplantation by administering the recipient with an amount of adipose tissue-derived stromal cells effective to... Agent: Kathryn Doyle, Ph.d., J.d. Drinker Biddle & Reath

20070122396 - Morphogenic proteins and stimulatory factors in gene therapy: Gene therapy methods for tissue formation, repair and regeneration using nucleic acids encoding morphogenic proteins and morphogenic protein stimulatory factors (MPSFs) are provided.... Agent: Fish & NeaveIPGroup Ropes & Gray LLP

20070122392 - Propagation of undifferentiated embryonic stem cells in hyaluronic acid hydrogel: Embryonic stem cells are propagated in a hyaluronic acid.... Agent: Choate, Hall & Stewart LLP

20070122398 - Encapsulated hydrophilic compounds: The present invention relates to capsules for encapsulating functional agents, such as flavors, fragrances, pharmaceuticals, vitamins, etc. The capsules are suitable for the encapsulation of hydrophobic as well as hydrophilic substances. The capsules include a micro-organism, a matrix component and the encapsulatable material, wherein the latter comprises the functional agent... Agent: Winston & Strawn LLP Patent Department

20070122397 - Probiotic storage and delivery: Probiotic microorganisms are micro encapsulated by dispersing the probiotic microorganism in an aqueous suspension of a film forming protein and a carbohydrate; in an oil in water emulsion of a film forming protein and a carbohydrate and a fat; or in an oil which is subsequently dispersed in a film... Agent: Foley And Lardner LLP Suite 500

20070122390 - Graft with increased resistance to enzymatic degradation: Described are devices, methods, and systems for grafting tissues or organs that are exposed to bacterial or mammalian enzymes that degrade collagenous materials. Illustrative medical grafts are processed by contacting a collagenous extracellular matrix (ECM) material with a mono-carboxylic acid having from four to about twelve carbon atoms, or mixtures... Agent: Woodard, Emhardt, Moriarty, Mcnett & Henry LLP

20070122387 - Hair grafts derived from plucked hair: The present invention is a hair graft derived from a plucked hair comprising a plucked hair having adhered epidermal stem cells and associated follicular dermal cells. The present invention also includes methods of making a hair graft, methods of implanting a hair graft and methods of identifying inductive follicular dermal... Agent: Michael Best & Friedrich, LLP

20070122386 - Preparation method of a hair dermal papilla cell preparation, composition and method for regenerating hair follicles, and animal having regenerated hair follicles: The present invention provides a method for preparing a hair dermal papilla cell preparation comprising preparing a cell suspension by removing epidermal tissue from skin tissue and subjecting the resulting dermal tissue fraction to collagenase treatment, and cyropreserving the cell suspension to kill the follicular epidermal cells. The present invention... Agent: Snider & Associates

20070122389 - Stage specific follicle maturation systems: A three-dimensional matrix system is described herein. The system is used to surround developing tissue and support continued interaction between, for example, an oocyte and a supporting cellular structure. Oocytes grown to maturity can then be retrieved from the matrix for subsequent research use and/or fertilization. The systems and methods... Agent: Todd S. Parkhurst Holland & Knight LLP

20070122388 - Tissue graft compositions and methods for producing same: A tissue graft composition is described herein that includes a segment of small intestinal submucosa having at least one nanoparticle incorporated therein such that the permeability of the segment of small intestinal submucosa is altered, thereby providing the segment of small intestinal submucosa with a more substantially uniform structure for... Agent: Dunlap, Codding & Rogers P.C.

20070122399 - Composition and method for facilitating bone healing: The present invention provides a nutritional composition effective in facilitating bone healing in human, comprising lysine, proline, ascorbic acid, copper, vitamin B6. The nutritional composition contains 27-34% wt lysine, 14-16% wt proline, and 42-47% wt ascorbic acid. The nutritional composition further comprises vitamin A, vitamin D3, vitamin E, vitamin B1,... Agent: Kenyon & Kenyon LLP

20070122400 - Composition having liver function protecting effect: The present invention provides a highly safe composition which is effective for protecting liver functions and preventing liver dysfunctions in the case where liver dysfunctions rise by various causes. The present inventors found that oxidized coenzyme Q is effective for protecting liver functions in the absence of selenium and that... Agent: Sughrue Mion, PLLC

20070122401 - Methods and compositions for modulating telomerase reverse transcriptase (tert) expression: Nucleic acid compositions comprising an Ikaros or WT1 repressor binding site that act to repress transcription of the telomerase reverse transcriptase (TERT) coding sequence, as well as vectors and constructs including the same, are provided. Also provided are methods of modulating, e.g., inhibiting, the TERT transcription repressing activity of the... Agent: Bozicevic, Field & Francis LLP

20070122402 - Immunoglobulin preparations having increased stability: The present invention relates to a protein preparation having increased stability, comprising a stabiliser selected from the group consisting of non-polar and basic amino acids and having a pH of 4.0 to 5.2. The invention further relates to a pharmaceutical composition and a method of stabilising protein preparations.... Agent: Finnegan, Henderson, Farabow, Garrett & Dunner LLP

20070122403 - Molecules with extended half-lives, compositions and uses thereof: The present invention provides molecules, including IgGs, non-IgG immunoglobulins, proteins and non-protein agents, that have increased in vivo half-lives due to the presence of an IgG constant domain, or a portion thereof that binds the FcRn, having one or more amino acid modifications that increase the affinity of the constant... Agent: Jones Day

20070122404 - Humanized immunoglobulin reactive with alpha4beta7 integrin: The present invention relates to a humanized immunoglobulin that has binding specificity for α4β7 integrin and comprises the complementarity determining regions (CDRs) of mouse Act-1 antibody, and to the humanized light chain of the humanized immunoglobulin. The present invention further relates to a humanized immunoglobulin light chain. The invention also... Agent: Hamilton, Brook, Smith & Reynolds, P.C.

20070122405 - Human g-protein chemokine receptor (ccr5) hdgnr10: The present invention relates to a human protein called Human G-protein Chemokine Receptor (CCR5) HDGNR10, and isolated polynucleotides encoding this protein. The invention is also directed to human antibodies that bind Human G-protein Chemokine Receptor (CCR5) HDGNR10 and to polynucleotides encoding those antibodies. Also provided are vectors, host cells, antibodies,... Agent: Sterne, Kessler, Goldstein & Fox P.l.l.c.

20070122409 - Compounds, compositions and methods for the endocytic presentation of immunosuppressive factors: Immunomodulating agents comprising at least one Fc receptor ligand and at least one immunosuppressive factor are provided as are methods for their manufacture and use. The immunomodulating agents may be in the form of polypeptides or chimeric antibodies and preferably incorporate an immunosuppressive factor comprising a T cell receptor antagonist.... Agent: Catalyst Law Group, Apc

20070122408 - Fc labeling for immunostaining and immunotargeting: The present invention discloses methods of labeling Fc portions of antibodies, or fusion proteins incorporating Fc portions of antibodies, so that they can be used in immunostaining or immunolabeling procedures. A wide variety of labels can be used. A linker can be used between the label and the protein to... Agent: Catalyst Law Group, Apc

20070122407 - Isolated nucleic acids, vectors and host cells encoding erbb3 antibodies: Antibodies are disclosed which bind to ErbB3 protein and further possess any one or more of the following properties: an ability to reduce heregulin-induced formation of an ErbB2-ErbB3 protein complex in a cell which expresses ErbB2 and ErbB3; the ability to increase the binding affinity of heregulin for ErbB3 protein;... Agent: Genentech, Inc.

20070122406 - Optimized proteins that target ep-cam: Humanized Ep-CAM-targeting antibodies and methods of making and using the same are provided.... Agent: Morgan, Lewis & Bockius, LLP

20070122410 - Use of an active substance binding to cd28 for producing a pharmaceutical composition for the treatment of b-cll: The invention relates to the use of a superagonistic monoclonal antibody (mAb), which is specific for a naturally costimulatory receptor expressed on T cells, or a mimicry compound thereto, for producing a pharmaceutical composition for the treatment of diseases occurring with lacking costimulability of T cells, in particular of the... Agent: Mayer & Williams PC

20070122412 - Eg-vegf nucleic acids and polypeptides and methods of use: The present invention is directed to novel polypeptides designated herein as EG-VEGF and to nucleic acid molecules encoding those polypeptides. Also provided herein are vectors and host cells comprising those nucleic acid sequences, chimeric polypeptide molecules comprising the polypeptides of the present invention fused to heterologous polypeptide sequences, antibodies which... Agent: Merchant & Gould PC

20070122413 - Il-21 antagonists: Monoclonal antibodies are identified that bind the IL-21 protein. These antibodies are used to identify regions of the IL-21 protein to where binding neutralizes IL-21 activity. Hybridomas and methods of producing anti-IL-21 monoclonal antibodies are described. The monoclonal antibodies are useful in treating IL-21-mediated diseases, which may include autoimmune and... Agent: Zymogenetics, Inc. Intellectual Property Department

20070122411 - Solid forms of anti-egfr antibodies: The invention relates to solid forms of antibodies against the EGF receptor, in particular precipitates and crystals of monoclonal antibodies against the EGF receptor, particularly preferably of Mab C225 (cetuximab) and Mab h425 (EMD 72000), which result in biologically active antibody protein through dissolution or suspension in aqueous medium, obtainable... Agent: Millen, White, Zelano & Branigan, P.C.

20070122414 - Surface marker-directed cancer therapeutics: Disclosed are methods for treating and/or preventing neoplasms in a patient by contacting the neoplasm with therapeutic agents capable of binding, hybridizing, or interacting with proteins on the cell surface of neoplastic cells. In addition, therapeutic compositions are disclosed for the treatment and/or prevention of a neoplasm in a patient... Agent: Wilmer Cutler Pickering Hale And Dorr LLP

20070122415 - Compound and method for suppressing retroviral replication: In one aspect, the invention provides an antiretroviral peptide that suppresses replication of a retrovirus and the use thereof to inhibit retroviral replication within cells infected with a retrovirus. The method can be used in vivo to treat retroviral infection in human or veterinary subjects, and the inventive antiretroviral peptide... Agent: Leydig Voit & Mayer, Ltd

20070122416 - Cross-reactive displacing antibodies from collagen-binding proteins and method of identification and use: Antibodies to the CNA protein and to other regions from the collagen binding domain, including domain CNA19, are provided, and antibodies produced in this manner have been shown to be cross reactive to both Staphylococcus aureus and Staphylococcus epidermidis bacteria and which can thus be used in the prevention and... Agent: Stites & Harbison PLLC

20070122418 - Compositions and methods for the pulmonary delivery of aerosolized medicaments: Therapeutic dried compositions are described. The composition is in solid dose form and includes a polyol and an immunogenic agent.... Agent: Fish & Richardson P.C.

20070122417 - Immunotherapy method: The present invention relates to the use of immunomodifying agents to effect change in the T helper-type 1 (TH1) or T helper-type 2 (TH2) arms of the immune response and thereby treat TH1 or TH2 mediated diseases. In particular, the present invention relates to a method of altering a specific... Agent: Edwards Angell Palmer & Dodge LLP

20070122423 - Derp1 and proderp1 allergen derivatives: The present invention provides a novel treatment for allergy comprising the provision of a recombinant DerP1/ProDerP1 allergen derivative with hypoallergenic activity. Pharmaceutical compositions comprising said mutant allergens which stimulate a Th1-type immune response in allergic or naive individuals thereby reducing the potential for an allergic response upon contact with the... Agent: Glaxosmithkline Corporate Intellectual Property - Uw2220

20070122421 - Innate immune system-directed vaccines: The present invention provides novel vaccines, methods for the production of such vaccines and methods of using such vaccines. The novel vaccines of the present invention combine both of the signals necessary to activate native T-cells—a specific antigen and the co-stimulatory signal—leading to a robust and specific T-cell immune response.... Agent: Hamilton, Brook, Smith & Reynolds, P.C.

20070122419 - Methods and compositions for treating atherosclerosis: During the progression of atherosclerosis, autoantibodies are induced to epitopes of oxidized low-density lipoprotein (OxLDL), and active immunization of hypercholesterolemic mice with OxLDL ameliorates athero-genesis. The present studies have identified anti-OXLDL autoantibodies that share complete genetic and structural identity with antibodies produced by anti-phosphorylcholine B-cell clone, T15.... Agent: Buchanan, Ingersoll & Rooney LLP

20070122420 - Protein antigens useful for cancer therapy and vaccination: PstS1 protein or fragments thereof are highly immunogenic protein antigens for vaccination and immunotherapy of cancer in humans and animals. A wild-type or a recombinant mycobacterial PstS1 protein are used for the preparation of a vaccine or therapeutical composition for the treatment of cancer, in particular for the treatment of... Agent: Whitham, Curtis & Christofferson & Cook, P.C.

20070122422 - Sodium-independent small neutral amino acid transporter transporting l- and d- amino acids: Novel sodium-independent small neutral amino acid transporters which transport L- and D-amino acids. A protein comprising the amino acid sequence represented by SEQ ID NO:1 or 4 or an amino acid derived therefrom by deletion, substitution or addition of one or more amino acids and being capable of sodium-independently transporting... Agent: Edwards Angell Palmer & Dodge LLP

20070122424 - Peptide-based vaccine for influenza: A human synthetic peptide-based influenza vaccine for intranasal administration comprises a mixture of flagella containing at least four epitopes of influenza virus reactive with human cells, each expressed individually in Salmonella flagellin, said influenza virus epitopes being selected from the group consisting of: (i) one B-cell hemagglutinin (HA) epitope; (ii)... Agent: Browdy And Neimark, P.l.l.c. 624 Ninth Street, Nw

20070122425 - Process for recombinant expression and purification of antimicrobial peptides using periplasmic targeting signals as precipitable hydrophobic tags: A process was developed for expressing antimicrobial peptides in a recombinant host cell that eliminates host cell toxicity and antimicrobial peptide degradation, as well as providing a process for rapid purification. Fusion proteins comprising a periplasmic targeting signal, cleavage site, and antimicrobial peptides provide the basis for this process which... Agent: E I Du Pont De Nemours And Company Legal Patent Records Center

20070122426 - Composition containing fractionated bee propolis: A composition containing fractioned propolis wax isolated without the use of solvents. The composition contains about 24-50 mg/g of total polyphenols, about 11-18% resins, about 77-87% wax, about 2.4-5.0% polyphenols and about 0-5% other materials.... Agent: Armstrong, Kratz, Quintos, Hanson & Brooks, LLP

20070122427 - Delivery of trefoil peptides: The present invention relates to a microorganism, preferably a bacterial strain, preferably a non-pathogenic strain, preferably a non-invasive strain, preferably a food grade strain, preferably a gram-positive bacterial strain, delivering a trefoil peptide in vivo. Preferably said trefoil peptide is TFF1. The present invention further relates to a method for... Agent: Howrey LLP

20070122428 - Mutant forms of cholera holotoxin as an adjuvant: Mutant cholera holotoxins having single or double amino acid substitutions or insertions have reduced toxicity compared to the wild-type cholera holotoxin. The mutant cholera holotoxins are useful as adjuvants in antigenic compositions to enhance the immune response in a vertebrate host to a selected antigen from a pathogenic bacterium, virus,... Agent: Howson And Howson

20070122432 - Compositions and methods of treating retroviral infections: The present invention relates to hyaluronidase enzyme methods, vaccines and compositions for treating or preventing pathogenic infections, such as HIV, in a patient. The invention also relates to methods, vaccines and compositions for providing immunity against HIV infection in a patient comprising treating the patient with HIV virus or HIV... Agent: Sherri L. Oslick Mcdonnell Boehnen Hulbert & Berghoff

20070122429 - Designed antigens to elicit neutralizing antibodies against sterically restricted antigen and method of using same: The invention relates to the production of sterically restricted antigens, antibodies useful for the recognition of sterically restricted antigens, and methods of identifying and/or using the same. The invention further relates to methods of using the sterically restricted antigens and antibodies to treat a disease or to prevent infection with... Agent: Trask Britt

20070122430 - Influenza vaccine compositions and methods of use thereof: Compositions of anti-influenza vaccine containing nucleic acids encoding influenza proteins NP, M1 and NS-1 and methods of inducing a protective immune response using these compositions. Also included is the enhancement of antigenic presentation or increasing immunogenicity of an influenza NP, M1 and/or NS-1 polypeptide by modifying the three dimensional structure... Agent: Dla Piper US LLP

20070122431 - Reverse genetic system for rift valley fever virus and uses thereof: The present invention describes a reverse genetic system for Phlebovirus such as Rift Valley fever virus. This system comprised of RNA expression plasmids and protein expression plasmids. Additionally, the present invention also discloses the modification of this system to generate a recombinant virus that expresses a non-viral foreign gene. Furthermore,... Agent: Benjamin Aaron Adler Adler & Associates

20070122433 - Formulations of hydrophobic proteins in an immunogenic composition having improved tolerability: The present invention provides a method for producing a less-painful immunogenic composition of a hydrophobic protein in a pharmaceutically acceptable carrier suitable for administering to a mammal, comprising the steps of (a) solubilizing said hydrophobic protein with a zwitterionic detergent to make a first composition; (b) altering said first composition,... Agent: Wyeth Patent Law Group

20070122434 - Heat shock genes and proteins from neisseria meningitidis, candida glabrata and aspergillus fumigatus: Methods and compositions comprising isolated nucleic acid molecules specific to Neisseria meningitidis, Candida glabrata and Aspergillus fumigatus heat shock proteins (Hsps), as well as vector constructs and isolated polypeptides specific to the same are provided. Such compositions and methods are useful for the diagnosis of infections by these organisms and... Agent: Fish & Richardson PC

20070122435 - Topical dapsone for the treatment of acne: The present invention relates to a method of treating acne by topically applying a dermatological composition comprising dapsone. In addition to inflammatory lesions, the composition also treats non-inflammatory acne. The composition is formulated to include dapsone in a both a dissolved and microparticulate state.... Agent: Schwegman, Lundberg, Woessner & Kluth, P.A.

20070122441 - Biocidal surfaces, articles with biocidal surface agents and methods of synthesizing and evaluating biocidal surface agents: A biocidal article, includes a surface including a plurality of polymers covalently attached to the surface. The polymers include biocidal cationic groups. The polymers have a molecular weight distribution or polydispersity less than 3. A grafting density of the polymers on the surface is controlled, average degree of polymerization of... Agent: Bartony & Hare, LLP

20070122440 - Methods for producing nanoparticles: The present invention relates to methods of preparing nanoparticles from reactively formed block and/or graft copolymers and nanoparticles derived therefrom... Agent: Mueting, Raasch & Gebhardt, P.A.

20070122438 - Multifunctional self-decontaminating surface coating: e

20070122436 - Nanoparticulate active substance formulations: The invention relates to nanoparticulate formulations comprising at least one active compound or compound with a special effect and at least one random radical copolymer. The copolymers are formed from monomers carrying sulfonic acid groups and additional olefinically unsaturated compounds. The formulations are dispersible as nanoparticles in an aqueous medium.... Agent: Hutchison Law Group PLLC

20070122437 - Novel insecticide composition and use thereof particularly for impregnating mosquito nets, fly screens and the like: Materials containing at least one non-pyrethroid insecticide and at least one insect repellent, wherein the concentration of the insecticide is lower than its lethal concentration 100 (LC100) when used alone, for use as combination materials for simultaneous, separate or sequential use in the preparation of an insecticide composition.... Agent: Young & Thompson

20070122439 - Test medium, system and method for the evaluation of surfaces: The present invention provides a test medium for the evaluation of the resistance of surfaces comprising at least about 20 % by weight 3-(4-methoxyphenyl)-2-propenoic acid-2-ethylhexyl ester, at least about 20% by weight 2-ethylhexyl-2-cyano-3,3-diphenylacrylate, at least about 20% by weight 3,3,5-trimethylcyclohexyl salicylate and at least about 20% by weight N,N-diethyl-m-toluamide. Furthermore,... Agent: General Motors Corporation Legal Staff

20070122442 - Triple-action pest control formulation and method: The present disclosure provides a triple-action pest control formulation for controlling rodents, insects, and terrestrial mollusks, the formulation including: a first active ingredient which is a rodenticide; a second active ingredient which is both an insecticide and a molluscicide; an optional attractant; and a carrier matrix. The present disclosure also... Agent: Luedeka, Neely & Graham, P.C.

20070122445 - Absorbable fatigue-enduring phosphate composites: Precursors of fatigue-enduring phosphate composites, particularly useful as self-hardening bone cement, are formed of a calcium phosphate cement grafted with trimethylene carbonate, phosphate glass, a liquid amine-bearing derivative poly(ethylene glycol-b-propylene glycol) and a liquid C-succinylated polyalkylene glycol and preferably contain at least one bioactive agent.... Agent: Leigh P. Gregory Attorney At Law

20070122443 - Amphiphilic copolymer compositions: The present invention provides an amphiphilic coating material for applying on at least a portion of one surface of an article. The amphiphilic coating material comprises a copolymer containing one or more alkyl methacrylate or alkyl acrylate co-monomer units; one or more vinyl acetate co-monomer units; and up to 40%... Agent: Philip S. Johnson Johnson & Johnson

20070122446 - Implants for treatment of symptomatic or degenerated intervertebral discs: Devices for the treatment of intervertebral discs are described. The devices, when implanted into the nucleus pulposus of an intervertebral disc, provide for the controlled release of one or more active agents into the disc. The active agent can be a chemonucleolytic agent such as chymopapain. The device can also... Agent: Fox Rothschild, LLP

20070122444 - Medical devices employing triazine compounds and compositions thereof: The present invention relates to methods, compounds, and compositions comprising compounds that treat pathophysiological conditions arising from inflammatory responses, and is directed to compounds that inhibit or block glycated protein produced induction of the signaling-associated inflammatory response in endothelial cells. The present invention also relates to compounds that inhibit smooth... Agent: Dr. Reddy's Laboratories, Inc.

20070122447 - Shaped bodies and methods for their production and use: Shaped, composite bodies are provided. One portion of the shaped bodies comprises an RPR-derived porous inorganic material, preferably a calcium phosphate. Another portion of the composite bodies is a different solid material, preferably metal, glass, ceramic or polymeric. The shaped bodies are especially suitable for orthopaedic and other surgical use.... Agent: Woodcock Washburn LLP

20070122449 - Biodegradable implantable drug delivery device: The invention relates to biodegradable and implantable devices for the in situ delivery of a pharmaceutical composition to a human or animal that comprise a generally discoid body, having at least one aperture through which the body is anchorable by suture, and that are formed from biodegradable polymeric compositions. The... Agent: Hamilton, Brook, Smith & Reynolds, P.C.

20070122448 - Compositions and methods to create a vascularized environment for cellular transplantation: The present invention generally relates to biocompatible devices suitable for increasing cellular HIF-1 α protein levels. In particular, the present invention relates to an implant comprising a biocompatible support loaded with at least one pharmaceutical agent capable of increasing cellular HIF-1 α protein levels to promote vascularization at or near... Agent: Philip S. Johnson Johnson & Johnson

20070122450 - Treatment of ophthalmic conditions: Ophthalmic conditions such as presbyopia, myopia, and astigmatism can be corrected by the use of a molding contact lens in combination with a pharmaceutical composition suitable for delivery to the eye. The molding contact lenses are preferably commercially available and are not specifically designed for orthokeratology. The agents in the... Agent: Choate, Hall & Stewart LLP

20070122451 - Biogically non-degradable peptides, angiostensin converting enzyme inhibitor, drug and functional food: The present invention provides novel in vivo indigestible peptides that are highly absorbable and hardly digestible in living organism when administered orally or through other route, and expected to effectively exhibit functions, such as hypotensive effect, in living organism, and ACE inhibitors prepared with the peptides, and medicine or functional... Agent: Darby & Darby P.C.

20070122452 - Fat composition: Provided is a composition permitting high systemic absorption of n-3 polyunsaturated fatty acids and high transfer of them to tissues and capable of fully exhibiting pharmacological effects which the fatty acids have. A fat composition containing one or more phospholipids having, as a constituent fatty acid, an n-3 polyunsaturated fatty... Agent: Oblon, Spivak, Mcclelland, Maier & Neustadt, P.C.

20070122453 - Moderating the effect of endotoxins: The present invention relates to the use of an oral composition comprising meat extract and peptones, separately or in combination, in the manufacture of an oral composition to treat the effects of infection by pathogenic bacteria such as Clostridium difficile. Such effects may include the failure of the integrity of... Agent: Bell, Boyd & Lloyd LLP

20070122457 - Nicotine and chocolate compositions: The present invention is drawn to nicotine-containing pharmaceutical compositions that comprise chocolate and method of using the compositions in different therapies, such as nicotine replacement therapy.... Agent: Fulbright & Jaworski, LLP

20070122458 - Nicotine and chocolate compositions: The present invention is drawn to nicotine-containing pharmaceutical compositions that comprise chocolate and method of using the compositions in different therapies, such as nicotine replacement therapy.... Agent: Fulbright & Jaworski, LLP

20070122456 - Nicotine and cocoa powder compositions: The present invention relates to a nicotine-containing pharmaceutical composition and methods of using the composition in therapies, such as nicotine replacement therapy.... Agent: Fulbright & Jaworski, LLP

20070122454 - Skin moisturizing agent for oral intake and functional foods and drinks: The present invention provides functional food and beverage that produce a skin moisturizing effect through oral intake, that is excellently safe, and that may be taken regularly. The invention also provides a skin moisturizer for oral intake to be used in the functional food and beverage, as well as use... Agent: Sughrue Mion, PLLC

20070122455 - Uniform films for rapid-dissolve dosage form incorporating anti-tacking compositions: The present invention relates to water-soluble films incorporating anti-tacking agents and methods of their preparation. Anti-tacking agents may improve the flow characteristics of the compositions and thereby reduce the problem of film adhering to a user's mouth or to other units of film. In particular, the present invention relates to... Agent: Hoffmann & Baron, LLP

20070122459 - Composition and method for preventing or treating urolithiasis: A method for preventing or treating urolithiasis in an animal by feeding the animal a food composition comprising potassium in an amount equivalent to more than about 1% by weight potassium chloride and a food composition suitable for preventing or treating urolithiasis in an animal comprising potassium in an amount... Agent: Colgate-palmolive Company

20070122460 - Hot-flash wipes and clothing: Disclosed are cooling clothing and wipes to alleviate some of the symptoms of menopause, especially hot flashes and night sweats. A wipe is made of a wicking material that does not disintegrate or leave a residue as do current tissues. The wipe carries a cooling agent, such as menthol. When... Agent: Leydig Voit & Mayer, Ltd

20070122461 - Antimicrobial compositions and wound dressings: The present invention relates to a wound dressing comprising a flexible base layer and an antimicrobial material, wherein the antimicrobial material comprises an actived carbon-carried noble metal, the actived carbon is selected from the group consisting of an actived carbon powder, an actived carbon particle, an actived carbon fiber, and... Agent: Patterson, Thuente, Skaar & Christensen, P.A.

20070122463 - Antimicrobial compositions and wound dressings: A wound dressing and an antimicrobial composition are provided. The wound dressing comprises a carbonaceous material, a noble metal carried on the carbonaceous material, and, optionally, a flexible base layer, wherein the carbonaceous material is selected from a group consisting of activated carbon, graphite, carbon, and a combination thereof, while... Agent: Patterson, Thuente, Skaar & Christensen, P.A.

20070122462 - Bandage with a hydrophilic foam containing silver: A compression stretch bandage formed from at least one layer of a stretchable, textile material forming a body of the bandage, a base material attached to the stretchable, textile material on a first side, and a silver material attached to the base material for reducing risk of infection. The bandage... Agent: Akerman Senterfitt

20070122467 - Anaesthetic formulations: Propofol Solubilised in aqueous micellar preparations of poloxamers is stable at low concentrations and that such preparations are effective administration forms for Propofol.... Agent: Fish & Richardson PC

20070122469 - Method for producing a vesicle dispersion: A method for preparing a vesicle dispersion wherein a water-soluble substance is encupsulated in the vesicle, which comprises successively performing: a step of dispersing at least one lipid in an aqueous medium to pre-construct a vesicle dispersion, a step of drying the pre-constructed vesicles to obtain dried vesicles, a step... Agent: Wenderoth, Lind & Ponack, L.L.P.

20070122465 - Novel formulations of pharmacological agents, methods for the preparation thereof and methods for the use thereof: In accordance with the present invention, there are provided compositions and methods useful for the in vivo delivery of substantially water insoluble pharmacologically active agents (such as the anticancer drug paclitaxel) in which the pharmacologically active agent is delivered in the form of suspended particles coated with protein (which acts... Agent: Morrison & Foerster LLP

20070122468 - Novel formulations of pharmacological agents, methods for the preparation thereof and methods for the use thereof: In accordance with the present invention, there are provided compositions and methods useful for the in vivo delivery of substantially water insoluble pharmacologically active agents (such as the anticancer drug paclitaxel) in which the pharmacologically active agent is delivered in the form of suspended particles coated with protein (which acts... Agent: Morrison & Foerster LLP

20070122466 - Sphingomyelin liposomes for the treatment of hyperactive bladder disorders: The present invention provides pharmaceutical compositions and methods for the instillation of lipid vehicles comprised of liposomes containing sphingomyelin or sphingomyelin metabolites to prevent, manage, ameliorate and/or treat disorders involving neuropathic pain and aberrant muscle contractions, such as what occurs in bladder hyperactivity disorders such as interstitial cystitis (IC) in... Agent: The Webb Law Firm, P.C.

20070122464 - Use of osmolytes obtained from extremophilic bacteria for producing medicine for the external treatment of neurodermatitis: The invention relates to the use of osmolytes, in particular ectoine and hydroxyectoine, as well as their pharmacologically compatible salts and/or derivatives having equivalent effects, for producing dermatological preparations such as tinctures, lotions, O/W emulsions, W/O emulsions, creams, ointments, hydrogels or sprays for the topical prophylaxis, care and/or treatment of... Agent: Berliner & Associates

20070122470 - New combination dosage form: The present invention relates to an oral pharmaceutical preparation for use in the prevention and/or reduction of gastrointestinal complications associated with the use of acetyl salicylic acid. The present preparation comprises a fixed oral dosage form comprising a proton pump inhibitor in combination with acetyl salicylic acid. Furthermore, the present... Agent: White & Case LLP Patent Department

20070122473 - Aminosugar and/or glycosaminoglycan composition having therapeutic use: An embodiment of the invention provides a composition having one or more active ingredients such as an aminosugar, more particularly, glucosamine, glucosamine salt, and mixtures thereof, and a glycosaminoglycan, more particularly, chondroitin, chondroitin salts, and mixtures thereof having a therapeutic use and is stable for at least 24 months. Additionally,... Agent: Edward J. Timmer

20070122471 - Method of improving suitability for granulation: The present invention provides a granulated product having improved granulatability which contains a compound with poor wettability and a surfactant, particularly the granulated product wherein at least about 35% by weight with respect to the total weight of the product does not pass through a 100-mesh sieve, and a method... Agent: Foley And Lardner LLP Suite 500

20070122474 - Pharmaceutical preparation comprising an active dispersed on a matrix: The present invention relates to the field of pharmaceutical technology and describes a novel advantageous preparation for an active ingredient. The novel preparation is suitable for producing a large number of pharmaceutical dosage forms. In the new preparation, an active ingredient is present essentially uniformly dispersed in an excipient matrix... Agent: Gary M. Nath Nath & Associates PLLC

20070122476 - Storage stable thyroxine active drug formulations and methods for their production: This invention provides a storage-stable dosage form of a thyroxine active drug composition which exhibits an improved stability. The formulation contains a thyroxine active drug substance, an alditol, and a saccharide, and, optionally, additional pharmaceutically accepted excipients. Levothyroxine sodium is the preferred active drug substance, mannitol is the preferred alditol,... Agent: Rothwell, Figg, Ernst & Manbeck, P.C.

20070122472 - Synergistic binder composition, method for making same, and tablets of an active and said binder having advantageous hardness and friability: Tablets of a pharmaceutical, nutritional or vitamin active compound or composition, e.g. a poorly compressible drug are made by direct compression using a synergistic binder composition of co-processed (a) copolymer of vinylpyrrolidone (VP) and vinyl acetate (VA) and (b) microcrystalline cellulose (MCC), in a wt. ratio of (a):(b) of 1-30:99-70,... Agent: Attn: William J. Davis, Esq. International Specialty Products

20070122475 - Taste masking composition: A composition for delivery of a medicament that has a bitter taste and/or causes throat catch is provided. The composition contains Carbomer 934, Carbomer 971, Carbomer 974, PEG-5M or a mixture thereof in an amount sufficient to mask the bitter taste of the medicament and/or throat catch.... Agent: Novartis Corporate Intellectual Property

20070122478 - Extended release composition containing tramadol: The preparation provides, effective blood concentration for a period of about 24 hours with reduced peak concentrations. It is characterized that effective Tramadol levels appears within the first hours after administration, the time to maximal Tramadol content Tmax is at least 10 hours and the peak Tramadol concentration is less... Agent: Merchant & Gould PC

20070122477 - Methods and articles for treating 25-hydroxyvitamin d insufficiency and deficiency: A controlled-release pharmaceutical formulation including cholecalciferol and/or ergocalciferol, a method of making the formulation, and a method of administering the formulation to treat 25-hydroxyvitamin D insufficiency or deficiency, are disclosed. The composition and method of administration preferably result in delayed release of the vitamin(s) in the ileum of the small... Agent: Marshall, Gerstein & Borun LLP

20070122479 - Threo-dops controlled release formulation: The present invention relates to pharmaceutical formulations for the controlled delivery of threo-3-(3,4-dihydroxyphenyl)serine (threo-DOPS) and derivatives of it. Such formulations can contain an extended or slow release component that maintains therapeutic concentration of threo-DOPS in the blood plasma over a prolonged time period. They can be further combined with an... Agent: Millen, White, Zelano & Branigan, P.C.

20070122481 - Modified release compositions comprising a fluorocytidine derivative for the treatment of cancer: The invention relates to a multiparticulate modified release composition comprising a fluorocytidine derivative, preferably capecitabine, and a modified release component comprising a modified release coating, a modified release matrix material, or both. Following oral delivery, the composition in operation delivers the fluorocytidine derivative in a pulsatile manner at about six... Agent: Christian Bauer

20070122480 - Sustained release formulations: Provided is a sustained-release formulation: (a) a sustained-release core including an active ingredient and a polymer having erosion and swelling property in mammalian intestinal secretions, (b) an enteric film coating layer coated on the sustained-release core, and (c) an active ingredient-containing film coating layer coated on the enteric film coating... Agent: Rothwell, Figg, Ernst & Manbeck, P.C.

20070122483 - Fluocinolone acetonide drug substance polymorphic interconversion: Disclosed in embodiments herein is a method of providing the same form of FA. Regardless of which form or mixture of forms are present by forming a slurry from samples of fluocinolone acetonide containing mostly Form A and little to no Form A.... Agent: Bausch & Lomb Incorporated

20070122482 - Method for preparing modified release pharmaceutical compositions: A method for the preparation of a pharmaceutical particulate composition for modified release of one or more therapeutically, prophylactically and/or diagnostically active substances, the method involving spraying of a composition comprising an oily material on a solid composition in order to subject the solid composition to a controlled agglomeration process,... Agent: Cheryl H Agris Phd

20070122486 - Nanoparticulate insulin: Nanoparticulate insulin compositions having effective an average particle size of less than about 5 microns are described. The compositions exhibit retention of insulin bioactivity, increased bioavailability, and increased consistency of bioavailability as compared to prior macro-sized insulin compositions. Methods of making nanoparticulate insulin compositions, dosage forms containing them, and the... Agent: Elan Drug Delivery, Inc. C/o Foley & Lardner LLP

20070122485 - Organic compounds: A pharmaceutical composition comprises octreotide acetate microparticles of linear poly (lactide-co-glycolide) polymer wherein the polymer contains less than 1% silicone oil or heptane.... Agent: Novartis Corporate Intellectual Property

20070122484 - Parenterally administrable microparticles: A process for producing microparticles containing biologically active substance, in which process an aqueous solution of the said substance is prepared, this solution is mixed with an aqueous solution of PEG such that the substance is concentrated and/or solidified, the substance is optionally washed, the substance is mixed with an... Agent: Mintz Levin Cohn Ferris Glovsky & Popeo

20070122487 - (poly(acryloyl-hydroxyethyl starch)-plga composition microspheres: The present invention relates to a composite microsphere system comprising poly(D,L-lactide-co-glycolide) (PLGA), poly(acryloyl hydroxyethyl starch) (AcHES), and a pharmaceutically effective amount of a biologically active compound. The active compound may be, for example, an insulin, an interferon, a luteinizing hormone-releasing hormone (LHRH) analog, a somatostatin and/or derivatives thereof, a calicitonin,... Agent: Buchanan, Ingersoll & Rooney PC

20070122488 - Multi-functional microcapsules and method and device for manufacturing same: Multimicrocapsules that include encapsulated components of at least one nutritionally, pharmacologically, or medically active functional substance, wherein, within an encapsulation of one or more layers of a first encapsulating material around a common capsule matrix, there are provided a first active functional component in an amount sufficient to provide functional... Agent: Winston & Strawn LLP Patent Department

20070122489 - Putamen ovi: The present invention pertains to a method for the preparation of putamen ovi, putamen ovi having a defined grain size distribution, and to the use of putamen ovi for the treatment of calcium deficiency and other disease conditions.... Agent: Hunton & Williams LLP Intellectual Property Department

20070122490 - Wound healing compound: This invention pertains to therapeutic antibacterial/antifungal-wound healing compositions comprise a therapeutically effective amount of antibacterial agents and/or antifungal agents and/or wound healing composition alone. In one embodiment, the wound healing composition comprises (a) zinc oxide and (b) fat-soluble vitamins. The therapeutic antibacterial/antifungal-wound healing compositions may be utilized in a wide... Agent: Keaty Professional Law Corporation Thomas S. Keaty

20070122491 - Methods and compositions for altering cell function: The present invention relates to compositions and methods for altering cell function. In particular, the present invention provides compositions comprising selenium (e.g., SEL-PLEX) and methods of using the same (e.g., as a therapeutic and/or prophylactic treatment for neurodegenerative disease). Additionally, the present invention demonstrates that specific forms of selenium (e.g.,... Agent: Medlen & Carroll, LLP

20070122498 - Compositions for safe and effective regression of dermal vessel tortuosity: Topical compositions for Safe and Effective regression of Dermal Vessel Tortuosity in the form of ointment, cream, oil, soap and shampoo contain non aqueous herbal extract of Wrightia Tinctoria, cocos nucifera, and suitable pharmaceutically/cosmetically accepted excipients for dermal use.... Agent: Bregen Technical Consultants L.L.C.

20070122494 - Herbal composition for treatment and maintenance of hormone dependent conditions and circulatory conditions, and immunostimulation: A pharmaceutical or medicinal preparation comprising a mixture of herbs including Glycine max, Asparagus racemosa, Boerhavia diffusa, Withania somnifera, Saraca indica, and Coleus forskohlii, or a mixture of the active ingredients that have been extracted from those herbs. The herbal formulations of the present invention are effective for the treatment... Agent: Volpe And Koenig, P.C.

20070122497 - Herbal composition for treatment and maintenance of hormone dependent conditions, osteoporosis, circulatory conditions, and for use as an immunostimulant: A pharmaceutical or medicinal preparation comprising a mixture of herbs including Glycine max, Coleus forskohlii, Camellia sinensis, Allium sativum, Withania somnifera, Boerhavia diffusa, and Curcuma longa, or a mixture of the active ingredients that have been extracted from those herbs. The herbal formulations of the present invention are effective for... Agent: Volpe And Koenig, P.C.

20070122496 - Herbal composition for treatment of immunocompromised conditions: According to the present invention there is provided pharmaceutical or medicinal preparation comprising a combination of two herbal compositions to be administered together. The first herbal composition comprises a mixture of the following herbs: Asparagus racemosa, Curcuma longa, Glycyrrhiza glabra, Momordica charantia, Tinospora cordifolia, Withania somnifera, Spirulina, Allium sativum, Emblica... Agent: Volpe And Koenig, P.C.

20070122495 - Herbal composition to improve psychological functions as an anxiolytic, tranquilizer, and non-narcotic sedative, as well as other physiological functions: A pharmaceutical or medicinal preparation comprising a mixture of herbs including Bacopa monniera, Convolvulus pluricaulis, Nardostachys jatamansi, Valerian wallichi, Myristica fragrans, Centella asiatica, Withania somnifera, Ocimum sanctum, Acorus calamus, Boerhavia diffusa and Tinospora cordifolia or a mixture of the active ingredients that have been extracted from such herbs for treatment... Agent: Volpe And Koenig, P.C.

20070122493 - Marine algae extract and glycosidase inhibitor containing the same: A glycosidase inhibitor comprising as an active ingredient an extract of Ascophyllum nodosum which is a kind of brown algae can be used as a useful healthy food or food for specified health uses for the treatment and/or prevention of diabetes.... Agent: Wenderoth, Lind & Ponack, L.L.P.

20070122492 - Plant extracts and dermatological uses thereof: The present invention provides for plant extracts and dermatological formulations comprising one or more plant extracts that are capable of inhibiting one or more extracellular proteases selected from the group of: matrix metalloprotease-1 (MMP-1), matrix metalloprotease-2 (MMP-2), matrix metalloprotease-3 (MMP-3), matrix metalloprotease-9 (MMP-9) and human leukocyte elastase (HLE). The present... Agent: Heller Ehrman LLP

20070122499 - Antiseptic composition: p-Menthane-3,8-diol (PMD) has antiseptic, antibiotic, fungicidal and bactericidal properties. It is used for these purposes in the form of compositions and method comprising the PMD and optionally a carrier. A method of treating acne, folliculitis body, scalp folliculitis, Hydradinitis suppuritiva dandruff, seborrhoeic dermatitis (scalp or body), pityriasis versicolor, pityrosporun folliculitis,... Agent: Rankin, Hill, Porter & Clark, LLP

20070122500 - Cosmetic compositions in particular with anti-ageing activity comprising an extract of aframomum angustifolium or longoza plant: M

20070122501 - Formulations containing astragalus extracts and uses thereof: Formulations containing plant extracts, in particular Astragalus extracts, and their use in inducing telomerase activity in cells, are described. Such compositions include pharmaceutical, including topical, and nutraceutical formulations. The methods and compositions are useful for treating diseases subject to treatment by an increase in telomerase activity in selected cells, such... Agent: Perkins Coie LLP

20070122502 - Therapeutic juice composition for women: A therapeutic juice composition is provided which is particularly advantageous and beneficial to women. This composition comprises noni fruit and a vitamin blend comprising black cohosh, a chromium composition, a calcium composition and a source of trans-resveratrol.... Agent: Karambelas & Associates

20070122503 - Use of extracts from cimicifuga racemosa and of tectorigenin as an estrogen-type, organoselective medicament having no uterotrophic effect: The present invention relates to the use of extracts from Cimicifuga racemosa, and of tectorigenin as an estrogen-type, organoselective medicament for the selective treatment and/or prophylaxis of cardiovascular diseases, atherosclerosis, osteoporosis and climacteric disorders, e.g. for preventing or alleviating hot flushes. Uterotrophic effects are practically not observed.... Agent: Akerman Senterfitt

20070122504 - Grape seed extract having neuronal cell-protection activity and the composition comprising the same for preventing and treating degenerative brain disease: The present invention relates to a grape seed extract showing neuronal cell protecting activity and the composition comprising the same having neuronal cell protecting activity for preventing and treating degenerative brain disease. The grape seed extract shows potent inhibiting activity of neuronal cell apoptosis occurred in brain ischemia as well... Agent: Kirk Hahn

20070122505 - Natural antioxidant additive for feed and drinking water: A natural intestine-functional additive with antioxidative properties for utilization as an additive in animal feed containing natural and/or nature identical active substances. The substance include a first active component containing antioxidative active substances derived from plant material from olive plants (Olea europaea L) and a second active component containing antioxidative... Agent: Patrick W. Rasche Armstrong Teasdale LLP

20070122507 - Histone deacetylase and tumor necrosis factor converting enzyme inhibition: The present invention relates to methods and compositions for inhibiting Histone Deacetylase (“HDAC”) and/or Tumor Necrosis Factor Converting Enzyme (“TACE”) in living organisms. More particularly, the present invention relates to methods and compositions involving the inhibition of HDAC and/or TACE using processed Morinda citrifolia L. plant products.... Agent: Kirton And Mcconkie

20070122506 - Process for the isolation of oleane compounds isolated from the bark of arjun tree terminalia arjuna (roxb.): The present invention provides an improved process for the isolation of oleane compounds from the bark of Terminallia arjuna (Roxb.). More particularly, the present invention relates to an improved process for the isolation of arjunic acid and its derivates from the bark of Terminallia arjuna (Roxb.). The present invention further... Agent: Dickinson Wright PLLC

20070122509 - Antioxidant dietary supplement compositions and methods for maintaining healthy skin: Compositions and methods for maintaining healthy skin and alleviating skin conditions such as redness, inflammation, irritation and skin aging, as well as for maintaining healthy scalp and hair are disclosed. The oral compositions disclosed comprise antioxidants including lycopene, gallic acid and ascorbic acid. Preferably lycopene containing tomato compositions has been... Agent: Frost Brown Todd, LLC

20070122508 - Composition comprising the extract of actinidia arguta and related species for the prevention and treatment of allergic disease and non-allergic inflammatory disease: The present invention provides a pharmaceutical composition comprising the extract of hardy kiwifruit as an active ingredient in an effective amount to treat and prevent allergic disease and non-allergic inflammatory disease by reducing inflammation action, by inhibiting histamine release from mast cell, and by increasing the level of Th1 cytokines,... Agent: Sterne, Kessler, Goldstein & Fox P.l.l.c.

20070116644 - Cobalamin conjugates useful as imaging and therapeutic agents: The invention provides detectably labeled cobalamin derivatives which are useful for medical treatment and diagnosis.... Agent: Fish & Richardson P.C.

20070116645 - Methods and compositions for inhibiting cholesterol uptake: The present invention is directed to a method for the lowering of levels of LDL cholesterol in an individual comprising administering to the individual an agent which modulates the activity of the protein annexin 2, cyclophilin A, cyclophilin 40, or HSP 56 or the complex of annexin 2 and caveolin... Agent: David S Rastrick Nixon Peabody

20070116648 - Optimized relaxivity and specificity hepatobiliary mri contrast agent: An adamantane functionalized magnetic resonance imaging (MRI) contrast agent has been synthesized, and shows high liver specificity, prolonged retention time in both the liver and kidneys, the highest relaxivity among clinical contrast agents, high water solubility, thermodynamic stability, signal intensity enhancement, hepatocellular uptake, and low osmolality and toxicity.... Agent: Cooper & Dunham, LLP

20070116647 - Medicinal preparation particularly for the treatment of slipped discs hernias: The invention concerns a product consisting in an injection medicinal formulations comprising at least one compound to provide a viscous formulation, ethanol and at least one compound making said formulation opaque to X rays so as to control its delivery and its action. Said formulation is in particular useful for... Agent: Browdy And Neimark, P.l.l.c. 624 Ninth Street, Nw

20070116646 - Optical imaging of endometriosis: The invention provides contrast agents for optical imaging of endometriosis in patients. The contrast agent may be used in diagnosis of endometriosis, for follow-up of progress in disease development, and for follow-up of treatment of endometriosis. Further, the invention provides methods for optical imaging of endometriosis. The contrast agent has... Agent: Ge Healthcare, Inc.

20070116649 - Antibiotic formulations, unit doses, kits, and methods: An aqueous or powder composition includes anti-gram-negative antibiotic or salt thereof being present at an amount ranging from about 100 mg/ml to about 200 mg/ml. Another aqueous or powder composition includes anti-gram-positive antibiotic or salt thereof being present at a concentration ranging from about 0.6 to about 0.9 of the... Agent: Nektar Therapeutics

20070116650 - Device, method and use for the formation of small particles: The invention relates to a device for producing small particles of a certain substance. The device includes first inlet means (4) for a solution or a suspension containing the substance and second inlet means (3) for an atomizing agent. The device further includes mixing means (12) for the solution and... Agent: Cantor Colburn, LLP

20070116651 - Recombinant protein comprising starch binding domain and use thereof: A recombinant protein is prepared comprising a polypeptide of interest and a starch binding domain (SBD). The said SBD is obtainable from glucoamylase of fungi genus Rhizopus. The said recombinant protein comprising the said SBD can be purified by contacting with an affinity matrix such as starch, the SBD binds... Agent: Harness, Dickey & Pierce, P.L.C

20070116652 - Red herbal dentifrice: A dentifrice composition of the invention can be applied to teeth and/or gums by any conventional A dentifrice composition comprises (a) calcium carbonate having properties of particle size and angularity effective to provide mild abrasivity to dental enamel; (b) red iron oxide of low abrasivity in an effective amount on... Agent: Colgate-palmolive Company

20070116654 - Cosmetics: The cosmetic of the present invention is a cosmetic that alleviates skin irritation by blending in polypropylene glycol, a specific polar oil, or polybutylene glycol, as well as an ultraviolet absorbent. The present invention also relates to an agent and a method for alleviating irritation by lipophilic drugs. Since the... Agent: Townsend & Banta C/o Portfolio Ip

20070116653 - Hair treatment compositions: The present invention relates to hair treatment compositions and methods. More particularly, the invention relates to hair treatment compositions comprising lipids and creatine. The hair treatment compositions of the present invention may be used to improve the tensile properties of hair, such as hair elasticity and strength.... Agent: Bryan Cave LLP

20070116655 - Malodor counteractant compounds: e

20070116656 - Optically appealing cosmetic or dermatological preparation: A cosmetic or dermatological preparation which comprises an aluminum containing antiperspirant active ingredient, an α-hydroxycarboxylic acid, water and optionally, a plurality of particles in a stably suspended state. This Abstract is not intended to define the invention disclosed in the specification, nor intended to limit the scope of the invention... Agent: Greenblum & Bernstein, P.L.C

20070116657 - Hair growth promotor composition: c

20070116658 - Hair tonic composition: A hair tonic composition containing adenosine, adenosine 5′-phosphate, and/or an adenosine 5′-phosphate salt as an active ingredient.... Agent: Foley And Lardner LLP Suite 500

20070116659 - Elastase inhibitor: The present invention relates to an elastase inhibitor containing, as an active ingredient, a protein hydrolysate (with soybean protein hydrolysate and almond protein hydrolysate being excluded). According to the present invention, there can be provided pharmaceuticals and cosmetics which exhibit inhibitory effect against the growth of body hair, and skin... Agent: Oblon, Spivak, Mcclelland, Maier & Neustadt, P.C.

20070116662 - Antiperspirant/deodorant compositions: Disclosed herein is a composition for topical. application to human skin, comprising a biologically active material and a cosmetically suitable carrier, wherein the cosmetically suitable carrier comprises 5-95 wt % of a mixed feed polyolefin based on the total weight of the composition, wherein the mixed feed polyolefin comprises two... Agent: Exxonmobil Chemical Company

20070116660 - Copolymers based on tertbutyl(meth) acrylate and use thereof: Copolymers which contain tert-butyl (meth)acrylate, at least one α,β-ethylenically unsaturated amido-containing compound and acrylic acid incorporated in the form of polymerized units, cosmetic and pharmaceutical compositions which contain at least one such copolymer and the use of these copolymers are described.... Agent: Connolly Bove Lodge & Hutz, LLP

20070116661 - Hair restorative compositions and methods for treating damaged hair and safely chemically treating hair: Hair restorative compositions useful in repairing damaged hair include at least one hair shaft bonding agent dispersed within an appropriate solvent or carrier, such as water. When applied to damaged hair, the hair shaft bonding agent adsorbs into and bonds to the damaged hair shaft, filling in discontinuities and adhering... Agent: Workman Nydegger (f/k/a Workman Nydegger & Seeley)

20070116663 - Composition containing polyglycerol/medium-chain fatty acid ester: An object of the present invention is to provide a polyglycerol medium-chain fatty acid ester-containing composition capable of forming a water-in-oil microemulsion, the microemulsion being capable of solubilizing a large amount of water, and the composition having excellent dispersibility and self-emulsifiability in water, and cosmetics comprising the composition. The present... Agent: Birch Stewart Kolasch & Birch

20070116664 - Methods and compositions for treating hair and skin afflictions: Method and composition for promoting hair growth, preventing or minimizing hair loss and treating other hair and skin afflictions are disclosed. The methods include topical application of a composition comprising at least a phyto-steroid to the skin or hair follicles being treated.... Agent: Pearl Cohen Zedek Latzer, LLP

20070116666 - Methods and compositions for reducing or eliminating post-surgical adhesion formation: The present invention relates to a method for reducing adhesions associated with post-operative surgery. The present method comprises administering or affixing a polymeric composition preferably comprising chain extended, coupled or crosslinked polyester/poly(oxyalkylene) ABA triblocks or AB diblocks having favorable EO/LA ratios to a site in the body which has been... Agent: Coleman Sudol Sapone, P.C.

20070116665 - Novel derivatives of morphine-6-glucuronide, pharmaceutical compositions containing them, their preparation method and their uses: The invention relates to novel derivatives of morphine-6-glucuronide, the preparation method thereof and the uses of same in therapy, for example, as analgesics.... Agent: Hunton & Williams LLP Intellectual Property Department

20070116667 - Colon cleansing compositions and methods: A composition comprising, per litre of aqueous solution, from 30 to 350 g polyethylene glycol, from 3 to 20 g of an ascorbic acid component selected form the group consisting of ascorbic acid, a salt of ascorbic acid, or a mixture thereof, an alkali metal or alkaline earth metal sulphate,... Agent: Leon R. Yankwich Yankwich & Associates, P.C.

20070116669 - Interferon-inducible protein-10 (ip-10 or cxcl10) chemokine analogs for the treatment of human diseases: This invention is directed to peptide analogs of interferon-inducible protein-10 (IP-10 or CXCL10) chemokine that bind to the CXCR3 receptor or any other receptor in which IP-10 analogs can bind to as a ligand, such that the analogs can be designed to serve as agonists or antagonists of IP-10 chemokine.... Agent: Perkins Coie LLP

20070116668 - Lymphotoxin-beta, lymphotoxin-beta complexes, pharmaceutical preparations and therapeutic uses thereof: This invention relates to lymphotoxin-β, a lymphocyte membrane type protein. This protein is found on the surface of a number of cells, including phorbol ester (PMA) stimulated T cell hybridoma II-23.D7 cells. This invention also relates to complexes formed between lymphotoxin-β and other peptides such as lymphotoxin-α and to complexes... Agent: Lahive & Cockfield, LLP

20070116671 - Cell and enzyme compositions for modulating bile acids, cholesterol and triglycerides: The invention relates to immobilized or encapsulated enzyme and/or cells to lower bile acids and cholesterol. The invention also relates to methods of quantitatively measuring bile acids. The invention provides a composition for decreasing the amount of a target compound in the gastrointestinal tract of an animal, comprising: a) a... Agent: Bereskin And Parr

20070116673 - Method for activating t cell protein phosphatase and therapeutical methods based thereon: This invention relates to methods for activation of T cell protein tyrosine phosphatase (TCPTP) and for inhibiting tyrosine kinase signalling in an individual. The invention concerns a method for preventing or treating a disease or disorder in an individual, wherein said disease or disorder is curable by inhibiting tyrosine kinase... Agent: Rothwell, Figg, Ernst & Manbeck, P.C.

20070116672 - Treatment of rheumatic diseases: The present invention relates to the treatment of rheumatic diseases with a vaccinia virus complement control protein (VCP).... Agent: Fish & Richardson P.C.

20070116670 - Use of the adenoviral e2 promoter: The invention relates to a nucleic acid construct comprising an adenoviral E2 late promoter or a fragment thereof and a nucleic acid. The nucleic acid is selected from the group of transgenes, genes and nucleic acids which are respectively different from adenoviral nucleic acid controlled by an E2 late promoter.... Agent: Wood, Phillips, Katz, Clark & Mortimer

20070116691 - Conditionally immortalized long-term stem cells and methods of making and using such cells: Disclosed are methods for conditionally immortalizing stem cells, including adult and embryonic stem cells, the cells produced by such methods, therapeutic and laboratory or research methods of using such cells, and methods to identify compounds related to cell differentiation and development or to treat diseases, using such cells. A mouse... Agent: Sheridan Ross PC

20070116692 - Host cells obtained by introducing and expressing vhl gene in cancer cells or embryonic stem cells: The present invention relates to host cells that can function as neurons which are obtained by introducing and expressing von Hippel-Lindau gene in cancer cells, such as neuroblastoma cells and anaplastic oncocytes derived from the nerve system, or embryonic stem cells. The obtained hosts that have grown in vitro are... Agent: Wenderoth, Lind & Ponack, L.L.P.

20070116689 - Lim mineralization protein splice variants: The present invention is directed to isolated nucleic acid molecules that encode LIM mineralization protein, or LMP. The invention further provides vectors comprising splice variants of nucleotide sequences that encode LMP, as well as host cells comprising those vectors. Moreover, the present invention relates to methods of inducing bone formation... Agent: Fox Rothschild LLP Princeton Pike Corporate Center

20070116686 - Method for separating precursor cells producing gabaergic neuron alone: To treat epilepsy or schizophrenia by transplanting precursor cells of GABAergic neurons into a region where GABAergic neurons are lost or decreased in the brain of a patient suffering from the disease, it is intended to provide a method for separating a precursor cell of GABAergic neuron in an adult... Agent: Wenderoth, Lind & Ponack, L.L.P.

20070116690 - Method for the generation of antigen-specific lymphocytes: The invention provides systems and methods for the generation of lymphocytes having a unique antigen specificity. In a preferred embodiment, the invention provides methods of virally infecting cells from bone marrow with one or more viral vectors that encode antigen-specific antibodies for the production of, for example B cells and... Agent: Knobbe Martens Olson & Bear LLP

20070116687 - Method of modulating cellular transmigration and agents for use therein: The present invention relates generally to a method of modulating cellular transendothelial migration and to agents useful for same. More particularly, the present invention relates to a method of modulating leukocyte extravasation by modulating an endothelial cell intracellular ERK (extracellular regulated kinase)-dependent signalling mechanism. The method of the present invention... Agent: Scully, Scott, Murphy & Presser, P.C.

20070116688 - Methods of organ regeneration: The invention features methods for increasing or maintaining the number of functional cells of a predetermined type in a mammal (e.g., a human patient), for example, the insulin producing cells of the pancreas, liver cells, spleen cells, or bone cells, that has injured or damaged cells of the predetermined type... Agent: Clark & Elbing LLP

20070116693 - Bacterial culture having effects of suppressing dermatitis development and accelerating skin wound healing, and product using the same: A culture prepared by culturing a bacteria group separated from kefir grains and a new species Lactobacillus sp. SIID 1719-6b of the family Lactobacillaceae in the presence of green tea and then removing the bacterial cells from the resulting bacterial culture.... Agent: Koda & Androlia

20070116679 - Augmentation of organ function: The present invention provides methods and compositions for augmenting organ functions using small-scale matrix implants generated by seeding tissue-specific or undifferentiated cells onto a matrix materials (e.g., a wafer, sponge, or hydrogel). The seeded matrix composition can then be implanted and will develop into an organ-supplementing structure in vivo. Continued... Agent: David S. Resnick

20070116677 - Brain tissue damages: A method of treating brain tissue damage, including administering to a subject in need thereof an effective amount of secretoneurin. Disclosed are methods of promoting angiogenesis or neurogenesis in the brain of subject. Also disclosed are a method of homing of stem cells to the brain of a subject and... Agent: Fish & Richardson PC

20070116675 - Drug and method for proliferating natural killer cells: NK cells are obtained by administering a Toll-like receptor ligand such as polyinosinic-polycytidylic acid into the peritoneal cavity of an animal to which lactoferrin has been administered to proliferate NK cells in the peritoneal cavity and collecting NK cells from the peritoneal cavity.... Agent: Knobbe Martens Olson & Bear LLP

20070116681 - Ex vivo and in vivo methods and related compositions for generating hematopoietic stem cell populations: Various embodiments provide methods and related compositions for increasing the population size of hematopoietic stem cells (HSCs) in patients that may benefit from reconstitution of stem cells and/or differentiated cells of the blood lineage. The present methods enable the production of HSCs ex vivo and in vivo by reducing latexin... Agent: Buchanan, Ingersoll & Rooney PC

20070116685 - Hematopoietic stem cells and methods of treatment of neovascular eye diseases therewith: Isolated, mammalian, bone marrow-derived, hematopoietic stem cell populations contain endothelial progenitor cells (EPC) capable of forming retinal blood vessels. At least about 50% of the cells in the isolated cell population express CD31 and c-kit. Up to about 8% of the cells can express Sca-1, and up to about 4%... Agent: Olson & Hierl, Ltd.

20070116678 - Medical device with living cell sheet: A novel method, using a thermoreversible MC/PBS/Collagen hydrogel coated on the TCPS dish, for harvesting a living cell sheet with ECM. The obtained living cell sheet is administered to a joint adapted for implantation and for cartilage regeneration.... Agent: Hosheng Tu

20070116676 - Method for three-dimensional cartilage tissue engineering using bone marrow cells in tissue engineering bone marrow cells in simulated microgravity environment: This invention provides a method for three-dimensional cartilage tissue engineering by culturing bone marrow cells in a simulated microgravity environment that is realized by a bioreactor such as an RWV.... Agent: Sughrue Mion, PLLC

20070116682 - Methods of isolation, expansion and differentiation of fetal stem cells from chorionic villus, amniotic fluid, and placenta and therapeutic uses thereof: The present invention is directed to pluripotent fetal stem cells derived from chorionic villus, amniotic fluid, and placenta and the methods for isolating, expanding and differentiating these cells, and their therapeutic uses such as manipulating the fetal stem cells by gene transfection and other means for therapeutic applications.... Agent: David S. Resnick

20070116683 - Methods of isolation, expansion and differentiation of fetal stem cells from chorionic villus, amniotic fluid, and placenta and therapeutic uses thereof: The present invention is directed to pluripotent fetal stem cells derived from chorionic villus, amniotic fluid, and placenta and the methods for isolating, expanding and differentiating these cells, and their therapeutic uses such as manipulating the fetal stem cells by gene transfection and other means for therapeutic applications.... Agent: David S. Resnick

20070116684 - Methods of isolation, expansion and differentiation of fetal stem cells from chorionic villus, amniotic fluid, and placenta and therapeutic uses thereof: The present invention is directed to pluripotent fetal stem cells derived from chorionic villus, amniotic fluid, and placenta and the methods for isolating, expanding and differentiating these cells, and their therapeutic uses such as manipulating the fetal stem cells by gene transfection and other means for therapeutic applications.... Agent: David S. Resnick

20070116680 - Stem cells within gel microenvironments: This invention provides a system to embed stem cells within three-dimensional (3D) hydrogel microenvironments consisting of naturally derived proteins, proteoglycans and/or polysaccharides. Pure matrices or combinations of materials can be used. The method involves suspending stem cells in solutions of the matrix components of interest, emulsifying these solutions in a... Agent: Dr. Raj Bawa Bawa Biotechnology Consulting, LLC

20070116674 - Use of adipose tisue cells for initiating the formation of a fuctional vascular network: The invention relates to the use of cells of a medullary or extra-medullary white adipose tissue, in particular of an extra-medullary stromal vascular fraction (SVF) and/or mature dedifferentiated adipocytes of any origin for initiating the formation of a functional vascularisation.... Agent: Alston & Bird LLP

20070116694 - Inhibitor of interaction of granzyme b with golgin-160: It is an object of the present invention to find a protein interacting with Granzyme B and to provide a means for preventing and/or treating diseases caused by the decomposition of the above protein by Granzyme B. The present invention provides a method of using Golgin-160 as a substrate of... Agent: Greenblum & Bernstein, P.L.C

20070116695 - Pharmaceutical preparations for attention deficit disorder, attention deficit hyperactivity disorder and other associated disorders: A pharmaceutical preparation for the treatment of attention deficit disorders combines a therapeutically effective amount of digestive enzymes, such as chymotrypsin, and medication used to treat attention deficit disorders, such as Ritalin®, Concert®, Adderall® and Strattera®. The preparation may be in the form of a tablet, capsule or time released... Agent: Maine & Asmus

20070116696 - Lotus and methyl donors: Cosmetic, dermatological and dietary compositions for treatment of aging of the skin are provided that contain a compound useful in promoting skin health and youthful appearance, such as extract of Lotus in combination with methyl donors, in a suitable carrier or vehicle along with methods of treatment to reduce signs... Agent: Buckingham, Doolittle & Burroughs, LLP

20070116697 - Nanosphere/microsphere delivery system for the treatment of spinal cord injury: A formulation including injectable biodegradable nanospheres and/or microspheres as a delivery system for chondroitinase ABC (cABC) or a functional derivative of cABC to treat acute and chronic spinal chord injury in a mammal having the same is provided. The biodegradable nanosphere/microsphere formulation releases cABC or a functional derivative of cABC... Agent: Scully Scott Murphy & Presser, PC

20070116698 - Novel methods and medicament for treating infectious diseases involving microbial biofilms: The present invention provides a method for prophylaxis and therapy of infectious diseases caused by microorganisms present in biofilms adherent to cell surfaces comprising the step of administering to an individual in need thereof a composition comprising a combination of at least one compound chosen from the group of peroxidase,... Agent: Amrmstrong, Kratz, Quintos, Hanson & Brooks, LLP

20070116699 - Nattokinase for reducing whole blood viscosity: Disclosed is a method for reducing whole blood viscosity in a patient in need thereof. The method includes administering a composition that comprises nattokinase. The composition may be administered to any patient that may benefit from a reduction in blood viscosity, such as a patient having or at risk for... Agent: Foley And Lardner LLP Suite 500

20070116700 - Reduced-viscosity concentrated protein formulations: The present application concerns concentrated protein formulations with reduced viscosity, which are particularly suitable for subcutaneous administration. The application further concerns a method for reducing the viscosity of concentrated protein formulations.... Agent: Genentech, Inc.

20070116701 - Compositions and methods for diagnosing and treating cancer: An isolated antibody that specifically binds to an extracellular domain of two or more human FZD receptors and inhibits growth of tumor cells is described. Also described is a method of treating cancer comprising administering an antibody of the present disclosure in an amount effective to inhibit tumor cell growth.... Agent: Sterne, Kessler, Goldstein & Fox P.l.l.c.

20070116702 - Survival promoting ncam binding and mcam ligand binding compounds: The present invention relates to compounds capable of stimulating survival of cells presenting the neural cell adhesion molecule (NCAM) or an NCAM-ligand (counter-receptor), such as neurons. Further, the present invention relates to the use of pharmaceutical compositions and medicaments in the treatment or protection of cells presenting NCAM or NCAM... Agent: Browdy And Neimark, P.l.l.c.

20070116703 - Isolated mammalian membrane proteins; related agents: Nucleic acids encoding various lymphocyte cell proteins from mammalian, including primate, reagents related thereto, including specific antibodies, and purified proteins are described. Methods of using said reagents and related diagnostic kits are also provided.... Agent: Schering-plough Corporation Patent Department (k-6-1, 1990)

20070116704 - Method for the production of an immunostimulating mucin (muc1): The present invention relates to a method for producing or identifying a MUC1 molecule which is able to generate an immune response in humans. The invention also relates to a method for producing or identifying a cell, cell lines or cell lysates containing a MUC1 molecule that is able to... Agent: Finnegan, Henderson, Farabow, Garrett & Dunner LLP

20070116705 - Novel pdes and uses thereof: The present invention provides isolated full-length nucleic acid molecules encoding the novel PDE protein of the invention, and methods for uses thereof. The nucleic acid molecules of the invention also include peptide nucleic acids (PNA), and antisense molecules that react with the nucleic acid molecules of the invention. The invention... Agent: Townsend And Townsend And Crew, LLP

20070116706 - Antibodies to the propeptide of candida albicans and methods of use: Antibodies and agents which can bind to the propeptide of the Int1p protein of yeast microorganisms such as Candida albicans are provided which can be useful in methods for treating or preventing infections arising from such microorganisms. Microorganisms expressing the Int1p protein, such as C. albicans and S. cerevisiae, can... Agent: Stites & Harbison PLLC

20070116708 - Antibodies directed to monocyte chemo-attractant protein-1 (mcp-1) and uses thereof: Embodiments of the invention described herein relate to antibodies directed to the antigen monocyte chemo-attractant protein-1 (MCP-1) and uses of such antibodies. In particular, in accordance with some embodiments, there are provided fully human monoclonal antibodies directed to the antigen MCP-1. Nucleotide sequences encoding, and amino acid sequences comprising, heavy... Agent: Knobbe Martens Olson & Bear LLP

20070116707 - Antibody and antibody fragments for inhibiting the growth of tumors: Chimerized and humanized versions of anti EGF receptor antibody 225 and fragments thereof for treatment of tumors.... Agent: Kenyon & Kenyon LLP

20070116709 - Microemulsions with adsorbed macromolecules and microparticles: Microparticles with adsorbent surfaces, methods of making such microparticles, and uses thereof, are disclosed. The microparticles comprise a polymer, such as a poly(α-hydroxy acid), a polyhydroxy butyric acid, a polycaprolactone, a polyorthoester, a polyanhydride, and the like, and are formed using cationic, anionic, or nonionic detergents. The surface of the... Agent: Helen Lee Chiron Corporation

20070116710 - Methods of treating hemolytic anemia: Paroxysmal nocturnal hemoglobinuria or other hemolytic diseases are treated using a compound which binds to or otherwise blocks the generation and/or the activity of one or more complement components, such as, for example, a complement-inhibiting antibody.... Agent: Fish & NeaveIPGroup Ropes & Gray LLP

20070116712 - Novel streptococcus antigens: Streptococcus proteins and polynucleotides encoding them are disclosed. Said proteins are antigenic and therefore useful vaccine components for the prophylaxis or therapy of streptococcus infection in animals. Also disclosed are recombinant methods of producing the protein antigens as well as diagnostic assays for detecting streptococcus bacterial infection.... Agent: Seed Intellectual Property Law Group PLLC

20070116711 - Pertussis antigens and use thereof in vaccination: The invention provides BASB232 polypeptides and polynucleotides encoding BASB232 polypeptides and methods for producing such polypeptides by recombinant techniques. Also provided are diagnostic, prophylactic and therapeutic uses. The invention further provides immunogenic compositions comprising a plurality of antigens selected from at least two different categories of antigen, having different functions... Agent: Smithkline Beecham Corporation Corporate Intellectual Property-us, Uw2220

20070116713 - Compositions and methods for reducing or controlling blood cholesterol, lipoproteins, triglycerides and atherosclerosis: Compositions and methods related to the administration of red yeast rice, nicotinic acid, L-carnitine, folic acid, chromium picolinate, and selenium to reduce or control blood cholesterol, triglycerides, and lipoproteins in a mammal, and to reduce inflammation associated with coronary artery disease.... Agent: Walker & Jocke, L.p.a.

20070116715 - Mutant forms of cholera holotoxin as an adjuvant: Mutant cholera holotoxins comprising a cholera toxin subunit A having single amino acid substitutions in the amino acid positions 16 or 72 or a double amino acid substitution in the amino acid positions 16 and 68 or 68 and 72 have reduced toxicity compared to the wild-type cholera holotoxin. The... Agent: Howson And Howson

20070116714 - Vaccine comprising a polysaccharide antigen-carrier protein conjugate and free carrier protein: The present invention relates to combination vaccines comprising a conjugated polysaccharide antigen linked to a carrier protein, and wherein the carrier protein is also present as a free antigen in the vaccine composition, characterised in that the ratio of polysaccharide to protein is from 1:0:3 to 1:2. In particular, the... Agent: Smithkline Beecham Corporation Corporate Intellectual Property-us, Uw2220

20070116718 - Fusion proteins comprising bacteriophage coat protein and asingle-chain t cell receptor: The present invention relates to novel fusion proteins comprising a bacteriophage coat protein and a single-chain T cell receptor and uses of such complexes. In one aspect, the invention relates to soluble fusion protein comprising a bacteriophage coat protein covalently linked to a single-chain T cell receptor which comprises a... Agent: Edwards & Angell, LLP

20070116721 - Hepatitis b virus pre-s1 derived synthetic polypeptides and uses thereof: The invention relates to a group of synthetic polypeptides, derived from the pre-S 1 region of HBV, that efficiently interfere with early steps of an HBV infection. The peptides of the invention can be used in diagnostics for the detection of antigens and/or antibodies.... Agent: Stites & Harbison PLLC

20070116720 - Infectious cdna clone of north american porcine reproductive and respiratory syndrome (prrs) virus and uses thereof: The invention provides isolated polynucleotide molecules that comprise a DNA sequence encoding an infectious RNA sequence encoding a genetically-modified North American PRRS virus, wherein the polynucleotide molecule lacks at least one detectable antigenic epitope of North American PRRS virus. The invention also provides vaccines comprising genetically modified North American PRRS... Agent: Pharmacia & Upjohn

20070116717 - Influenza vaccine compositions and methods: Compositions of anti-influenza vaccine containing nucleic acids encoding influenza proteins NP, M1 and NS-1 and methods of inducing an immune response using these compositions. Also included is the enhancement of antigenic presentation or increasing immunogenicity of an influenza NP, M1 and/or NS-1 polypeptide by modifying the three dimensional structure of... Agent: Cure Lab, Inc.

20070116716 - Sars coronavirus s proteins and uses thereof: The present invention relates to the use of a matured, glycosylated Spike (S) protein of SARS Coronavirus, fragments of the S protein, methods for producing the same, their use in detecting SARS infection, and their use or the use of their corresponding antibodies to treat patients suffering from SARS.... Agent: Cohen, Pontani, Lieberman & Pavane

20070116719 - Vaccine delivery: The present invention provides an immunogen composition and methods for using the same for the development of immunity. In one method, the immunogen composition is administered to prepare a person for a later booster administration. This immunogen composition includes an antigen and a polyoxyalkylene block copolymer. In another method the... Agent: Marsh, Fischmann & Breyfogle LLP

20070116722 - Ovo vaccination of campylobacter in avian species: The present invention provides a method of inducing an immune response against Campylobacter in an avian species, especially a domesticated avian species such as chicken, turkey, duck, goose and quail, by administering, in ovo, live cells of Campylobacter.... Agent: Pharmacia & Upjohn

20070116724 - Compositions and methods of topical application and transdermal delivery of botulinum toxins without reduced non-toxin proteins: This invention relates to novel compositions of botulinum toxin that can be applied topically for various therapeutic, aesthetic and/or cosmetic purposes. The compositions may include botulinum toxin complexes, wherein the amounts of hemagglutinin, non-toxin non-hemagglutinin and/or exogenous albumin are selectively and independently reduced compared to conventional commercially available botulinum toxin.... Agent: King & Spalding

20070116723 - Topically applied clostridium botulinum toxin compositions and treatment methods: Hyperactive glandular conditions are treated using topically formulated botulinum toxin compositions. In the preferred embodiment of the invention, topical botulinum preparations are applied directly to the skin by a patient as needed to suppress his or her hyperhidrosis, bromhidrosis, chromhidrosis, nevus sudoriferous, acne, seborrhiec dermatitis or other glandular condition. In... Agent: Quarles & Brady LLP

20070116725 - Live attenuated samonella strains for producing monovalent or multivalent vaccines: Disclosed herein methods for producing live attenuated Salmonella typhi, Salmonella paratyphi A and B and other Salmonella mutants which can be used in vaccines to prevent diseases caused by Salmonella infection. These mutants can also be used to prevent or treat diseases caused by other bacterial strains, by viral and... Agent: Mintz, Levin, Cohn, Ferris, Glovsky And Popeo, P.C.

20070116726 - Immunisation against chlamydia pneumoniae: The published genomic sequence of Chlamydia pneumoniae reveals over 1000 putative encoded proteins but does not itself indicate which of these might be useful antigens for immunisation and vaccination or for diagnosis. This difficulty is addressed by the invention, which provides a number of C. pneumoniae protein sequences suitable for... Agent: Novartis Vaccines And Diagnostics Inc.

20070116727 - Vaccines directed to cancer-associated carbohydrate antigens: A vaccine and method to prevent or to retard the growth and replication of cancer cells that express a carbohydrate wherein the vaccine comprises: (a) a pharmaceutically effective amount of a carbohydrate antigen found on said cancer cells, or a mimetic thereof; and (b) a pharmaceutically acceptable carrier. The carbohydrate... Agent: Bell, Boyd & Lloyd, LLP

20070116729 - Lyophilization process and products obtained thereby: A lyophilization process which comprises dissolving a material in one or more solvents for said material to form a solution; forcing said material at least partially out of solution by combining the solution and a non-solvent for the material, which non-solvent is miscible with the solvent or solvents used and... Agent: Irving M. Fishman C/o Cohen, Tauber, Spievack & Wagner

20070116728 - Novel galenical system for active transport, method for preparation and use: The invention relates to a novel galenical system for taste masking, protecting an active substance, in particular in an acid medium, modulating releasing properties, masking mucous irritability and toxicity of certain active substances, for preparing aqueous forms which have a masked taste, are stable and pH independent. Said invention also... Agent: Blank Rome LLP

20070116730 - Pharmaceutical compositions: A method of providing systemic analgesia to cats, dogs and other small mammals by the ophthalmic administration of opioids is disclosed. Compositions for use in such a method are also disclosed.... Agent: Schering-plough Corporation Patent Department (k-6-1, 1990)

20070116731 - Dermatological cream-gels containing avermectin compounds: Pharmaceutical cream-gel compositions useful for the treatment of a variety of dermatological conditions, disorders and afflictions, in particular of rosacea, contain at least one avermectin compound active principle, and which also contain an oily phase dispersed in an aqueous phase by means of a non-surfactant polymeric emulsifier, the oily phase... Agent: Buchanan, Ingersoll & Rooney PC

20070116732 - Methods for making treated and/or coated cellulose-containing substrates: Disclosed are methods for making treated and/or coated cellulose-containing substrates and methods for reducing the cycle time to make a treated and/or coated cellulose-containing substrate.... Agent: Ppg Industries Inc Intellectual Property Dept

20070116735 - Apparatus and method for preventing adhesions between an implant and surrounding tissues: An anti-adhesion membrane is placed onto an implant introduced into a surgical site of a patient to prevent post-surgical adhesions between the implant and surrounding tissue. The implant may comprise either biological material, such as a transplanted organ, or non-biological material such as a medical device. The membrane may be... Agent: Stout, Uxa, Buyan & Mullins LLP

20070116734 - Porous, load-bearing, ceramic or metal implant: A method and apparatus for adjusting the modulus of elasticity, flexural strength, or porosity of metal and ceramic implants is disclosed in one embodiment of the invention as including a green tape comprising metal or ceramic particles, or a combination thereof, for incorporation into a solid implant structure. Apertures are... Agent: Ceramatec, Inc.

20070116733 - Surface immobilised multilayer structure of vesicles: A surface-immobilised multilayer structure of a plurality of vesicles (2), said structure comprising at least one linker (4) immobilised onto said surface, said at least one linker (4) being bound to at least one other linker, which is attached to a vesicle, which optionally may have another linker (5) bound... Agent: Dinsmore & Shohl, LLP

20070116736 - Local vascular delivery of pi3 kinase inhibitors alone or in combination with sirolimus to prevent restinosis following vascular injury: Medical devices, and in particular implantable medical devices, may be coated to minimize or substantially eliminate a biological organism's reaction to the introduction of the medical device to the organism. The medical devices may be coated with any number of biocompatible materials. Therapeutic drugs, agents or compounds may be mixed... Agent: Philip S. Johnson Johnson & Johnson

20070116737 - Microporous articles comprising biodegradable medical polymers, method of preparation thereof and method of use thereof: The present invention relates to a highly controlled method of preparation of a microporous biodegradable polymeric article. Firstly, at least one biodegradable polymer A, one polymer B, biodegradable or not, partially or totally immiscible with A, and a compatibilizer C for A and B are selected. Secondly, the selected polymers... Agent: Godfrey & Kahn S.c.

20070116739 - Resorbable thin membranes: Resorbable lactide polymer thin membranes are disclosed. The thin membranes are constructed of polylactide resorbable polymers, which are engineered to be absorbed into the body relatively slowly over time in order to reduce potential negative side effects. The membranes are formed to have very thin thicknesses, for example, thicknesses between... Agent: Stout, Uxa, Buyan & Mullins LLP

20070116738 - Subcutaneous implants having limited initial release of the active principle and subsequent linearly varying extended release thereof: Subcutaneous implants having limited initial release of the active principle and subsequent linearly varying extended release thereof consisting of: a core (i) comprising an active principle dispersed in a polymeric matrix of polylactic-glycolic acid (PLGA) copolymer, a coating in film form (ii), comprising as the main component a lactic-glycolic acid... Agent: Jay S Cinamon Abelman Frayne & Schwab

20070116740 - Contact lenses with mucin affinity: A biomedical device, such as a contact lens, has a surface linked to a polymer comprising boronic acid moieties. The boronic acid monomeric units may be derived from an ethylenically unsaturated monomer containing a boronic acid moiety, such as a vinylphenyl boronic acid or a (meth)acrylamido phenyl boronic acid. The... Agent: Bausch & Lomb Incorporated

20070116741 - Contact lenses with mucin affinity: A biomedical device surface, such as a contact lens surface, is covalently linked to a cationic copolymer. The copolymer may include monomeric units derived from an ethylenically unsaturated monomer containing a quaternary ammonium moiety and monomeric units derived from an ethylenically unsaturated monomer containing a moiety reactive with complementary reactive... Agent: Bausch & Lomb Incorporated

20070116742 - Confectionary products containing a human pheromone component: Confectionary products, such as hard or soft candies, having a human pheromone compound as an ingredient of the product, and which causes a person eating the product to experience unique, mood altering effects. The effect may be an overall sense of well-being or one of heightened sexual attractiveness.... Agent: Barry J. Marenberg, Esq.

20070116743 - Dietary supplement enhancing the muscular energy metabolism, comprising an alkanoyl carnitine and ribose: A health food/dietary supplement is disclosed suitable for enhancing muscular energy metabolism, comprising as its characterizing active ingredits an alkanoyl L-carnitine and ribose.... Agent: Nixon & Vanderhye, PC

20070116744 - Pectate lyases: The present invention relates to pectate lyases comprising the amino acid sequence Asn Leu Asn Ser Arg Val Pro (NLNSRVP) (amino acids 236-242 of SEQ ID NO: 2) belonging to Family 1 of polysaccharide lyases have good performance in industrial processes under neutral or alkaline conditions such as laundering and... Agent: Novozymes North America, Inc.

20070116747 - Disposable plastic glove with antiseptic coating: A disposable plastic glove is provided the inside surface of which carries an antiseptic agent. The glove is thin and elastic, and it can be made of any material that will produce a glove with such attributes. Preferred materials include both natural and synthetic rubber latex, acrylonitrile and polyvinylchloride. The... Agent: Whyte Hirschboeck Dudek S C

20070116746 - Packaging items containing a human pheromone component: Packaging products including a packaging substrate and a human pheromone component are disclosed. The packaging product and incorporated human pheromone components causes a person exposed to the product to experience unique, mood altering effects. The effect may be an overall sense of well-being or one of heightened sexual attractiveness.... Agent: Barry J. Marenberg

20070116745 - Spermicidal preparations and uses thereof: A method of controlling sperm comprising the step of contacting the sperm with an effective amount of copper silicate.... Agent: Marshall, Gerstein & Borun LLP

20070116748 - Top-biased beneficial components on substrates: A treated substrate with improved availability of a beneficial component for transfer to a target surface and methods for making the same are described. The substrate has a contacting surface with a beneficial component that is transferred from the contacting surface to a target surface during use of the article.... Agent: The Procter & Gamble Company Intellectual Property Division

20070116750 - Compositions for disrupting and inhibiting reconstitution of wound biofilm: Disclosed are compositions and methods for wound care, especially for treatment of chronic wounds. Compositions are methods are described for inhibiting reconstitution of biofilm in a chronic wound or preventing expansion of a biofilm in a chronic or acute wound.... Agent: Donna J. Russell

20070116749 - Method for treatment of cellulitis: A method of treating a patient having a skin infection comprises steps of: (i) covering the area of afflicted with infection with a dressing including an absorbent layer soaked in alcohol, such that the alcohol is in contact with the area of skin afflicted with infection; and (ii) keeping said... Agent: Svetlana Short Ny Center For Plastic Surgery

20070116751 - Medical active substance patch with reduced optical conspicuousness on the skin: A medical active substance patch comprising a matrix of monolayer or multilayer configuration with at least one active substance-containing layer and comprising a backing layer connected with the matrix. The active substance patch is transparent or at least translucent, and in the state of having been applied to the skin... Agent: D Peter Hochberg

20070116752 - Transdermal drug delivery device comprising extensor-relaxor means: A transdermal drug delivery device comprises a reservoir layer, which consists of one or more chambers for containing a drug. A lower surface of the reservoir layer is bounded by a resilient membrane, which is perforated by pores through which the drug may be delivered from the chambers. Connected to... Agent: Reinhart Boerner Van Deuren P.C.

20070116754 - Dissolution of arterial cholesterol plaques by pharmacological preparation: A pharmacological substance namely a biliary salt or acid or precursor or derivative with emulsifying properties administered into the systemic circulation of a patient via a variety of routes of administration including topical-mucous membrane such as sublingual, topical-dermatological such as via a skin patch, intravenous, subcutaneous, rectal, intramuscular, intradermal, inhalatory... Agent: Filiberto P. Zadini

20070116755 - Dissolution of arterial cholesterol plaques by pharmacological preparation: A pharmacological substance namely a biliary salt or acid or precursor or derivative with emulsifying properties administered into the systemic circulation of a patient via a variety of routes of administration including topical-mucous membrane such as sublingual, topical-dermatological such as via a skin patch, intravenous, subcutaneous, rectal, intramuscular, intradermal, inhalatory... Agent: Filiberto P. Zadini

20070116753 - Liposomes useful for drug delivery: The present invention provides liposome compositions containing substituted ammonium and/or polyanion, and optionally with a desired therapeutic or imaging entity. The present invention also provide methods of making the liposome compositions provided by the present invention.... Agent: Dla Piper Rudnick Gray Cary Us, LLP

20070116756 - Stable pharmaceutical compositions: A pharmaceutical dosage form, comprising an outer capsule containing at least one capsule, tablet, and/or particles comprising different drug substances.... Agent: Dr. Reddy's Laboratories, Inc.

20070116757 - Methylene blue derivatives: Pharmaceutical compositions comprising a fatty acid salt, a dicarboxylic acid salt, an alkyl sulfate salt, an aryl sulfate salt or an alkyl aryl sulfonate salt of methylene blue or a derivative of methylene blue are described herein. The compositions are preferably administered orally and can be administered as tablets, soft... Agent: Patrea L. Pabst Pabst Patent Group LLP

20070116758 - Atorvastatin formulation: Provided are atorvastatin compositions which reduce the effect of food on the bioavailability of atorvastatin and methods for making such compositions. Also provided are methods of reducing low density lipoprotein by administering the compositions of the invention.... Agent: Kenyon & Kenyon LLP

20070116762 - Compositions of stabilized ramipril in combination with another active agent: A pharmaceutical composition comprising ramipril, another active agent, and a blending agent, wherein in the ramipril is coated by the blending agent, and wherein the blending agent is glyceryl behenate, glyceryl stearate, stearyl alcohol, macrogol stearate ether, palmitosearate, ethylene glycol, polyethylene glycol, stearic acid, cetyl alcohol, lauryl alcohol, amylopectin, poloxymer... Agent: Jones Day

20070116761 - Novel formulations of pharmacological agents, methods for the preparation thereof and methods for the use thereof: In accordance with the present invention, there are provided compositions and methods useful for the in vivo delivery of substantially water insoluble pharmacologically active agents (such as the anticancer drug paclitaxel) in which the pharmacologically active agent is delivered in the form of suspended particles coated with protein (which acts... Agent: Morrison & Foerster LLP

20070116760 - Pharmaceutical compositions comprising meloxicam and methods of their preparation: The present invention encompasses a method of evaluating pharmaceutical compositions of meloxicam whereby one can correlate in vitro properties to in vivo properties, and pharmaceutical compositions developed using the method.... Agent: Kenyon & Kenyon LLP

20070116759 - Pharmaceutical compositions of telmisartan: The present invention provides a pharmaceutical composition of telmisartan comprising a) a telmisartan compound, b) a surfactant, c) a basic agent, and d) at least one diluent wherein the composition comprises less than 25% of water soluble diluents. The telmisartan compound is preferably present from about 12.5% to about 15.5%.... Agent: Kenyon & Kenyon LLP

20070116763 - Sustained release oral preparations: An object of the present invention is to provide a pharmaceutical preparation containing the drug as an active ingredient, which is capable of improving the QOL and the compliance of the patient who doses the drug while avoiding any excessive increase in the plasma level of the drug by means... Agent: Greenberg Traurig, LLP

20070116764 - Method for treatment of solid pharmaceutical preparation prior to printing and solid pharmaceutical preparation subjected to treatment prior to printing: The present invention provides a method for treating a solid dosage form to improve the printability and abrasion resistance of a print to be produced on a surface of the solid dosage form, which includes treating the surface of the solid dosage form with a polyethylene glycol-containing aqueous solution before... Agent: Foley And Lardner LLP Suite 500

20070116765 - Aqueous dispersion of hydrogel nanoparticles with inverse thermoreversible gelation: An aqueous dispersion of hydrogel nanoparticles and methods of making the aqueous dispersion of hydrogel nanoparticless having an interpenetrating polymer network (“IPN”) are described. The uniformed sized mono-disperse IPN nanoparticles have inverse thermo gelation properties that allow therapeutic medications to be uniformly distributed in a liquid form of the aqueous... Agent: T Ling Chwang Jackson Walker

20070116766 - Gel compositions as muscle tissue simulant and related articles and methods: Gel composition comprising thermoplastic block copolymer and oil suitable for use as simulants for body tissue, and methods related to the compositions.... Agent: Ganz Law, P.C.

20070116767 - Chitosan-microparticles for ifn gene delivery: The present invention provides particles comprising chitosan, or a derivative thereof, useful as delivery vehicles for polynucleotides encoding polypeptides, compositions comprising such particles and a pharmaceutically acceptable carrier, and methods for delivering polynucleotides using such particles. Optionally, the particles of the invention further comprise a lipid component. The present invention... Agent: Saliwanchik Lloyd & Saliwanchik A Professional Association

20070116769 - Continuous encapsulation process: The present invention relates to a process for coating of particles comprising the steps of: feeding particles to a coating unit wherein said particles are coated; directly transferring coated particles from the coating unit to a separator unit; separating finished coated particles from unfinished coated particles; removing the finished coated... Agent: Novozymes North America, Inc.

20070116773 - Metal nanostructures and pharmaceutical compositions: A metal nanostructure is described. Such a metal nanostructure may comprise a nanometric metal core comprising gold, silver or an assembly or alloy of gold and silver, and one or more molecules attached to one or more surfaces of the nanometric metal core, where each of the molecules has the... Agent: Mcdonnell Boehnen Hulbert & Berghoff LLP

20070116774 - Methods and compositions for treating proliferative diseases: The present invention provides combination therapy methods of treating proliferative diseases (such as cancer) comprising a first therapy comprising administering to an individual an effective amount of a taxane in a nanoparticle composition, and a second therapy which may include, for example, radiation, surgery, administration of chemotherapeutic agents, or combinations... Agent: Morrison & Foerster LLP

20070116771 - Nanoparticles for protein drug delivery: The invention discloses the nanoparticles composed of chitosan, poly-glutamic acid, and at least one bioactive agent characterized with a positive surface charge and their enhanced permeability for paracellular drug delivery.... Agent: Hosheng Tu

20070116772 - Nanoparticles for protein drug delivery: The invention discloses the nanoparticles composed of chitosan, poly-glutamic acid, and at least one bioactive agent characterized with a positive surface charge and their enhanced permeability for paracellular drug delivery.... Agent: Hosheng Tu

20070116776 - Particulate drug-containing products and method of manufacture: Provided is a compressed anti-solvent technique for manufacture of drug-containing powders for pulmonary delivery. The drug is processed in a cosolvent system including two or more mutually soluble organic solvents. Also provided are powders manufacturable by the manufacture method, including powders of substantially pure drug and powders including a biocompatible... Agent: Marsh, Fischmann & Breyfogle LLP

20070116775 - Plastic caviar bead for filling of pillow having function of anti-bacteria: The present invention relates to the plastic caviar bead for filling of pillow having function of anti-bacteria that combines the raw materials of synthetic resins of 100 in weight, antimicrobial of 0.5˜2 in weight, ceramic with hydrogen silicon and hydrogen aluminum of 3˜15 in weight that are pressed and corrected... Agent: Lee, Hong, Degerman, Kang & Schmadeka

20070116768 - Sustained release preparations composed of biocompatible complex microparticles: A particle includes a complex between a bioactive agent and a complexing agent, provided that the bioactive agent is other than a polynucleotide and an oligonucleotide, and wherein the particle has a bioactive function. The particle has a diameter from about 5 nm to about 100 microns. In certain embodiments,... Agent: Ratnerprestia

20070116770 - Tazobactam/piperacillin lyophilizate: The present invention relates to a lyophilizate which contains tazobactam and piperacillin, a process for the preparation of this lyophilizate, the use of this lyophilizate for the preparation of a drug, and drugs which comprise this lyophilizate.... Agent: Smith Patent Consulting Consulting, LLC

20070116777 - Ophthalmic preparation containing menthyl ester of indomethacin: There is provided an ophthalmic pharmaceutical preparation comprising menthyl ester of indomethacin as an active ingredient. Also provided are different possible formulations of the ophthalmic preparation, and different methods of treating ophthalmic irritation using the ophthalmic preparation.... Agent: Mccarthy Tetrault LLP

20070116778 - Antibacterial, antiviral, and antifungal nutritional supplement: a combination of natural or neutraceutical compounds shown to have antibacterial, antiviral, and antifungal properties, to help boost the immune system in humans, and to protect against cert: Certain compounds have been shown to provide antibacterial, antiviral, and antifungal properties. These compounds can provide some of the beneficial aspects of medicinal antibiotics without damaging or destroying beneficial bacteria in the human body. By combining these compounds into a single product in capsule form, an effective wide-spectrum natural ‘antibiotic’... Agent: Dr Arthur A. Fierro

20070116779 - Comprehensive nutraceutical agent for treatment/ prevention of parkinson's disease: This invention discloses a comprehensive nutraceutical designed to antagonize major mitigating factors specific to the degenerative process that occurs in Parkinson's disease (PD). The formulation is comprised of pyruvate, succinate and/or oxaloacetate further combined with specific macro/micronutrients, trace elements, amino acids, flavonoids and concentrated plant sources. The formula is based... Agent: Elizabeth Mazzio Florida A & M University

20070116780 - Composition comprising sodium, potassium, calcium and magnesium: The composition comprises a source of sodium, a source of potassium, a source of calcium and a source of magnesium, which consist of physiologically acceptable compounds of sodium, potassium, calcium and magnesium, soluble or dispersible in an aqueous medium, which in solution or dispersion in said aqueous medium provide ions... Agent: Michael Best & Friedrich LLP

20070116781 - Hydrogen cyanamide pesticide formulations: Agricultural crops are protected from the growth of undesirable vegetation as well as nematode and insect infestations, by the application of hydrogen cyanamide in combination with a short-chain, water-soluble monocarboxylic or polycarboxylic acid, the acid containing 1-3 carboxy groups and either no hydroxy groups or 1-3 hydroxy groups.... Agent: Townsend And Townsend And Crew, LLP

20070116782 - Use of rare earth compounds for the prevention of kidney stone disease: Conditions such as kidney stones, which are characterized by undesired absorption of oxalate from the intestinal tract are conveniently treated using nontoxic salts of rare earth metal ions.... Agent: Darby & Darby P.C.

20070116783 - Silver-based inorganic antibacterial agent dispersion: The invention provides a silver-based inorganic antibacterial agent dispersion that has excellent dispersibility and storage stability and allows the silver-based inorganic antibacterial agent to fully exhibit its antibacterial performance. Furthermore, it provides an antibacterial-processed product that is processed using this silver-based inorganic antibacterial agent dispersion. The silver-based inorganic antibacterial agent... Agent: Sughrue Mion, PLLC

20070116784 - Imatinib combinations for head and neck cancers: e

20070116785 - Nitric oxide as an anti-viral agent, vaccine and vaccine adjuvant: The invention relates to uses of nitric oxide gas to inactivate any whole, part or subunit of a microbe, such as a virus. Such an inactivated or attenuated virus after treatment with NO gas may be used in formulations for a vaccine. Nitric oxide may be administered directly to create... Agent: Sidley Austin Brown & Wood LLP (laip Group)

20070116786 - A lipidic extract from lepidium meynii and its effect on the libido: The present invention relates to compositions containing particular components that can be obtained from a plant which can have pharmaceutical applications. More particularly, the plant genus is Lepidium and the composition may contain in the range of between about 0.3% and 0.7% of benzyl isothiocyanate, b) between about 0.06% and... Agent: Townsend And Townsend And Crew, LLP

20070116787 - Cancer treatment: This invention relates to a method of treating cancer by administering to a subject in need thereof an effective amount of a mevalonate pathway inhibitor and an effective amount of an Antrodia camphorata extract.... Agent: Fish & Richardson PC

20070116788 - Method of enhancing motor function: This invention relates to a method for enhancing physical activities by administering catechins. The combined use of catechin ingestion and exercise makes it possible to promote the oxidation of fat and hence, to inhibit obesity, liver enlargement and diabetes.... Agent: Oblon, Spivak, Mcclelland, Maier & Neustadt, P.C.

20070116789 - Extracts of durian fruit for use in skin care compositions: The present invention relates to compositions comprising extracts of Durio zibethinus. The compositions of the present invention are useful for improving the appearance, texture, and/or moisture of mammalian skin. In particular, the compositions of the present invention decrease inflammation in the skin, inhibit matrix metalloprotease-9, which degrades skin proteins such... Agent: In Re: Alticor Inc. 28533 Brinks, Hofer, Gilson & Lione

20070110664 - Method and apparatus for synthesis of [11c] phosgen using concentrated [11c] carbon monoxide with uv light: Methods and systems for labeling synthesis of phosgen by UV light are provided. Methods of synthesizing labeled compounds useful as PET tracers from labeled phosgen are also provided. The resultant carbon-isotope labeled compounds are useful as radiopharmaceuticals, especially for use in Positron Emission Tomography. Associated kits for PET studies are... Agent: Ge Healthcare, Inc.

20070110666 - Methods for preparation of live body tissues for examination: A minimally invasive procedure for perfusion-impregnation of tissues, organs and cells is provided that aids in the retention of tissue and cellular architecture without the formation of artifacts. The procedure allows for monitoring drug disposition, for detecting diseased tissue and for monitoring the presence of target molecules in a sample... Agent: Klauber & Jackson

20070110667 - Radionuclide labeling of vitamin b12 and coenzymes thereof: m

20070110665 - Tissue marker for multimodality radiographic imaging: An implantable tissue marker incorporates a contrast agent sealed within a chamber in a container formed from a solid material. The contrast agent is selected to produce a change, such as an increase, in signal intensity under magnetic resonance imaging (MRI). An additional contrast agent may also be sealed within... Agent: Moore & Hansen, Pllp

20070110668 - Modulation of immunity and ceacam1 activity: The present technology comprises methods for regulating an the immune system, and in particular methods for the regulation of a specific immune response, including the regulation of lymphocyte activity. Methods of the present technology comprise both the negative and positive modulation of CEACAM1 protein function.... Agent: Mcandrews Held & Malloy, Ltd

20070110669 - Methods for in vivo evaluation of pulmonary physiology and/or function using nmr signals of polarized 129xe: In certain embodiments, methods of the present invention obtain dynamic data sets of an NMR spectroscopy signal of polarized 129Xe in a selected structure, environment, or system. The signal data can be used to evaluate: (a) the physiology of a membrane or tissue; (b) the operational condition or function of... Agent: Ge Healthcare, Inc.

20070110674 - Sono-active liposomes and lipid particles and use thereof as contrast agents and active-agent delivery systems: The present invention is directed to a novel class of gas filled liposomal delivery system particles, and to methods of making these particles, including the production of gas filled liposomal delivery system particles via chemical reaction to produce gas bubbles inside the particles. The present invention also includes: gas filled... Agent: Rosenbaum & Associates

20070110670 - Method for evaluating hair damage using an oxidized protein in hair as an indicator: The present invention provides a method for evaluating hair damage. The method comprises specifically labeling the carbonyl group of an oxidized protein in hair with fluorescence and detecting the fluorescence. The damage can be caused by any of perm treatment, bleach treatment, treatment with an oxidation hairdye, combing, heat treatment,... Agent: Snider & Associates

20070110671 - Sensitivity enhancement of poct devices using gold and silver nanoparticles on patterned substrates: The present invention relates to a substrate including a nanoparticle lattice having uniform interparticle spacing. A system includes a nanoparticle lattice including a ordered pattern of individual nanoparticles, wherein the lattice nanoparticles are assembled by affinity binding.... Agent: Agilent Technologies Inc.

20070110672 - Smmr (small molecule metabolite reporters) for use as in vivo glucose biosensors: Small Molecule Metabolite Reporters (SMMRs) for use as in vivo glucose biosensors, sensor compositions, and methods of use, are described. The SMMRs include boronic acid-containing xanthene, coumarin, carbostyril and phenalene-based small molecules which are used for monitoring glucose in vivo, advantageously on the skin.... Agent: Knobbe Martens Olson & Bear LLP

20070110673 - Allergen peptide fragments and use thereof: The present invention relates generally to in vivo methods and compositions designed for allergen specific immunotherapy. The compositions include contiguous overlapping peptide fragments which together form an entire amino acid sequence of an allergen.... Agent: Marshall, Gerstein & Borun LLP

20070110675 - Method for predicting the developmetn of allergic disease: The present invention relates to a method for improving the effectiveness of immunotherapy. In particular, the present invention relates to method for predicting the development of an allergic disease in a subject, comprising providing a biological sample; stimulating said sample with an allergen in vitro to produce one or more... Agent: Edwards & Angell, LLP

20070110676 - Compositions useful for prevention and treatment of common cold and influenza-like symptoms: The present invention is directed to compositions that are useful in the prevention and treatment of common cold and influenza-like symptoms due to respiratory tract viral infections. These compositions comprise a guaiacol component, and a mucoadhesive polymer wherein the pH of the composition is about 5.5 or less.... Agent: The Procter & Gamble Company Intellectual Property Division

20070110677 - Delivery of drugs to mucosal surfaces: Liquid pharmaceutical compositions for administration to a mucosal surface, including fentanyl and a pectin with a low degree of esterification are described. Such compositions gel, or can be adapted to gel, at the site of application in the absence of an extraneous source of divalent metal ions.... Agent: Akin Gump Strauss Hauer & Feld L.L.P.

20070110678 - Method for administration of tiotropium: A method for administration and preparation of pharmaceutical dry powder doses are disclosed. The metered dry powder doses are formed from a finely divided dry powder of an selected anticholinergic agent to be used in a dry powder inhaler device. The metered dry powder medicinal dose is arranged as a... Agent: Sughrue Mion, PLLC

20070110679 - Process for determining the particle size distribution of an aerosol and apparatus for carrying out such a process: The measurement of the particle size distribution of an aerosol is of crucial importance in pharmaceutical development. A prerequisite for this is a valid method, e.g. the cascade impactor method described in the pharmacopoeias. It requires measurement of the active substance concentration in order to determine the particle size distribution.... Agent: Michael P. Morris Boehringer Ingelheim Corporation

20070110681 - Flavor-stable dental devices: Flavor-stable, dental devices are coated with a flavor-absorbing, saliva soluble coating and packaged in unit-dose packaging with a flavor-compatible wrapping material, wherein said unit-doses are contained in a flavor-sealed dispenser that has been purged with an inert gas and fitted with a volatile flavor reservoir, prior to sealing, whereby said... Agent: Banner & Witcoff, Ltd.

20070110680 - Methods and compositions for controlling biofilm development: A method of cleaning or protecting surfaces by treatment with compositions comprising N-(3-oxododecanoyl)-L-homoserine lactone (OdDHL) blocking compounds and/or N-butyryl-L-homoserine lactone (BHL) analogs, either in combination or separately.... Agent: Lahive & Cockfield, LLP

20070110682 - Non-peroxide preparation for whitening natural and manufactured teeth: The present invention relates to compositions and methods for the whitening of natural and manufactured teeth without the use of peroxides or abrasives. The active ingredient in the present invention is “actinidin” (crude or purified) and is produced from kiwifruit. The present invention provides for the use of the compositions... Agent: Kevin Farrell Pierce Atwood

20070110684 - Morinda citrifolia-based oral care compositions and methods: Methods and formulations that utilize components of the Indian Mulberry plant, scientifically known as Morinda citrifola L., to treat one or more oral and dental disorders, including periodontal diseases such as gingivitis and periodontitis, tooth decay, halitosis, and other mouth disorders and irritations.... Agent: Michael F. Krieger Kirton & Mcconkie

20070110683 - Oral care formulation: An oral care formulation comprises disclosed ranges of proportions of Pycnogenol, Uncaria Tomentosa Extract, CoQ10, Stabilized Vitamin C, Green Tea Extract, flavorant, sweetener and water. The inventive formulation is applied within the oral cavity using any suitable applicator. The formulation is operative to reduce bad breath, gingivitis, gingival bleeding, plaque... Agent: H. Jay Spiegel - H. Jay Spiegel & Associates

20070110685 - Combination therapy for the treatment of immunoinflammatory disorders: The invention features a method for treating a patient diagnosed with, or at risk of developing, an immunoinflammatory disorder by administering a non-steroidal immunophilin-dependent immunosuppressant (NsIDI) and a Group A enhancer (e.g., antifungal agent, antigout agent, anti-infective agent, antiprotozoal agent, antiviral agent, humectant, sunscreen, vitamin D compound, microtubuline inhibitor, or... Agent: Clark & Elbing LLP

20070110686 - Peptide-based organic sunscreens: Peptide-based organic sunscreens, formed by coupling a skin-binding peptide with an organic sunscreen agent, are described. The skin-binding peptide part of the peptide-based organic sunscreen binds strongly to the skin, thus keeping the organic sunscreen agent attached to the skin for long lasting protection. Sunscreen compositions comprising the peptide-based organic... Agent: E I Du Pont De Nemours And Company Legal Patent Records Center

20070110687 - Antiperspirant compositions: An antiperspirant composition comprising a mixing product of at least one salt chosen from at least one aluminum salt, at least one aluminum-zirconium salt, at least one aluminum salt complex, and at least one aluminum-zirconium salt complex; at least one cosmetically acceptable hydroxy acid; and at least one cosmetically acceptable... Agent: Colgate-palmolive Company

20070110688 - Method of dermal protection: A method of dermal protection following contact between the skin and a composition containing a bipyridylium herbicide such as paraquat or diquat comprises incorporating an alginate in said composition.... Agent: Syngenta Crop Protection , Inc. Patent And Trademark Department

20070110689 - Oral anaesthetic gel: A gel-based anaesthetic, which is also palatable and can be used on mucosal surfaces, includes an anaesthetic in a transdermal gel-base having added flavoring with a bitterness suppressant. The gel base is preferably pluronic gel and the anaesthetic is preferably lignocaine.... Agent: Edwin D. Schindler

20070110691 - Process for inhibiting dyed hair fibers from losing their color during shampooing: A process for inhibiting dyed hair fibers from losing their color during shampooing involving contacting the dyed hair fibers with a composition containing: (a) at least one polyamine compound having at least two amino groups; (b) at least one anionic silicone; and (c) optionally, at least one surfactant, and wherein... Agent: Lerner, David, Littenberg, Krumholz & Mentlik

20070110690 - Process for inhibiting hair from becoming frizzy: A process for inhibiting hair fibers from becoming frizzy, involving contacting the hair fibers with a composition containing: (a) at least one polyamine compound having at least two amino groups; (b) at least one anionic silicone; (c) optionally, at least one surfactant; and (d) optionally, at least one film-forming polymer,... Agent: Lerner, David, Littenberg, Krumholz & Mentlik

20070110693 - Compositions containing peptide copper complexes and soft tissue fillers, and methods related thereto: Novel compositions for treating skin defects and effecting desired cosmetic changes by way of soft tissue augmentation, combine at least one soft tissue filler and at least one peptide copper complex. Typically, the compositions are suitable for injection into skin areas in need of such treatment. Also disclosed are methods... Agent: Seed Intellectual Property Law Group PLLC

20070110695 - Conditioning composition for hair: Present invention relates to aqueous conditioning composition for keratin fibres especially for hair, which provides hair long lasting, several hair washes, conditioning effect. Accordingly, present invention is a conditioning composition for hair which comprises at least one polydimethylsiloxane with a viscosity of maximum mm2/s at a concentration of 12.5% by... Agent: Norris, Mclaughlin & Marcus, P.A.

20070110694 - Leave-in hair conditioning compostion: Present invention relates to a non-aqueous leave-in conditioning composition for hair, especially for strongly damaged hair by chemical processes such as permanent shaping, oxidative colouration and bleaching. Accordingly, conditioning compositions of present invention comprise one or more cyclomethicone at a concentration of at least 50% by weight calculated to total... Agent: Norris, Mclaughlin & Marcus, P.A.

20070110696 - Shampoo containing a gel network and a non-guar galactomannan polymer derivative: Shampoo compositions comprise (a) from about 5% to about 50% of one or more detersive surfactants; (b) a dispersed gel network phase comprising: (i) at least about 0.05% of one or more fatty amphiphiles; (ii) at least about 0.01% of one or more secondary surfactants; and (iii) water; (c) at... Agent: The Procter & Gamble Company Intellectual Property Division

20070110697 - Cleansing composition based on oily substances: A cleansing composition based on oily substances, particularly for cleansing skin and/or hair and having excellent dermatological properties, is described. The composition is characterized in that it comprises one or more oily substances at a total concentration of between 10% and 90% by weight relative to the composition and one... Agent: Merchant & Gould PC

20070110698 - Regulation of epithelial tissue by hedgehog-like polypeptides, and formulations and uses related thereto: One aspect of the present application relates to a method for modulating the growth state of an epithelial cell by ectopically contacting the epithelial cell, in vitro or in vivo, with a hedgehog therapeutic or ptc therapeutic in an amount effective to alter the rate (promote or inhibit) of proliferation... Agent: Fish & NeaveIPGroup Ropes & Gray LLP

20070110699 - Use and application of defined zwitterionic copolymer: B represents a linear or branched C2-C12, polymethylene chain optionally interrupted by one or more heteroatoms or heterogroups, and optionally substituted by one or more hydroxyl or amino groups; X, which are identical or different, represent counterions; and (b) at least one hydrophilic monomer carrying a functional acidic group which... Agent: The Procter & Gamble Company Intellectual Property Division

20070110692 - Hair straightener composition: r

20070110700 - Shampoo containing a gel network: Shampoo compositions comprise (a) from about 5% to about 50% of one or more detersive surfactants, by weight of the shampoo composition; (b) a dispersed gel network phase comprising, by weight of the shampoo composition, (i) at least about 0.05% of one or more fatty amphiphiles; (ii) at least about... Agent: The Procter & Gamble Company Intellectual Property Division

20070110701 - Acyloxyacetic acid polymer and process for producing the same: wherein R1 and R2 are each independently a hydrogen atom or a linear or branched lower alkyl group; and n is an integer of not less than 5. In the preferred embodiment of the present invention, the acyloxyacetic acid polymer is produced by reacting a formaldehyde compound, carbon monoxide, and... Agent: Nixon & Vanderhye, PC

20070110702 - Liquid ester compositions and cosmetic compositions containing the same: The present invention provides a liquid ester composition which is obtained by esterifying a branched isostearic acid such as 2-(1,3,3-trimethyl)butyl-5,7,7-trimethyl octanoic acid with dipentaerythritol, and said liquid ester composition having a viscosity at 25° C. of 100,000 to 2,000,000 mPa·s; hydroxyl value of 10 to 160; and cloud point of... Agent: Buchanan, Ingersoll & Rooney PC

20070110703 - Molded shaving aid compositions, components and methods of manufacture: Razors and components thereof are provided, as well as methods of making such.... Agent: The Procter & Gamble Company Intellectual Property Division

20070110704 - Combination of 2,3-dibenzylbutyrolactone and licochalcone-a: Active ingredient combinations of (a) one or more 2,3-dibenzylbutyrolactone derivatives and (b) licochalcone A or an aqueous extract of Radix Glycyrrhizae inflatae containing licochalcone A.... Agent: Greenblum & Bernstein, P.L.C

20070110705 - Composition comprising urginea maritima or drimia maritima, laurus nobilis, adiantum capillus-veneris, and persea americana and its use against hair greasiness, hair loss and for promoting hair growth: A main active mixture in liquid form or powder or cream form, prepared by the plants urginea maritime or drimia maritime, laurus nobilis, adiantum capillus-veneris, persea americana and also by distilled distilled pure petroleum, appropriate for dermatological use. The above main active mixture can be mixed with any liquid soap... Agent: Christopher & Weisberg, P.A.

20070110707 - Method of treating diseases involving non-enzymatic glycation: Methods for preventing or diminishing non-enzymatic glycation as well as methods for treating diseases involving non-enzymatic glycation are disclosed. The methods involve administering to a patient an agent that decreases serum inorganic phosphate levels. The agent can be a carbonic anhydrase inhibitor diuretic agent or an agent that binds phosphate... Agent: Sonnenschein Nath & Rosenthal LLP

20070110706 - Treatment of hyperphosphatemia using crosslinked small molecule amine polymers: Anion-binding polymers are described. The anion-binding polymers in some cases are low swelling anion-binding polymers. In some cases, the anion-binding polymers have a pore volume distribution such that a fraction of the polymer is not available for non-interacting solutes above a certain percentage of the MW of the target ion... Agent: Wilson Sonsini Goodrich And Rosati / Ilypsa, Inc.

20070110708 - Silicon compounds and their use: A compound of formula (I) or formula (II) wherein the variables are as defined in the claims.... Agent: Saliwanchik Lloyd & Saliwanchik A Professional Association

20070110709 - Water-soluble stabilized self-assembled polyelectrolytes: The present invention is directed toward water-soluble supramolecular self-assemblies and a process for their preparation via micellization of polyelectrolytes through the use of hydrophobic monomeric units. In this invention the polyelectrolyte segment ultimately forms the core of the supramolecular assembly whereas the shell consists of uncharged hydrophilic polymers or oligomers.... Agent: Mchale & Slavin, P.A.

20070110711 - Agent for enhancing the production of cytokines and/or chemokines: The present invention has an object to provide a means to effectively enhance the production of cytokines and/or chemokines in mammals. The object is solved by providing an agent for enhancing the production of cytokines and/or chemokines, which comprises, as an effective ingredient, a polypeptide having any one of the... Agent: Browdy And Neimark, P.l.l.c. 624 Ninth Street, Nw

20070110712 - Method of modulating fertility in animals: The present invention relates generally to a method for controlling fertility and/or modulating the maintenance of pregnancy in animals. The present invention further provides an animal model useful for screening for therapeutic agents to treat infertility, to prevent or reduce spontaneous abortion and/or as contraceptive agents in animals.... Agent: Scully Scott Murphy & Presser, PC

20070110710 - Treatment with immunoregulatory t cells: Methods and compositions are provided for the treatment of an autoimmune disease. The methods include administering immunoregulatory T cells (Tregs) to patients. The therapeutic Tregs can express the CD25, CD4, and/or ICOS antigens. The therapeutic T cells can be CD25+ ICOS+, CD4+ICOS+, and/or CD25+ CD4+ ICOS+, and they can be... Agent: Fish & Richardson PC

20070110714 - Medicinal composition for treatment of chronic hepatitis c: The present invention provides a pharmaceutical composition for treating chronic hepatitis C characterized by comprising at least one active ingredient selected from the group consisting of IL-15, myeloid dendritic cell maturation stimulators (for example, CpG oligo deoxynucleotide, GM-CSF, IL-4, LPS, CD40L, polyI:C, TNF-a and IFN-?) and lectin-binding substances (for example,... Agent: Foley And Lardner LLP Suite 500

20070110713 - Novel multifunctional cytokines: The present invention relates to a novel fusion protein with the formula X—Y, or Y—X, wherein X represents a first immunoregulating polypeptide and Y represents a second immunoregulating polypeptide different from X. The present invention also relates to a nucleic acid molecule encoding such a fusion protein and a vector... Agent: Buchanan, Ingersoll & Rooney PC

20070110715 - Treatment of alzheimer's disease: The present invention. The invention relates to the use of interferon-β (IFN-β) for treating and/or preventing Alzheimer's disease (AD), Creutzfeld-Jakob disease (CJD) or Gerstmann-Sträussler-Scheinker disease (GSSD). It further relates to the use of IFN-β in combination with an Alzheimer's disease treating agent for treating and/or preventing Alzheimer's disease. The use... Agent: Saliwanchik Lloyd & Saliwanchik A Professional Association

20070110723 - Delivery of trefoil peptides: The present invention relates to a microorganism, preferably a bacterial strain, preferably a non-pathogenic strain, preferably a non-invasive strain, preferably a food grade strain, preferably a gram-positive bacterial strain, delivering a trefoil peptide in vivo. Preferably said trefoil peptide is TFF1. The present invention further relates to a method for... Agent: Howrey LLP

20070110717 - Dna vaccines against tumor growth and methods of use thereof: A DNA vaccine suitable for eliciting an immune response against cancer cells comprises a polynucleotide construct operably encoding an a Fra-1 protein, such as a polyubiquitinated human Fra-1 protein, and IL-18, such as human IL-18, in a pharmaceutically acceptable carrier. In a preferred embodiment, the polynucleotide construct is operably incorporated... Agent: Olson & Hierl, Ltd.

20070110724 - Duplexed parvovirus vectors: The present invention provides duplexed parvovirus vector genomes that are capable under appropriate conditions of forming a double-stranded molecule by intrastrand base-pairing. Also provided are duplexed parvovirus particles comprising the vector genome. Further disclosed are templates and methods for producing the duplexed vector genomes and duplexed parvovirus particles of the... Agent: Myers Bigel Sibley & Sajovec

20070110722 - Methods and compositions for the synthesis of rna and dna: Methods for the production of duplexes and single-stranded RNA and/or DNA of a desired length and sequence based on a novel template design which incorporates 2 polymerase promoters, primers, and production sequences within a single molecule are provided. This Single-stranded Template molecule design allows high-efficiency, high-yield production of single or... Agent: Demian Obregon

20070110719 - Novel use of adenoviruses and nucleic acids that code for said viruses: The present invention is related to the use of a virus, preferably an adenovirus, for the manufacture of a medicament, whereby the virus is replication deficient in cells which do not have YB-1 in the nucleus, and the virus codes for an oncogene or oncogene product, in particular an oncogene... Agent: Wood, Phillips, Katz, Clark & Mortimer

20070110721 - Plasmid maintenance: The invention relates to a system for stable maintenance of a plasmid, to host cells for use in this system and to methods of using the system to obtain a plasmid useful in medical applications. In particular, the invention provides transformed host cell containing: i) a chromosomal gene which inhibits... Agent: Woodcock Washburn LLP

20070110716 - Relationship of a specific metabolite to insulin resistance: Provided are methods and reagents for reducing ketone levels (for example, β-hydroxybutyrate) in skeletal muscle. Also provided are methods and reagents for treating insulin resistant states, such as diabetes. Further provided are screening methods for identifying compounds to reduce skeletal muscle ketone levels and/or to treat insulin resistance, for example,... Agent: Myers Bigel Sibley & Sajovec

20070110718 - System for treating and preventing breast cancer: The present invention is directed to a system for treating individuals at risk of or suffering from breast cancer. The system comprises administering to the individual a recombinant poxvirus, where the poxvirus contains in a foreign nucleic acid encoding at least one breast cancer antigen.... Agent: Ronald I Eisenstein Nixon Peabody

20070110720 - Vectors, mutant viruses and methods for generating mutant viruses: A nucleic acid vector comprising first and second nucleotide sequences corresponding to nucleotide sequences flanking an insertion site in the genome of a selected herpes simplex virus strain; and a cassette located between said first and second nucleotide sequences comprising nucleic acid encoding: (a) one or a plurality of insertion... Agent: Klarquist Sparkman, LLP

20070110736 - Buffer solution for electroporation and a method comprising the use of the same: The invention relates to a buffer solution for suspending animal or human cells and for dissolving biologically active molecules in order to introduce said biologically active molecules into the cells using an electric current and to a method for introducing biologically active molecules into animal or human cells using an... Agent: Mandel & Adriano

20070110733 - Compositions and methods for stem cell delivery: This invention provides compositions of matter, articles of manufacture and methods for delivering and/or affixing a stem cell to a target tissue. This invention also provides related nucleic acids, vectors, cell, methods of production, and kits.... Agent: Cooper & Dunham, LLP

20070110734 - Methods and compositions using cellular asialodeterminants and glycoconjugates for targeting cells to tissues and organs: The present invention is directed to methods for delivering cells to a target tissue in a mammal using glycoconjugate to traffic the cell to a desired organ in the mammal. The methods according to the present invention are especially applicable to administering lymphoid cells such as natural killer (NK) cells... Agent: Biotechnology Law Group C/o Portfolioip

20070110735 - Methods for regulating angiogenesis and vascular integrity using trk receptor ligands: The present invention relates to methods of inducing or inhibiting the angiogenic process and promoting vessel growth or stabilization in an organ by modulating the trk receptor pathway. The present invention also relates to a method for treating a pathological disorder in a patient which includes administering a trk receptor... Agent: Nixon Peabody LLP - Patent Group

20070110725 - Formulation and method for treating plants to control or suppress a plant pathogen: The present invention provides formulations and methods for controlling or suppressing bacterial or fungal plant pathogens, including Erwina amylovora the bacteria that causes fire blight. A formulation for controlling of suppressing a plant pathogen may include at least one beneficial species of bacteria, at least one beneficial species of fungi,... Agent: Woodard, Emhardt, Moriarty, Mcnett & Henry LLP

20070110726 - Rust disease control by aphanocladium album and/or beauveria brongniartii: There is disclosed a method and composition for controlling rust disease in plants. Metabolites produced by Aphanocladium album mycoparasites are recovered and applied in an effective amount to plants at risk for acquiring rust disease More specifically, the application of the metabolite converts infective urediniospores that cause rust disease into... Agent: Daniels Daniels & Verdonik, P.A.

20070110731 - Integument cell regeneration formulation: The invention relates to a composition-of-matter and method of using a topical composition having 10-99 999% by weight of a topical base formulation and other active ingredients including stem cell or growth factors and/or antioxidants, as well as others for the purpose of regenerating integument cells... Agent: Buckingham, Doolittle & Burroughs, LLP

20070110728 - Method for preventing and treating diabetes using dg119: The present invention relates generally to methods for preventing and/or treating pancreatic disorders, particularly those related to diabetes, by administering a DG119-1 product or a DG119-1 agonist and/or an antagonist To a DG 119-2 product.... Agent: Rothwell, Figg, Ernst & Manbeck, P.C.

20070110729 - Multipotent stem cells derived from human adipose tissue and cellular therapeutic agents comprising the same: This invention relates to human adipose tissue-derived multipotent adult stem cells. More particularly, the invention relates to human adipose tissue-derived multipotent stem cells, which can be maintained in an undifferentiated state for a long period of time by forming spheres and have high proliferation rates, as well as methods for... Agent: Intellectual Property / Technology Law

20070110730 - Multipotent stem cells from peripheral tissues and uses thereof: This invention relates to multipotent stem cells, purified from the peripheral tissue of mammals, and capable of differentiating into neural and non-neural cell types. These stem cells provide an accessible source for autologous transplantation into CNS, PNS, and other damaged tissues.... Agent: Philip Swain, Phd C/o Gowling Lafleur Henderson

20070110727 - Multipotent stem cells isolated from umbilical cord blood and the cellular therapeutic agent comprising the same for treating ischemic disease: The present invention relates to multipotent stem cells, adult stem cells isolated by culturing umbilical cord blood in a medium containing human serum or plasma, and a cellular therapeutic agent for ischemic necrosis resulting from occlusive arterial disease, which contains the multipotent stem cells as active ingredients. The multipotent stem... Agent: Intellectual Property / Technology Law

20070110732 - Use of synovium and omentum for tissue engineering: A method for treating a patient to repair or regenerate damaged tissues or organs in which synovium from a joint or omentum from the abdomen are harvested to provide explants, optionally separating cells from the synovium or omentum explants for culture or tissue specification, and introducting the explants or separated... Agent: Wilson Daniel Swayze, Jr.

20070110737 - Compositions and method for decreasing the appearance of skin wrinkles: Compositions which include platelet-rich plasma and fibroblast cells are disclosed for the treatment of skin. In particular, administration of platelet-rich plasma in a dermatologically acceptable carrier repeatedly to skin is disclosed to reduce the appearance of wrinkles.... Agent: Knobbe Martens Olson & Bear LLP

20070110738 - Receptor antagonists as therapeutic agents for inos generating illness: A treatment for SIRS, sepsis, severe sepsis and septic shock in a mammalian subject by utilizing a method and therapeutic agent for inhibiting the binding of particulate iNOS to cells. The agent takes the form of a cellular receptor antagonist.... Agent: Theodore J. Bielen Jr.

20070110739 - Wipe away pain: A topical composition for treating stings and insect bites effectively significantly reducing pain and/or eliminating it (wiping away pain, or WAP) is disclosed comprising a stabilized proteonaise, antibacterial/anti-microbial, a cooling agent, an anti-inflammatory agent, a debriding agent and an exfoliating agent.... Agent: Karambelas & Associates

20070110740 - Composition and methods for tissue preservation: The present invention provides for compositions and methods for the preservation of tissues and organs ex vivo and in situ. In addition, the present invention provides for kits that may be used in the preparation of the solutions of the present invention.... Agent: Medlen & Carroll, LLP

20070110741 - Single-wall carbon nanotube-egg white protein composite and preparation thereof: The present invention relates to single-wall carbon nanotube-egg white protein composite, an aqueous dispersion comprising the same and preparation method thereof. The EW-SWNT obtained by reacting single-wall carbon nanotubes with egg white protein under ultrasonication and centrifugation can be used in various fields in which well-preserved properties of isolated single-... Agent: Sughrue Mion, PLLC

20070110742 - Recombinant peptide vector comprising the gene for treatment for autoimmune diseases: The present invention provides a recombinant peptide vector comprising a leader peptide, linker DNAs and a DNA construct formed by operably linking expression control sequences with a therapeutic gene encoding a fusion protein where the extracellular domain of CTLA4 is bound to the Fc fragment of immunoglobulin, wherein the leader... Agent: Buchanan, Ingersoll & Rooney PC

20070110743 - Methods of protein production using anti-senescence compounds: Methods of producing a protein in cell culture comprising an anti-senescence compound, such as the antioxidant carnosine, are provided. According to teachings of the present invention, cells grown in a cell culture medium comprising an anti-senescence compound exhibit increased viability and productivity. Furthermore, cell cultures grown in the presence of... Agent: Choate, Hall & Stewart LLP

20070110745 - Antagonists of tweak and of tweak receptor and their use to treat immunological disorders: The present invention relates to reagents which modify the activity of TWEAK and their use as therapeutic agents for the treatment of immunological disorders.... Agent: Fish & Richardson PC

20070110744 - Lymphatic and blood endothelial cell genes: The invention provides polynucleotides and genes that are differentially expressed in lymphatic versus blood vascular endothelial cells. These genes are useful targets for treating diseases involving lymphatic vessels, such as lymphedeman, various inflammatory diseases, and cancer metastasis via the lymphatic system.... Agent: Marshall, Gerstein & Borun LLP

20070110746 - Pharmaceutical composition for treatment of immunological disorders: Disclosed is a pharmaceutical composition for treating immunological disorders by inhibiting the activation of T lymphocytes, comprising, as active ingredients, two or more selected from the group consisting of a substance capable of blocking binding of an MHC (Major Histocompatibility Complex) Class II molecule and a receptor thereof, a substance... Agent: Sheridan Ross PC

20070110747 - Binding agents: Compositions and methods relating to epitopes of sclerostin protein, and sclerostin binding agents, such as antibodies capable of binding to sclerostin, are provided.... Agent: Davis Wright Tremaine, LLP

20070110749 - Centrosome proteins and uses thereof: The invention includes nucleic acids and polypeptides that play important roles in centrosomes and cellular functions involving centrosomes. In addition, the invention encompasses antibodies, ribozymes, antisense nucleic acids, RNAis, and siRNAs that can be used to modulate the function of the nucleic acids and polypeptides of the invention. Such modulation... Agent: Fish & Richardson PC

20070110748 - Fibronectin binding protein compositions and methods of use: Disclosed are antibodies that block the binding of fibronectin protein to fibronectin. Also disclosed are site specifically-mutated and truncated peptide epitopes derived from the fnbA and fnbB genes of Staphylococcus aureus, the fnbA and fnbB genes of Streptococcus dysgalactiae, and the sfb gene of Streptococcus pyogenes, and nucleic acid segments... Agent: Stites & Harbison PLLC

20070110751 - Compositions and methods for reducing infarct size: Disclosed are compositions and methods for Disclosed are methods related to the use of Cdk2 inhibitors to reducing myocardial ischemic/reperfusion injury including but not limited to reduced infarct size. It is also disclosed that the same methods are equally appropriate for use in reducing injury following stroke including but not... Agent: Needle & Rosenberg, P.C.

20070110752 - Fibroblast growth factor receptors and methods for their use: Isolated fibroblast growth factor receptor 5 (FGFR5) polypeptides are provided, together with polynucleotides encoding such polypeptides. Also provided are modulators of FGFR5 gene expression and binding molecules that specifically bind to, and agonize or antagonize, FGFR5 polypeptide finction. Binding molecules include antibodies, and functional fragments thereof, as well as scFv... Agent: Speckman Law Group PLLC

20070110750 - Monoclonal antibodies specific for high molecular weight aggregation intermediates common to amyloids formed from proteins of differing sequence: Methods for the production of monoclonal antibodies specific to conformational epitope(s) of a prefibrilar aggregate(s) which contribute to amyloid fibril formation in human or animal subjects who suffer from amyloid diseases (e.g. Alzheimer's Disease) and the hybridomas and monoclonal antibodies produced therefrom. Also, the use of such monoclonal antibodies in... Agent: Stout Uxa Buyan & Mullins

20070110756 - Method for modulating p53 activity via methylation: The present invention relates to the modulation of p53 activity based upon the stabilization of p53 via methylation by Set9. Stabilization or destablization of p53 is useful in methods for modulating apoptosis and treating cancer, either alone or in combination with exogenous p53 or antineoplastic agents. Antibodies which specifically recognize... Agent: Jane Massey Licata Licata & Tyrrell P.C.

20070110753 - Therapeutic agents for solid tumors: A therapeutic agent for solid tumors, said agent comprising as an active ingredient, an antibody that specifically binds to a protein having the amino acid sequence as set forth in SEQ ID NO: 2 or an antibody fragment that maintains the antibody activity.... Agent: Foley And Lardner LLP Suite 500

20070110754 - Use of antagonist anti-cd40 antibodies for treatment of chronic lymphocytic leukemia: Methods of therapy for treating a subject for chronic lymphocytic leukemia are provided. The methods comprise administering a therapeutically effective amount of an antagonist anti-CN40 antibody or antigen-binding fragment thereof to a patient in need thereof. The antagonist anti-CD40 antibody or antigen-binding fragment thereof is free of significant agonist activity,... Agent: Alston & Bird LLP

20070110755 - Vascular endothelial cell growth factor antagonists: The present invention provides vascular endothelial cell growth factor (hVEGF) antagonists, including monoclonal antibodies, hVEGF receptors, and hVEGF variants that inhibit the mitogenic, angiogenic, or other biological activity of hVEGF. The antagonists thus are useful for the treatment of diseases and disorders characterized by undesirable or excessive endothelial cell proliferation... Agent: Genentech, Inc.

20070110757 - Antibody formulations having optimized aggregation and fragmentation profiles: The present invention provides methods of optimizing the production and purification of antibody formulations that immunospecifically bind to antigens of interest and are suitable for parenteral administration to a subject, which formulations exhibit increased stability due to reduced degradation and aggregation of the antibody component on long term storage. Such... Agent: Johnathan Klein-evans

20070110758 - Method for inhibiting bacterial colonisation: The present invention relates to a method for inhibiting bacterial colonisation of mucous epithelium in a biological system. The method includes the step of administering to the biological system an effective amount of a mucolytic agent and one or more of colostrum, hyperimmune milk, or a component of colostrum and/or... Agent: The Mccallum Law Firm, P. C.

20070110759 - Methods: The presence of aldehydic groups on proteins and lipoproteins is associated with various pathological conditions such as atherosclerosis, diabetes and alcoholic liver disease. Respiratory syncytial virus (RSV) is a major cause of severe respiratory disease in infants and the elderly. RSV vaccine research has been impeded because a formalin-inactivated vaccine... Agent: Nikolai & Mersereau, P.A.

20070110760 - Methods and compositions targeting viral and cellular itam motifs, and use of same in identifying compounds with therapeutic activity: This invention provides methods of treating, reducing the incidence of, and inhibiting metastasis formation of carcinomas, sarcomas, Epstein-Barr virus-induced malignancies, B cell proliferative disorders, and mast cell activation disorders, comprising administering to a subject a compound that inhibits an interaction of a first protein and an immunoreceptor tyrosine-based activation motif... Agent: Pearl Cohen Zedek Latzer, LLP Suite 1001

20070110765 - Helicobacter pylori bacterioferritin: A nucleic acid sequence encoding all or part of an 18-19 kDa Helicobater pylori protein is described to which immunoreactivity is detected in H. pylori negative individuals. A process for the production of a recombinant form of this protein and its use, particularly as a vaccine to provide immunological protection... Agent: Alisa A. Harbin, Esquire Head Of Global Patents, Vaccines And Diagnostics

20070110763 - Polypeptides of streptococcus pyogenes: The present invention relates to polypeptides of S. pyogenes which may be useful to prevent, diagnose and/or treat S. pyogenes infections.... Agent: Seed Intellectual Property Law Group PLLC

20070110762 - Process for preparing polysaccharide-protein conjugate vaccines: Methods for the manufacture of polysaccharide-protein conjugate vaccines at high yield are provided. The methods involve reaction of a hydrazide group on one reactant with an aldehyde group on the other reactant. The reaction proceeds rapidly with a high conjugation efficiency. Simplified purification processes can be employed to separate the... Agent: Knobbe, Martens, Olson & Bear, LLP

20070110761 - Protein purification means: Described is a novel purification tag, SNUT, based on the gene product of a sortase gene, in particular the srtA gene of Staphylococcus aureus and uses thereof. Also provided are expression constructs comprising DNA enoding the tag for the production of recombinant polypeptides. The tag can be used in methods... Agent: Drinker Biddle & Reath Attn: Intellectual Property Group

20070110766 - Proteinase k resistant surface protein of neisseria meningitidis: The identification of a highly conserved, immunologically accessible antigen at the surface of Neisseria facilitates treatment, prophylaxis, and diagnosis of Neisseria diseases. This antigen is highly resistant to Proteinase K and has an apparent molecular weight of 22 kDa on SDS-PAGE. Specific polynucleotides encoding proteins of this class have been... Agent: Seed Intellectual Property Law Group PLLC

20070110764 - Proteins with repetitive bacterial-ig-like (big) domains present in leptospira species: The invention relates to three isolated DNA molecules that encode for proteins, BigL1, BigL2 and BigL3, in the Leptospira sp bacterium which have repetitive Bacterial-Ig-like (Big) domains and their use in diagnostic, therapeutic and vaccine applications. According to the present invention, the isolated molecules encoding for BigL1, BigL2 and BigL3... Agent: Nixon & Vanderhye, PC

20070110767 - Circovirus sequences associated with piglet weight loss disease (pwd): The genome sequences and the nucleotide sequences coding for the PWD circovirus polypeptides, such as the circovirus structural and non-structural polypeptides, vectors including the sequences, and cells and animals transformed by the vectors are provided. Methods for detecting the nucleic acids or polypeptides, and kits for diagnosing infection by a... Agent: Foley And Lardner LLP Suite 500

20070110768 - Use of histones for the early diagnosis and/or preventive therapy of virally-infected living cells and a biochip for carrying out said diagnosis: The invention relates to a biologically-active agent, in particular, for the early diagnosis and/or preventative therapy of virally-infected living cells, the efficacy of which is selective for the cell membranes of the virally-infected cells, which are modified in a characteristic manner after viral infection. The agent includes at least one... Agent: Takeuchi & Kubotera, LLP

20070110769 - Clostridial toxin derivatives and methods for treating pain: Agents for treating pain, methods for producing the agents and methods for treating pain by administration to a patient of a therapeutically effective amount of the agent. The agent can include a clostridial neurotoxin, or a component or fragment or derivative thereof, attached to a targeting moiety, wherein the targeting... Agent: Allergan, Inc.

20070110770 - Apolipoprotein e as an adjuvant for lipid antigens: The present invention is directed to pharmaceutical compositions that contain a combination of apolipoprotein E and an antigenic lipid. The compositions may be administered to a subject for the purpose of inducing an immune response against the lipid and in immunization protocols.... Agent: Wolf Greenfield & Sacks, PC

20070110771 - Immunogenic agent and pharmaceutical composition for use against homologous and heterologous pathogens: The present invention relates to an immunogenic agent comprising a low dose of an antigenic component from one or more pathogens and an agent capable of increasing an amount of IL-12 in animal, and use thereof for reducing infection or improving recovery from an infection from the pathogen. The immunogenic... Agent: Leydig Voit & Mayer, Ltd

20070110772 - Vaccines for blocking transmission of plasmodium vivax: The present invention relates novel methods and compositions for blocking transmission of Plasmodium vivax which cause malaria. In particular, Pvs25 and Pvs28 polypeptides, variants, including deglycosylated forms, and fusion proteins thereof, are disclosed which, when administered to a susceptible organism, induce an immune response against a 25 kD and 28... Agent: Townsend And Townsend And Crew, LLP

20070110773 - Composition of restricted cancer cells which produce cancer cell proliferation suppressive materials, and uses thereof: Compositions of matter are described which contain restricted cancer cells. When so restricted, the cells produce an unexpectedly high amount of material which suppresses cancer cell proliferation. The phenomenon crosses cancer type and species lines. Processes for making these compositions, and their use, are also described.... Agent: Fulbright & Jaworski, LLP

20070110774 - Composition of restricted cancer cells which produce cancer cell proliferation suppressive materials, and uses thereof: Compositions of matter are described which contain restricted cancer cells. When so restricted, the cells produce an unexpectedly high amount of material which suppresses cancer cell proliferation. The phenomenon crosses cancer type and species lines. Processes for making these compositions, and their use, are also described.... Agent: Fulbright & Jaworski, LLP

20070110776 - In vitro methods for evaluating the in vivo effectivness of dosage forms of microparticulate or nanoparticulate active agent compositions: Disclosed are in vitro methods for evaluating the in vivo redispersibility of dosage forms of poorly water-soluble active agents. The methods utilize media representative of in vivo human physiological conditions.... Agent: Elan Drug Delivery, Inc. C/o Foley & Lardner LLP

20070110775 - Phospholipid gel compositions for delivery of aptamers and methods of treating conditions using same: The present invention relates to pharmaceutical compositions in the form of a gel for controlled- or sustained-release of an aptamer and to methods for treating or preventing a condition in an animal by administering to an animal in need thereof the pharmaceutical compositions.... Agent: Kenyon & Kenyon LLP

20070110778 - Method for improving the appearance of skin and topical compositions for practicing same: The present invention relates to novel topical compositions that are useful to enhance the overall appearance of the skin, such as reducing the appearance of fine lines and wrinkles. The present invention, which in brief summary, is a topical cosmetic composition having a spherical and/or substantially spherical optical diffuser particle... Agent: Charles J. Zeller, Esq. Avon Porducts Inc.

20070110777 - Method for loading amphiphile particles with active agents: The present invention provides a method for the production of amphiphile particles having incorporated therein at least one active agent. The method comprises forming a dispersion of particles comprising at least one amphiphilic structuring agent in a solution of at least one active agent, heating said dispersion to an elevated... Agent: Nixon & Vanderhye, PC

20070110779 - Activated peroxide solutions and a process for the preparation thereof: The present invention discloses an activated biocidal aqueous solution containing hydrogen peroxide (activated peroxide solution) obtainable by subjecting an initial solution of hydrogen peroxide in water to a non-thermal electrical discharge process, such as a glow discharge plasma or a corona discharge. The resulting activated peroxide solution has a pH... Agent: Oliff & Berridge, PLC

20070110781 - Antimicrobial article for use in medical environment: A medical bed article includes one or more components having an antimicrobial agent disposed therein or affixed thereto. Components can include a headboard, footboard, side rail, or other frame member, as well as cladding on such member. The bed components can be constructed of a metal or a polymeric material.... Agent: Cliff D. Weston

20070110780 - Building material surface treatment biocide, and method for treatment of building material surfaces: A building surface treatment biocide is provided for the treatment of offending bacteria, fungi, mycelium, spores and proteins on surfaces of common building materials, such as residential and commercial dwellings, office space, public schools, government buildings, modular buildings, and transportation systems. According to an embodiment of the invention, the biocide... Agent: Berenato, White & Stavish, LLC

20070110783 - Controlled release product and method for the production thereof: A controlled release product and a method for producing the controlled release product. The product includes a substrate material for release to a surrounding environment and a composition coating the substrate material in a coating layer for providing a controlled release of the substrate material. The composition includes a matrix... Agent: Rodman Rodman

20070110782 - L-histidine in ophthalmic solutions: The invention relates to an aqueous ophthalmic solution comprising 0.00001 to about 10.0 percent by weight L-histidine, 0.0001 to 3.0 percent by weight hydrogen peroxide, and optionally 0.1 to 500 parts per million of a preservative that provides superior preservative efficacy especially as against fungal microbes. These solutions may be... Agent: Hiscock & Barclay, LLP

20070110786 - Medical articles having enhanced therapeutic agent binding: According to an aspect of the present invention, medical articles are provided which comprise the following (a) a polymeric region having a first charge, and (b) a charged therapeutic agent having a second charge that is opposite in sign to that of the first charge. In certain beneficial embodiments, the... Agent: Mayer & Williams PC

20070110785 - Medical devices with proteasome inhibitors for the treatment of restenosis: Methods, compositions and devices for inhibiting restenosis are provided. Specifically, proteasome inhibitor compositions and medical devices useful for the site specific delivery of proteasome inhibitors are disclosed. In one embodiment the medical device is a vascular stent coated with a proteasome inhibitor selected from the group consisting of a boronic... Agent: Medtronic Vascular, Inc.IPLegal Department

20070110784 - Thermally reversible implant: The invention relates to the use of a thermal reversible gel, such as a copolymer composition, as a biological filler or implant. The gel has a semi-solid form at body temperature, but upon cooling to a temperature below a threshold level, the gel is liquefied and can be re-shaped, re-sized,... Agent: Borden Ladner Gervais LLP

20070110787 - Stent coatings incorporating nanoparticles: Coatings for implantable medical devices including nanoparticles incorporating an active agent, and methods for fabricating the coatings.... Agent: Squire, Sanders & Dempsey LLP

20070110788 - Injectable formulation capable of forming a drug-releasing device: The present invention relates to an injectable formulation comprising an active substance and capable of releasing a therapeutically effective amount of said active substance, wherein said formulation is made of a formable material designed to adapt and conform to the shape of at least a part of a cavity of... Agent: Dicke, Billig & Czaja, P.l.l.c.

20070110789 - Isoflavone compositions for reducing accumulation of body fat in male mammals, and methods for their use: Edible compositions useful for weight management in male animals are disclosed. The compositions comprise one or more isoflavones or isoflavone metabolites and are particularly useful for reducing or preventing the accumulation of body fat. Also disclosed are methods useful for weight management in an animal utilizing compositions comprising one or... Agent: Drinker Biddle & Reath Attn: Intellectual Property Group

20070110791 - Cleansing lotion with moisturising, protecting and odor controlling agents and cloth comprising said lotion: The invention relates to a soothing lotion, which cleanses, moisturizes and protects the skin and controls odor from feces and urine on skin. The invention also relates to a cloth comprising said lotion.... Agent: Jacobson Holman PLLC

20070110792 - Cosmetic or dermatological article comprising a medium that is soluble in water: A cosmetic or dermatological article may include: a medium in the form of at least one sheet of a material that is soluble in water at a temperature lower than 20° C.; and at least one cosmetic or dermatological compound carried by the medium.... Agent: Oliff & Berridge, PLC

20070110794 - Delivery system for topical medications: The present invention is a delivery system comprising a pad and a liquid composition, comprising an insoluble dermatologically active ingredient with a viscosity that permits substantially uniform absorption of the composition onto the pad, and the pad is in then packaged in a sealed container.... Agent: Reed Smith LLP

20070110793 - Disintegrating digestive tract barrier: A digestive tract barrier is provided that includes a material defining dimensions of a tube, said tube sized to deploy within the digestive tract of a subject. The material or stitches that make up the barrier disintegrate in a controlled manner. The disintegration precludes the need for a surgical procedure... Agent: Gifford, Krass, Sprinkle,anderson & Citkowski, P.c

20070110790 - Steam-generating warming article: A steam-generating warming article 1 which has a steam generating element 2 making use of chemical energy and is adapted to supply steam while in contact with a human body. The article 1, while in contact with the body, maintains the skin surface temperature at 38° to 49° C. for... Agent: Oblon, Spivak, Mcclelland, Maier & Neustadt, P.C.

20070110795 - Use of chitosan materials: The invention relates to the use of a biocompatible material based on chitosan and an acid, e.g. as flexible film or/and porous matrix, as remedy in the area of neurosurgery, in particular as nerve splint, and for repairing tendons and ligaments.... Agent: Rothwell, Figg, Ernst & Manbeck, P.C.

20070110796 - Devices and methods for reducing scar tissue formation: Disclosed is a cytostatic drug attached to a sterile sheet that is designed to be placed between internal body tissues to prevent the formation of post-operative adhesions, which adhesions are really scar tissue formation. This sheet onto or into which the drug is placed may be either a permanent implant... Agent: Medlen & Carroll, LLP

20070110797 - Methods and compositions for topical wound treatment: Wound Dressings for improved treatment of wounds on a patient. A wound dressing having a bandage and a healing composition. The healing composition includes from about 5 mg to about 40 mg lidocaine hydrochloride per gram of the healing composition, from about 250 units to about 2000 units polymyxin B... Agent: Dinsmore & Shohl, LLP

20070110798 - Liposomes useful for drug delivery to the brain: The present invention provides liposome compositions containing substituted ammonium and/or polyanion, and optionally with a desired therapeutic or imaging entity. The present invention also provide methods of making the liposome compositions provided by the present invention. The present invention also provides for the methods and kits for the delivery of... Agent: Dla Piper US LLP

20070110799 - Film-forming starchy composition: A film-forming starchy composition for the film-coating of solid forms or the preparation of films. The inventive composition has an amylose content of between 25 and 45%, preferably between 30 and 44% and still more preferably between 35 and 40%, the percentages being expressed by dry weight in relation to... Agent: Young & Thompson

20070110800 - Pharmaceutical composition having uniform drug distribution and potency: Pharmaceutical compositions having uniform drug distribution and potency utilizing laxofoxifene as an active ingredient and containing a silicon dioxide to reduce loss of the active ingredient during the manufacturing process and methods for manufacturing such compositions are disclosed.... Agent: Pfizer Inc.

20070110801 - Method for the diffusion of molecules which are insoluble in an aqueous medium and composition using said method: The object of the invention is a process for diffusion of lipophilic molecules in an aqueous medium, in particular derivatives of the aryl-carboxylic family for the treatment of buccopharyngeal ailments, molecules with anti-inflammatory, anti-mycotic, central action analgesic or anti-allergic activity, characterized in that it consists in resorting to salts of... Agent: Young & Thompson

20070110802 - Wet granulation process: The present invention relates to a process of wet granulation, and specifically wet granulation of material that is susceptible to convert from anhydrous form to hydrate form.... Agent: Amgen Inc.

20070110803 - Pharmaceutical formulation comprising levothyroxine sodium: There is provided a stable pharmaceutical formulation comprising (a) an effective amount of levothyroxine sodium, (b) microcrystalline cellulose which has a mean particle size of less than 125 μm and is present in an amount of 60 to 85% w/w based upon the total weight of the formulation, and (c)... Agent: Glaxosmithkline Corporate Intellectual Property, Mai B475

20070110804 - Drug polymer complexes: This invention relates to polymeric complexes of drugs to be employed as (or in) sustained release-formulations comprising a cationic active agent, and a polyanionic water soluble complexing polymer of sufficient molecular weight that it forms a gel when mixed with said active agent. The invention also relates to the manufacture... Agent: Nixon & Vanderhye, PC

20070110805 - Modified-release pharmaceutical compositions: This invention is directed generally to modified-release pharmaceutical compositions, and, more particularly, to modified-release anesthetic- or analgesic-comprising pharmaceutical compositions that are bioadherent to a vaginal cavity surface, vulva surface, or skin. This invention also is directed generally to methods for preparing such compositions, methods of treatment using such compositions, uses... Agent: Harness, Dickey, & Pierce, P.l.c

20070110806 - Controlled-release pharmaceutical composition and method for producing the same: It is an object of the present invention, in the case of a controlled-release pharmaceutical composition, particularly a pulsed-release pharmaceutical composition, containing an acid-unstable physiologically active substance, to provide a pharmaceutical composition having little variation in dissolution lag time and high reliability of dissolution characteristics. The present invention discloses a... Agent: Nixon & Vanderhye, PC

20070110807 - Delayed release tablet with defined core geometry: A press-coated tablet comprising a core containing an drug substance, and a coating, the core being disposed within the coating such that the coating has a first thickness about an axis A-B and a thickness about an orthogonal axis X-Y, such that the coating about the axis X-Y is thicker... Agent: Mintz, Levin, Cohn, Ferris, Glovsky And Popeo, P.C.

20070110808 - Extended release osmo-microsealed formulation: The extended release osmo-microsealed formulation includes three controlled release systems associated in series. First, there is an inner solid particulate phase containing Venlafaxine Hydrochloride (Active), and one or more hydrophobic polymers, one or more diluents required to increase the bulk one or more osmogen (agents which can generate osmotic pressure... Agent: Egbert Law Offices

20070110811 - Methods for reducing the mitogenicity of lectin compositions: Methods for reducing the T-cell mitogenicity of lectin compositions are provided. In one aspect this is achieved by chemically modifying mitogenic lectin compositions under optimized conditions. Additionally or alternatively, the reduction in T-cell mitogenicity is achieved by removing unmodified subunits chemically modified mixtures. Modified lectin compositions with reduced T-cell mitogenicity... Agent: Choate, Hall & Stewart LLP

20070110809 - Stabilised compositions: This invention relates to the stabilization of a bacterial ADP-ribosylating exotoxin class protein (bARE), a method for analysing a bARE class protein, a method for the stabilization of the bARE class bacterial protein, compositions comprising a stabilized bARE protein, compositions comprising a substantially integral bARE class protein and immunogenic composition... Agent: Novartis Vaccines And Diagnostics Inc.

20070110810 - Transdermal drug delivery systems, devices, and methods employing hydrogels: Systems, devices, and methods for transdermal delivery of one or more therapeutic active agents to a biological interface. An iontophoretic drug delivery system is provided for transdermal delivery of one or more therapeutic active agents to a biological interface of a subject. The iontophoretic drug delivery system includes at least... Agent: Seed Intellectual Property Law Group PLLC

20070110812 - Ophthalmic composition for dry eye therapy: Disclosed in embodiments are gel formulations which are not subject to the settling out phenomena that may be observed with Loteprednol etabonate suspensions.... Agent: Bausch & Lomb Incorporated

20070110814 - Bioconjugates comprising sulfated polysaccharides and their uses: The present invention provides bioconjugates comprising a sulfated polysaccharide such as alginate sulfate and hyaluronan sulfate and at least one bioactive polypeptide capable of binding a sulfate group of said sulfated polysaccharide. The bioactive polypeptide can be a heparin-binding polypeptide and/or a positively-charged polypeptide. Also, provided are delivery systems and... Agent: Browdy And Neimark, P.l.l.c. 624 Ninth Street, Nw

20070110813 - Polycation-polyanion complexes, compositions and methods of use thereof: One aspect of the present invention relates to compositions and methods comprising polyelectrolyte molecules for treating patients who have certain diseases. Aspects of the invention relate to using certain polyelectrolyte compositions in therapy. According to the invention polyelectrolyte compositions may be used, for example, to slow or stop cell growth,... Agent: Foley Hoag, LLP Patent Group, World Trade Center West

20070110815 - Micronised azodicarbonamide, and the preparation and use thereof: Azodicarbonamide (ADA) in the form of a micronised dry powder, said powder having a granulometric distribution of particles wherein the particles of the powder have a mean diameter (d50) equal to or less than 2 μm and a 90% diameter (d90) equal to or less than 4 μm.... Agent: Dykema Gossett PLLC

20070110816 - Method of coating nanoparticles: Disclosed herein is a method of coating nanoparticles with a metal oxide. The method includes substituting surfaces of hydrophobic nanoparticles with an organic substance having a hydrophilic group effective to render the nanoparticles hydrophilic; and injecting the hydrophilic nanoparticles and a precursor of the metal oxide into an organic solvent... Agent: Cantor Colburn, LLP

20070110817 - Biological active blood serum obtained by electrostimulation: The present invention relates to a method for preparing a blood serum product, the blood serum product and a pharmaceutical composition comprising said blood serum product as well as uses thereof in the treatment of various diseases and conditions, including epileptic seizures and apoplexy.... Agent: Leydig Voit & Mayer, Ltd

20070110818 - Milk fractions and milk preparations for treating and/or preventing cox-2 mediated diseases: The present invention pertains to nutritional and pharmaceutical compositions for treating and preventing cyclooxygenase-2 mediated diseases and to a process for increasing the cyclooxygenase-2 inhibiting activity of a product. In addition thereto, the present invention relates to the use of one ore more milk protein fractions and/or one ore more... Agent: Bell, Boyd & Lloyd LLP

20070110820 - Bone matrix compositions and methods: An osteoinductive composition, corresponding osteoimplants, and methods for making the osteoinductive composition are disclosed. The osteoinductive composition comprises osteoinductive factors, such as may be extracted from demineralized bone, and a carrier. The osteoinductive composition is prepared by providing demineralized bone, extracting osteoinductive factors from the demineralized bone, and adding the... Agent: Dorsey & Whitney LLP Intellectual Property Department

20070110819 - Composite structures containing hyaluronic acid the derivatives thereof as new bone substitutes and grafts: A composite material comprising: (i) hyaluronic acid and/or hyaluronic acid derivatives, (ii) demineralised bone and/or biocompatible partially or totally demineralised bone tissue matrix and/or biocompatible and bioresorbable ceramic materials. This material preferably associated with at least one layer comprising a hyaluronic acid derivative may be used in the preparation of... Agent: Clark & Elbing LLP

20070110822 - Use of an aqueous solution in the treatment of live animals: This invention relates to a composition for use in the treatment of pathogenic microorganisms in a live animal, the composition comprising an electro-chemically activated, anion-containing aqueous solution.... Agent: Fellers Snider Blankenship Bailey & Tippens

20070110821 - Use of xenon for treating neurointoxications: Methods for treating mammals for neurointoxication are provided comprising treating the mammal with a xenon-containing gas. Methods of providing neuroprotection in mammals are also disclosed comprising administering therapeutically effective amounts of xenon, preferably in combination with pharmaceutically acceptable carriers, diluents or excipients.... Agent: Lerner, David, Littenberg, Krumholz & Mentlik

20070110823 - Sintered bioactive ceramic composite implant and preparation thereof: A sintered bioactive ceramic composite for implant having high strength and superior bioactivity and a method of preparing the same are provided. The composite includes a zirconia-alumina nano-composite-powder and an apatite-related compound and is useful for a load-bearing implant.... Agent: Mckenna Long & Aldridge

20070110824 - Biocidal ceramic compositions, methods and articles of manufacture: The present invention provides biocidal ceramic compositions incorporating a bioactive ionic species that is chemically bound in a substantially single-phase, crystalline, [NZP]-type structure, methods for producing the crystalline structures, and articles of manufacture incorporating the crystalline structures, and uses of the articles of manufacture. Bioactive ionic species can be, but... Agent: Sara D. Jones Workman Nydegger

20070110825 - Antimicrobial zeolite and antimicrobial resin composition: The present invention herein provides antimicrobial zeolite which hardly causes any color change with the elapse of time even when it is incorporated into a resin to form an antimicrobial resin composition. The present invention thus relates to antimicrobial zeolite which comprises zeolite whose ion-exchangeable ions are partially or wholly... Agent: Nixon & Vanderhye, PC

20070110826 - Composition and methods for inhibiting the progression macular degeneration and promoting healthy vision: The present invention provides improved dietary supplements and methods for inhibiting the progression of macular degeneration and promoting healthy vision. The dietary supplements of the invention contain cobeadlets comprising vitamin E and carotenoids in the form of Vitamin A, lutein and/or zeaxanthing. The dietary supplements of the invention further contain... Agent: Alcon Research Teresa J Schultz

20070110827 - Pharmaceutical compositions for the administration of aptamers: Pharmaceutical compositions comprising an aptamer and an amino acid ester or amide or an aptamer; a divalent metal cation; and a carboxylic acid, a phospholipid, a phosphatidyl choline, or a sphingomyelin. Methods of treating or preventing a condition in an animal comprising administering to the animal the pharmaceutical compositions.... Agent: Kenyon & Kenyon LLP

20070110828 - Use of nf-kb inhibition in combination therapy for cancer: The use of NF-κB inhibitors to enhance the cytotoxic effects of chemotherapy or radiation therapy in the treatment of neoplastic conditions is described.... Agent: Kenneth D. Sibley Myers Bigel Sibley & Sajovec

20070110829 - Process for metabolic control and high solute clearance and solutions for use therein: The present disclosure describes novel standardized citrate replacement fluid solutions and a standardized dialysate solution for use with CRRT methods. The standardized citrate replacement fluid solutions and standardized dialysate solutions do not require modification based on the clinical status of the individual patients. The use of the standardized solutions described... Agent: Bradley Arant Rose & White, LLP Intellectual Property Department-nwj

20070110830 - Opposing blood group antibodies, foodstuffs and dietary supplements: A dietary supplement comprises substances selected so as not to trigger a blood type antibody response. A method of improving health of an individual comprises determining an individual's blood antigenicity and providing to said individual ingestible substances non-reactive to said blood antigenicity.... Agent: Stephen P. Mcnamara St. Onge Steward Johnston & Reens LLC

20070110831 - Plant-based formulations for improving liver health: The present invention is directed to plant based formulations for improving liver health by protecting the liver from alcohol and chemical insults and/or by inducing phase II enzymes. Formulations according to the present invention include wasabi root fiber powder, artichoke leaf extract, asparagus dehydrate, kudzu root extract, oregano extract, schisandra... Agent: Alticor Inc.

20070110832 - Scutellaria barbata extract for the treatment of cancer: An extract of Scutellaria barbata D. Don is effective in the arrest of cancer cell growth in the G1 phase, the induction of apoptosis in cancer cells and the shrinking of solid cancers. The extract may be prepared as a pharmaceutical composition for administration to mammals for the treatment of... Agent: Wilson Sonsini Goodrich & Rosati

20070110833 - Composition comprising the alcohol compound isolated from the extract of cucurbitaceae family plant having anti-adipogenic and anti-obesity activity: The present invention is related to an extract of Cucurbitaceae family plant or the purified extract isolated therefrom having anti-adipogenic and anti-obesity activity, and a composition comprising the same. The extract of Cucurbitaceae family plant of the present invention showed potent reducing activity of body weight, decreasing effect on the... Agent: Kirk Hahn

20070110834 - Composition comprising the alcohol compound isolated from the extract of cucurbitaceae family plant having anti-adipogenic and anti-obesity activity: The present invention is related to an alcohol compound isolated from the extract of Cucurbitaceae family plant having anti-adipogenic and anti-obesity activity, and a composition comprising the same. The compound showed potent reducing activity of body weight, decreasing effect on the blood triglyceride and cholesterol level, activating activity of PPAR... Agent: Kirk Hahn

20070110835 - Method for the production of enriched hop extracts having combined oestrogenic and antiproliferative bioactivity: The present invention relates to a method for the production of a hop extract which is enriched in 8-prenylnaringenin with respect to 6-prenylnaringenin, which method comprises the steps of subjecting a hop product to (1) an isomerisation reaction in the presence of water as a solvent and in the presence... Agent: Dykema Gossett PLLC

20070104645 - Chelate based scaffolds in tumor targeting: This invention relates to novel complexes that can be used to target tumor cells. The complexes include a ligand that can bind metal ions including radioactive lanthanide ions. The complexes can mimic ανβ3 integrin receptor antagonists and deliver the complexed radioactive metals to the tumor cells.... Agent: Woodard, Emhardt, Moriarty, Mcnett & Henry LLP

20070104644 - Inhibitor imaging agents: The present invention discloses that imaging agents which comprise a specific type of matrix metalloproteinase inhibitors (MMPi's) of the sulphonamide hydroxamate class labelled with an imaging moiety, are useful diagnostic imaging agents for in vivo imaging and diagnosis of the mammalian body.... Agent: Ge Healthcare, Inc.

20070104646 - Stabilized and lyophilized radiopharmaceutical agents: A novel method is set out of preparation of radioactive diagnostic radiopharmaceutical in a stable, shippable, lyophilized form by an apparatus designed to rapidly flash freeze and dehydrate a radiopharmaceutical composition to minimize auto radiolysis. The method proposes rapid cooling and removal of ambient vapor, and then ultra cold removal... Agent: Brooke Schumm Iii

20070104647 - Ovr115 antibody compositions and methods of use: The invention provides isolated anti-ovarian, pancreatic, lung or breast cancer antigen (Ovr115) antibodies that bind to Ovr115 on a mammalian cell in vivo. The invention also encompasses compositions comprising an anti-Ovr115 antibody and a carrier. These compositions can be provided in an article of manufacture or a kit. Another aspect... Agent: Licata & Tyrrell P.C.

20070104648 - Compositions, methods of preparing amino acids, and nuclear magnetic resonance spectroscopy: The present invention relates to amino acids, complexes, and compounds comprising deuterium and tritium isotopes preferably alpha deuterated amino acids, polypeptides, antibodies, derivatives and saccharide-amino acid complexes and conjugates. In some embodiments, the invention relates to methods of using compounds comprising deuterium for imaging biochemical concentrations and distributions in mammalian... Agent: Peter G. Carroll Medlen & Carroll, LLP

20070104650 - Method of off-resonance detection using complementary mr contrast agents: Off-resonance imaging uses two complementary contrast agents with the first agent (iron-oxide) particles transfected into cells which provide localized signals. The second agent is detected from a change in the off-resonance signal when present in the cells labeled by the first agent.... Agent: Beyer Weaver LLP

20070104649 - Optically fluorescent nanoparticles: The present invention refers to nanoparticles having optically fluorescent activity. In more detail, the invention refers to a nanoparticle matrix comprising a co-aggregate of at least one charged polyelectrolyte and at least one oppositely charged active agent, wherein the active agent is a hydrophilic optically fluorescent agent, and the invention... Agent: Millen, White, Zelano & Branigan, P.C.

20070104652 - Pharmaceutical spray formulation comprising a hydro fluor alkane and an acylated cyclodextrin: Novel Formulations Partially and fully acylated cyclodextrins have been found to be soluble in HFA propellants, and therefore can be used to formulate stable HFA pMDIs both as suspensions and solutions.... Agent: Fish & Richardson P.C.

20070104651 - Therapeutic foam: A therapeutic foam for the treatment of, inter alia, varicose veins comprises a sclerosing solution foamed with a physiological gas such as carbon dioxide, oxygen or a mixture thereof. The foam has a nitrogen content of less than 0.8%. It may be generated using a pressurised canister system incorporating a... Agent: Finnegan, Henderson, Farabow, Garrett & Dunner LLP

20070104653 - Use of inhaled gaseous nitric oxide as a mucolytic agent or expectorant: Methods and devices for treating excess mucus accumulation in mammals by administering gaseous inhaled nitric oxide or nitric oxide releasing compounds as a mucolytic agent or expectorant are provided. Delivery of gaseous nitric oxide can be made nasally or orally and is preferably substantially coincident with inhalation of the mammal... Agent: Sidley Austin Brown & Wood LLP (laip Group)

20070104654 - Amphiphilic block copolymers and nano particles comprising the same: An amphiphilic block copolymer. The amphiphilic block copolymer includes one or more hydrophilic polymers, one or more hydrophobic polymer, and one or more zwitterions. The invention also provides a nano particle and carrier comprising the amhpiphilic block copolymer for delivery of water-insoluble drugs, growth factors, genes, or cosmetic substances.... Agent: Birch Stewart Kolasch & Birch

20070104655 - Inhalable tiotropium and container therefor: A medical product suitable for storing and delivering a pre-metered dose of tiotropium, devices containing the same, and methods of using the same.... Agent: Sughrue Mion, PLLC

20070104656 - Matrices formed of polymer and hydrophobic compounds for use in drug delivery: A lipid or other hydrophobic or amphiphilic compound (collectively referred to herein as “hydrophobic compounds”) is integrated into a polymeric matrix for drug delivery to alter drug release kinetics. In embodiments where the drug is water soluble, the drug is released over longer periods of time as compared to release... Agent: Patrea L. Pabst Pabst Patent Group LLP

20070104657 - Particulate compositions for pulmonary delivery: This invention concerns an improved particulate composition for delivering a drug to the pulmonary system. Applicants disclose a method of identifying an optimal form of aerodynamically light particles which are highly dispersible. The particles of the instant invention are made by creating hollow, spherical drug particles (i.e., progenitor particles) that... Agent: Elmore Patent Law Group, PC

20070104658 - Use of simple amino acids to form porous particles: Particles having a tap density of less than 0.4 g/cm3 include a hydrophobic amino acid or salt thereof and a therapeutic, prophylactic or diagnostic agent or any combination thereof. Preferred particles include a phospholipid, have a median geometric diameter between about 5 and about 30 microns and an aerodynamic diameter... Agent: Elmore Patent Law Group, PC

20070104659 - Capsule-containing oral composition: The present invention provides an oral composition comprising capsule particles that are easily breakable to thereby readily release and distribute the capsule contents when used, while leaving substantially no feeling of capsule component residues or foreign matter in the mouth when rinsing. More specifically, the present invention relates to a... Agent: Posz Law Group, PLC

20070104660 - Particles that disrupt or impede bacterial adhesion, related compositions and methods: Oral care and other compositions comprising particles having cores attached to bioadhesive polymers for inhibition of pellicle formation, plaque formation, biofilm formation, biofouling, and microbial adhesion or attachment are described. Methods using said compositions to treat surfaces, such as oral surfaces.... Agent: Colgate-palmolive Company

20070104661 - Compositions for the treatment of affections of the oral cavity and upper respiratory tract: The present invention relates to compositions containing anthocyanosides and/or procyanidins in combination with floroglucinols for the treatment of the affections of the oral cavity and upper respiratory tract.... Agent: Young & Thompson

20070104662 - Ultraviolet ray absorbing composite powder: e

20070104663 - Effect pigments comprising an aluminium core or an aluminium alloy core, method for the production and use thereof: The invention relates to effect pigments comprising an aluminium core or an aluminium alloy core, and a layer containing aluminium oxide or aluminium oxide/hydroxide surrounding the aluminium core or the aluminium alloy core. Said pigments can be obtained by wet-chemical oxidation of plate-shaped aluminium pigments or aluminium alloy pigments. According... Agent: Ostrolenk Faber Gerb & Soffen

20070104664 - Treatment of toenail fungus: Aspects of the invention disclosed herein relate to devices that provide heat and/or ultraviolet light to fingernails or toenails that are afflicted by onychomycosis, as well as methods for treating onychomycosis by application of heat and/or ultraviolet light. The devices of the present invention may be used in connection with... Agent: Davis Wright Tremaine LLP

20070104665 - Surfactant-free dispersions, compositions, and use in topical formulations: The present invention provides for the preparation of stable surfactant-free dispersions of hydrophobic substances in low viscosity hydrophilic glyceryl polyacrylate or glyceryl polymethacrylate fluids, and topical vehicles formulated with the dispersions.... Agent: Fulbright & Jaworski L.L.P.

20070104666 - Styptic formulation and method of use: An astringent formulation of a double sulfate of a trivalent metal in combination with a univalent metal, cornstarch, water and a fragrance as an astringent for shaving and a method of use.... Agent: Patent Law & Venture Group

20070104674 - Aminofunctional silicone resins and emulsions containing them: This invention relates to aminofunctional silicone resins having high aryl content R2SiO2/2 content and amine content. The aminofunctional silicone resins of this invention are useful in making tough, water, solvent, and heat resistant hybrid materials when used in combination with selected organic materials, particularly epoxy-containing organic materials. The aminofunctional resins... Agent: Dow Corning Corporation Co1232

20070104669 - Cosmetic composition comprising at least one ester, at least one acrylic polymer, at least one cyclodextrin and at least one surfactant, and uses thereof: Disclosed herein are compositions comprising, in a cosmetically acceptable aqueous medium, at least one anionic surfactant, at least one liquid ester of a carboxylic acid comprising from 4 to 6 carbon atoms and of an alcohol comprising from 12 to 26 carbon atoms, at least one compound chosen from cyclodextrins... Agent: Finnegan, Henderson, Farabow, Garrett & Dunner LLP

20070104670 - Cosmetic composition comprising at least one specific fixative polymer and at least one sulphonated polymer: The present invention relates to a cosmetic composition for treating keratin fibers, especially human keratin fibers such as the hair, comprising in a cosmetically acceptable medium: at least one fixative polymer comprising as monomers at least a vinyl lactam, an ethylenically unsaturated carboxylic acid and an alkyl acrylate or methacrylate... Agent: Finnegan, Henderson, Farabow, Garrett & Dunner LLP

20070104671 - Cosmetic composition comprising a cation, a liquid fatty substance and a sorbitan ester, and cosmetic treatment process: The present disclosure relates to a cosmetic composition comprising, in a cosmetically acceptable aqueous medium, at least one cationic surfactant, at least one oxyethylenated ester of sorbitan and at least one non-silicone liquid fatty substance, the liquid fatty substance being present in an amount of less than 8% by weight... Agent: Finnegan, Henderson, Farabow, Garrett & Dunner LLP

20070104672 - Cosmetic composition comprising a cation, a solid fatty substance and a sorbitan ester, and cosmetic treatment process: The present disclosure relates to a cosmetic composition comprising, in a cosmetically acceptable aqueous medium, at least one cationic surfactant, at least one oxyethylenated sorbitan ester and at least one non-silicone solid fatty substance, in an oxyethylenated sorbitan ester/fatty substance weight ratio ranging from 0.2 to 50. The cosmetic compositions... Agent: Finnegan, Henderson, Farabow, Garrett & Dunner LLP

20070104673 - Base composition for cosmetic products: A cosmetic composition comprising (i) less than 10 wt % water, (ii) fatty acid, (iii) a structuring agent selected from the group comprising glycerine monostearate and glycol monostearate or a combination thereof, and (iv) at least 2 wt % neutralised fatty acid is a suitable base composition for forming a... Agent: Unilever Intellectual Property Group

20070104668 - Composition for the care of keratin material and cosmetic treatment process using said composition: c

20070104667 - Cosmetic composition comprising a cellulose or a liposoluble modified cellulose derivative: The invention relates to a cosmetic composition for making up the skin, the lips, the eyelashes or the nails, comprising, in a cosmetically acceptable medium, a liquid fatty phase and a liposoluble modified cellulose or cellulose derivative, the said modified cellulose or the said modified cellulose derivative comprising free hydroxyl... Agent: Finnegan, Henderson, Farabow, Garrett & Dunner LLP

20070104675 - Cosmetic product for shaving: e

20070104676 - Cosmetic and/or dermatological preparations containing an extract from the seeds of plants of the genus adenanthera: The invention provides cosmetic and dermatological preparation which contains an extract of plants of the genus Adenanthera and particularly seeds and hulled seed of the plants Adenanthera pavonina. The extracts are useful for inclusion in skin and hair treating preparations particularly for treating skin, scalp and hair for soothing irritations,... Agent: Cognis Corporation Patent Department

20070104677 - Preparation in the form of an emulsion: A preparation for application skin and mucous membrane comprises an emulsion having an aqueous phase which contains a film-forming polymer combination and an emulsified phase having at least one pigment.... Agent: Bachman & Lapointe, P.C.

20070104678 - Ancient defense polymer: The invention relates to an ancient defense polymer having biological activity. The polymer comprises both discrete hydrophilic blocks containing cationic charge(s) and discrete hydrophobic blocks, making it amphipathic and antimicrobial in a manner analogous to natural antimicrobial peptides that form an ancient defense mechanism employed by many organisms. Such a... Agent: Borden Ladner Gervais LLP

20070104680 - Antibodies to natural killer stimulatory factor: This application relates to antibodies reactive with a novel homogenous human cytokine, Natural Killer Stimulator Factor (NKSF), having the ability to induce the production of gamia interferon in vitro in human peripheral blood lymphocytes, and a pharmaceutical preparation containing such antibodies.... Agent: Finnegan, Henderson, Farabow, Garrett & Dunner LLP

20070104679 - Induction of differentiation of stem cells, and control of differentiation potency of stem cells: This invention provides a method to induce the differentiation of animal cells wherein said cells are brought into contact with cytokine only in a suitable growth phase of animal cells, and also provides a system to control the differentiation potency of animal cells wherein two or more cytokines are combined... Agent: Wenderoth, Lind & Ponack, L.L.P.

20070104681 - Isolated nucleic acid molecules which encode a soluble il-tif/il-22 receptor or binding protein which binds to il-tif/il-22, and uses thereof: The invention relates to soluble proteins which bind to the molecule known as IL-TIF/IL-22. The proteins can antagonize the effect of IL-TIF/IL-22 on target cells. The nucleic acid molecules encoding the proteins, and uses of the protein, are also described.... Agent: Wyeth/finnegan Henderson, LLP

20070104683 - Composition and methods for affecting metallocorrinoid uptake: The present invention is directed to compositions and methods for affecting metallocorrinoid uptake. The compositions and methods of the present invention are particularly useful in enhancing the uptake or availability of biologically active metallocorrinoids (e.g. cobalamin and its analogs). The present invention is particularly useful in the treatment or prevention... Agent: Hamilton, Brook, Smith & Reynolds, P.C.

20070104682 - Stabilized interferon liquid formulations: Stabilized liquid pharmaceutical composition comprising an interferon (IFN) or an isoform, mutein, fused protein, functional derivative, active fraction or salt thereof, wherein said formulation is a solution that comprises a buffer, a cyclodextrin, an isotonicity agent and an anti-oxidant are described here. Preferably the interferon is interferon beta-1a and the... Agent: Saliwanchik Lloyd & Saliwanchik A Professional Association

20070104687 - Aav vectors for in vivo gene therapy of rheumatoid arthritis: The present invention relates to the field of adeno-associated virus (AAV) based gene therapy, in particular in vivo gene therapy, of rheumatoid arthritis (RA). The invention provides recombinant AAV virions being highly efficient in delivering genes encoding therapeutic proteins to the arthritic joints, and method for using such virions in... Agent: The Webb Law Firm, P.C.

20070104689 - Compositions and methods for treating tumors presenting survivin antigens: The present invention provides compositions and methods that elicit an immune response against diseased cells. In particular, the present invention provides compositions and methods for the presentation of a peptide related to survivin on antigen-presenting cells. Presentation of the peptide leads to an immune response in a mammal against cells... Agent: Kirkpatrick & Lockhart Preston Gates Ellis LLP

20070104684 - Ocular gene therapy: Methods are provided for the treatment of choroidal neovascularization by increasing, in an individual afflicted with choroidal neovascularization, in vivo concentrations of an endostatin protein in the ocular tissues of the individual to a choroidal neovascularization inhibiting effective amount, where the endostatin protein has anti-choroidal neovascularization activity in vivo.... Agent: Bell, Boyd, & Lloyd LLC

20070104690 - Retroviral vectors: Retroviral vector production systems for producing lentivirus-based vector particles which are capable of infecting and transducing non-dividing target cells, wherein one or more of the auxiliary genes such as vpr, vif, tat, and nef in the case of HIV-1 are absent, from the system. The systems and resulting retrovirus vector... Agent: Frommer Lawrence & Haug

20070104688 - Small interfering rna mediated transcriptional gene silencing in mammalian cells: The present invention relates to transcriptional gene silencing (TGS) in mammalian, including human, cells that is mediated by small interfering RNA (siRNA) molecules. The present invention also relates to a method for directing histone and/or DNA methylation in mammalian, including human, cells. It has been found that siRNAs can be... Agent: Rothwell, Figg, Ernst & Manbeck, P.C.

20070104685 - Synthetic gene encoding human carcinoembryonic antigen and uses thereof: Synthetic polynucleotides encoding human carcinoembryonic antigen (CEA) are provided, the synthetic polynucleotides being codon-optimized for expression in a human cellular environment. The gene encoding CEA is commonly associated with the development of human carcinomas. The present invention provides compositions and methods to elicit or enhance immunity to the protein product... Agent: Merck And Co., Inc

20070104686 - Vaccines, immunotherapeutics and methods for using the same: Compositions, recombinant vaccines and live attenuated pathogens comprising one or more isolated nucleic acid molecules that encode an immunogen in combination with an isolated nucleic acid molecule that encodes an immunomodulator protein selected from the group consisting of: Fos, c-jun, Sp-1, Ap-1, Ap-2, p38, p65Rel, MyD88, IRAK, TRAF6, IkB, Inactive... Agent: Pepper Hamilton LLP

20070104697 - Adipose tissue derived stromal cells for the treatment of neurological disorders: The present invention relates to a treatment of neural injury and neurodegenerative diseases. Also included in the present invention is the use of adipose tissue derived stromal cells for the treatment of neural injury (stroke, traumatic brain injury, spinal cord injury) and neurodegeneration (i.e. Parkinson's disease).... Agent: Drinker Biddle & Reath Attn: Intellectual Property Group

20070104699 - Compositions for and methods of granzyme b inhibition: The present invention is related to the discovery that serpina3n, a secreted protein, binds to and inhibits granzyme B activity. The invention thus provides cells that include a polynucleotide encoding a granzyme B inhibitory serpin, pharmaceutical compositions including a granzyme B inhibitory serpin or a polynucleotide encoding a granzyme B... Agent: Clark & Elbing LLP

20070104698 - Construction and use of genes encoding pathogenic epitopes for treatment of autoimmune disease: This invention relates to the design and construction of a gene encoding an encephalogenic epitope of proteolipid protein (PLP), design and construction of a gene encoding an encephalogenic epitope of myelin based protein (MBP), to methods of expression of a PLP epitope, to methods of expression of a MBP epitope,... Agent: Bingham, Mccutchen LLP

20070104696 - Use of cell lines to produce active therapeutic proteins: This invention relates to the production of proteins, including therapeutic plasma proteins, by virally-immortalized hepatocyte cell lines and by other eukaryotic cells, as well as to the use of such proteins for screening and therapy, as well as to nucleic acids, vectors, and transformed or transfected cells that carry the... Agent: Catalyst Law Group, Apc

20070104700 - Nutritional formula for optimal gut barrier function: The present invention pertains to a composition for inducing a pattern of gut barrier maturation similar to that observed with breast-feeding and able to improve gut barrier maturation, e.g. during neonatal stress. In particular, the present invention relates to an infant formula containing a combination of specific ingredients designed to... Agent: Bell, Boyd & Lloyd LLP

20070104695 - Breast augmentation and reconstruction system: A breast template for delivering stem cell formulation to a breast defect of a patient for treating or augmenting a breast tissue defect comprising a flexible band with at least one throughput hole for guiding an injecting needle to penetrate into the breast of the patient, wherein the flexible band... Agent: Hosheng Tu

20070104693 - Breast augmentation system: A stem-cell-seeded porous scaffold implant and delivery systems for treating or augmenting a breast tissue defect in a patient.... Agent: Hosheng Tu

20070104694 - Breast stimulation and augmentation system: A stem-cell-seeded porous scaffold implant and electromagnetic growth stimulation for treating or augmenting a breast tissue defect in a patient.... Agent: Hosheng Tu

20070104692 - Breast tissue regeneration: A stem-cell-seeded porous scaffold implant and methods for treating a breast tissue defect in a patient.... Agent: Hosheng Tu

20070104691 - Follicular fluid for prolonged growth and survival of cells for cell therapies: The invention provides a method for preventing senescence and death of somatic cells by culturing the cells in the presence of serum and follicular fluid or components of follicular fluid. The somatic cells with a limited lifespan in vitro acquire properties of stem cells and can be passaged continuously, but... Agent: Wenderoth, Lind & Ponack, L.L.P.

20070104701 - Method for stabilizing reduced coenzyme q10: Reduced coenzyme Q10, which is readily oxidized in the air, is stabilized by causing ascorbic acid or a related compound thereof to coexist with a polyglycerol fatty acid ester with a polymerization degree of glycerol being not lower than 3 and/or a condensed ricinoleic acid polyglyceride in a mixture of... Agent: Sughrue Mion, PLLC

20070104702 - Method for treating diseases associated with changes of qualitative and/quantitative composition of blood extracellular dna: The invention relates to medicine and veterinary science and can be used for treating diseases associated with changes of the qualitative and/quantitative composition of blood extracellular DNA, namely generalised infection diseases provoked by bacteria, diseases provoked by fungi and protozoa, atherosclerosis, pancreatic diabetes, allergic diseases associated with delayed response hypersensitivity... Agent: Patent, Copyright & Trademark Law Group

20070104703 - Compositions and methods of using chondroitinase abci mutants: One aspect of the present invention relates to mutants of chondroitinase ABCI. Such chondroitinase ABCI mutants exhibit altered chondroitin lyase activity or increased resistance to inactivation from stressors including exposure to UV light or heat. Methods of using chondroitinase ABCI mutant enzymes are also provided.... Agent: Pepper Hamilton LLP

20070104704 - Erythropoietin receptor peptide formulations and uses: The present invention relates to peptide compounds that are agonists of the erythropoietin receptor (EPO-R). The invention also relates to therapeutic methods using such peptide compounds to treat disorders associated with insufficient or defective red blood cell production. Pharmaceutical compositions, which comprise the peptide compounds of the invention, and dosages... Agent: Darby & Darby P.C.

20070104706 - Preparation comprising batroxobin for inhibiting local invasion of malignant tumors: A preparation for inhibiting local invasion of malignant tumors is provided which comprises batroxobin and therefore can inhibit local invasion of malignant tumors. A preparation for encapsulating malignant tumor tissues is also provided which comprises batroxobin and therefore can cause or promote formation of capsule-like tissue around malignant tumor tissues.... Agent: Welsh & Katz, Ltd

20070104705 - Thrombin compositions: Compositions comprising thrombin and methods of preparing them are disclosed. The composition may be in the form of an aqueous solution at pH 5.7-7.4 consisiting essentially of 0.1 mg/mL to 5.0 mg/mL thrombin, 2% to 4% (w/v) sucrose, 3.5% to 5% (w/v) mannitol, 50 mM to 300 mM NaCl, 0-5... Agent: Zymogenetics, Inc. Intellectual Property Department

20070104708 - Compositions, methods, and kits relating to resistin: The invention relates to novel nucleic acids encoding a mammalian resistin gene, and proteins encoded thereby, whose expression is suppressed by the antidiabetic compounds thiazolidinediones. The invention further relates to methods of treating and detecting type 2 diabetes and Syndrome X comprising modulating or detecting resistin expression and/or production and... Agent: Howson And Howson

20070104707 - Methods of diagnosing and treating complications of pregnancy: Disclosed herein are methods for treating a pregnancy related hypertensive disorder, such as pre-eclampsia and eclampsia, using combinations of compounds that alter soluble endoglin and sF1t-1 expression levels or biological activity. Also disclosed are methods for treating a pregnancy related hypertensive disorder, such as pre-eclampsia and eclampsia, using compounds that... Agent: Clark & Elbing LLP

20070104709 - T1r hetero-oligomeric taste receptors, cell lines that express said receptors, and taste compounds: The invention relates to compounds that specifically bind a T1R1/T1R3 or T1R2/T1R3 receptor or fragments or sub-units thereof. The present invention also relates to the use of hetero-oligomeric and chimeric taste receptors comprising T1R1/T1R3 and T1R2/T1R3 in assays to identify compounds that respectively respond to umami taste stimuli and sweet... Agent: Needle & Rosenberg, P.C.

20070104710 - Ligand that has binding specificity for il-4 and/or il-13: The invention provides a dual-specific ligand comprising a first immunoglobulin variable domain having a first binding specificity and a complementary or non-complementary immunoglobulin variable domain having a second binding specificity.... Agent: Hamilton, Brook, Smith & Reynolds, P.C.

20070104713 - Nogo receptor homologs: The invention relates generally to genes that encode proteins that inhibit axonal growth. The invention relates specifically to genes encoding NgR protein homologs in humans and mice. The invention also includes compositions and methods for modulating the expression and activity of Nogo and the NgR proteins. Specifically, the invention includes... Agent: Sterne, Kessler, Goldstein & Fox, P.l.l.c.

20070104712 - Treatment of inflammatory bowel disease with ifn-gamma inhibitors: The invention concerns a method for the prevention or treatment of inflammatory bowel disease by administering an interferon-γ inhibitor. The invention further concerns pharmaceutical compositions and bispecific molecules useful in such method.... Agent: Merchant & Gould PC

20070104711 - Use of certain drugs for treating nerve root injury: The present invention relates to a method and a pharmaceutical composition for treatment of nerve disorders comprising administration of a therapeutically effective dosage of at least two substances selected from the group consisting of TNF inhibitors, IL-1 inhibitors, IL-6 inhibitors, IL-8 inhibitors, FAS inhibitors, FAS ligand inhibitors, and IFN-gamma inhibitors.... Agent: James R. Gorman Bioassets Development

20070104715 - Antibodies binding to a c-terminal fragment of apoliopoprotein e: A human antibody fragment, which antibody or fragment: (i) binds to a polypeptide having the amino acid sequence shown in SEQ ID NO: 1 of the C-terminal domain of Apolipoprotein E (ApoE-CTD) or the amino acid sequence of a part thereof; and (ii) binds to human plaques.... Agent: Nixon & Vanderhye, PC

20070104714 - Composition and method for the treatment of cancer and other physiologic conditins based on modulation of the ppar-gamma pathway and her-kinase axis: Described herein are methods of using a NSAID and a HER-kinase axis inhibitor in the treatment of various conditions including cancer, and especially prostate, breast, lung, ovarian, brain and colon cancers, through regulation of PPARγ activity. In various embodiments, the NSAID and HER-kinase axis inhibitor may be included in a... Agent: Davis Wright Tremaine LLP

20070104721 - Antineoplastic combinations with mtor inhibitor,herceptin, and/or hki-272: A combination of temsirolimus and herceptin in the treatment of cancer is provided. A combination of temsirolimus and HKI-272 is provided. A combination of herceptin and HKI-272 is also provided. Regimens and kits for treatment of metastatic breast cancer, containing herceptin, temsirolimus and/or HKI-272, optionally in combination with other anti-neoplastic... Agent: Howson And Howson Cathy A. Kodroff

20070104719 - Caspase activated prodrugs therapy: The invention provides novel method for the localized delivery of pharmaceutical agents by the administration of a caspase conjugate that targets a cell type of interest and the additional administration of a pro-agent that is locally converted, in the presence of the caspase, to an active agent. The invention further... Agent: Merchant & Gould PC

20070104717 - Compositions and methods for detecting and treating cancer: The present invention relates to compositions and methods for cancer diagnostics and treatment, including but not limited to, CD55 and/or CD97 cancer markers. In particular, the present invention provides compositions and methods of using CD55 and/or CD97 in the diagnosis and treatment of prostate cancers.... Agent: Medlen & Carroll, LLP

20070104718 - Gene brcc-1 and diagnostic and therapeutic uses thereof: A gene that is a modulator of tumor growth and metastasis in certain cancer types is provided. This gene and corresponding polypeptide have diagnostic and therapeutic application for detecting and treating cancers that involve expression of BRCC-1 such as breast cancer and lung cancer.... Agent: Ip Group Of Dla Piper US LLP

20070104716 - Methods for controlling pathological angiogenesis by inhibition of a6b4 integrin: It has now been determined that α6β4 integrin is a pro-angiogenic receptor, and thus that it provides a novel and heretofore unrecognized target for anti-angiogenic therapy. Thus, angiogenesis, particularly pathological angiogenesis, can be inhibited, and conditions with which pathological angiogenesis is associated treated using inhibitors of α6β4 integrin. A tissue... Agent: Marina Larson & Associates LLC Re: Msk

20070104720 - Novel serpentine transmembrane antigens expressed in human cancers and uses thereof: Described is a novel family of cell surface serpentine transmembrane antigens. Two of the proteins in this family are exclusively or predominantly expressed in the prostate, as well as in prostate cancer, and thus members of this family have been termed “STEAP” (SIX Transmembrane Epithelial Antigens of the Prostate). Four... Agent: Heller Ehrman LLP

20070104722 - Targeted biocides: The present invention relates to retroviral constructs that encode novel monoclonal antibodies, novel fusion proteins, and chimeric monoclonal antibodies and to methods of using and producing the same. In particular, the present invention relates to methods of producing a fusion protein comprising a microorganism targeting molecule (e.g., immunoglobulin or innate... Agent: Medlen & Carroll, LLP

20070104724 - Attaching substances to microorganisms: The invention relates to surface display of proteins on microorganisms via the targeting and anchoring of heterologous proteins to the outer surface of cells such as yeast, fungi, mammalian, plant cells, and bacteria. The invention provides a proteinaceous substance comprising a reactive group and at least one attaching peptide including... Agent: Trask Britt

20070104723 - Treatment of fibrotic disease: The invention relates to the use of INSP035 for treatment and/or prevention of fibrotic diseases, in particular of scleroderma.... Agent: Saliwanchik Lloyd & Saliwanchik A Professional Association

20070104725 - Use of modified extracellular matrix proteins in diagnosis and treatment of atherosclerosis: The present invention relates to the use of fibronectin, tenascin, collagens type I, III, VI and/or VIII modified by aldehyde or by glycosylation in ELISA for detection of antibodies in plasma and serum to diagnose atherosclerosis as well as the use of induction of tolerance and active as well as... Agent: Gauthier & Connors LLP

20070104726 - Multimeric complexes of antigens and adjuvants: The present invention provides a product comprising: a first component which is a scaffold; a second component which is an adjuvant, preferably a polypeptide which is a ligand for CD21 or a cell surface molecule on B cells or T cells or follicular dendritic or other antigen presenting cells; and... Agent: Nixon & Vanderhye, PC

20070104727 - Herbal powder extracts and methods of preparing and using the same: Methods for preparing an herbal powder extract from a polysaccharide-peptide rich mushroom, including Coriolus versicolor (Yunzhi), are disclosed. A more effective, highly pure Yunzhi powder extract, methods of preparing and using the same in ameliorating cancerous cell proliferations and hepatitis and are also disclosed.... Agent: Ostrolenk Faber Gerb & Soffen

20070104729 - Immuno-modulating antitumor activities of ganoderma lucidum (reishi) polysaccharides: The present invention provides medicinally active extracts and fractions, and a method for preparing the same by extracting and fractioning constituents from the tissue of components of Ganoderma lucidum. These active extracts and fractions are useful for inhibiting tumor growth, modulating immune response, and increasing hematopoietic activity.... Agent: Greenberg Traurig LLP

20070104728 - Synergistic phytoceutical compositions: Phytoceutical compositions for the prevention and treatment of circulatory disorders, feminine endocrine disorders, and dermal disorders. A specific combination of extracts of plants is taught, as well as principles for varying the formulations based on categorizing plants into one of three groups, Energy, Bio-Intelligence, and Organization and selecting several plants... Agent: Baker & Mckenzie LLP

20070104730 - Methods and compositions employing pomegranate extracts and fementation products of statin-producing fungi: Dietary supplements useful for treating or preventing cardiac disease are disclosed According to some embodiments, the presently disclosed supplement includes a pomegranate product fermented with a statin-producing fungus such one or more of Monascus, Aspergillus, Penicillium, Pleurotus, Pythium, Hypomyces, Paelicilomyces, Eupenicillium, and Doratomyces. Alternatively or additionally, the presently disclosed supplement... Agent: Dr. Mark Friedman Ltd. C/o Bill Polkinghorn

20070104731 - Helicobacter proteins and vaccines: A vaccine includes at least one Helicobacter, especially Helicobacter pylori protein to which immunoreactivity is detected in H. pylori negative individuals. The Helicobacter proteins are preferably less than 30 kDa and the vaccine especially includes 24 to 25 kDa and/or 18 to 19 kDa proteins. The vaccine may include interleukin... Agent: Alisa A. Harbin, Esquire Head Of Global Patents, Vaccines And Diagnostics

20070104732 - Ligand-pseudoreceptor system for generation of adenoviral vectors with altered tropism: In accordance with the present invention, there is provided a modified virus ablated of its natural receptors interactions with an unmodified or non-naturally occurring cell, said modified virus comprising a non-native polypeptide, said modified virus having an altered tropism conferred by said non-native peptide, and replicating only in cells that... Agent: Ogilvy Renault LLP

20070104733 - Tissue targeted antigenic activation of the immune response to cancers: The invention provides in part methods of treating cancers of a specific organ or tissue by administering an composition that is antigenically specific for one or more microbes that are pathogenic in the specific organ or tissue in which the cancer is situated. The formulations of the invention thereby facilitate... Agent: Bozicevic, Field & Francis LLP

20070104734 - Recombinant viruses with heterologous envelope proteins: The invention provides recombinant viruses comprising heterologous envelope proteins capable of mediating entry of the recombinant viruses into host cells. In one embodiment, a recombinant virus of the invention is a member of the Paramyx-ovirzdae family (e.g., a respiratory syncytial virus), and the heterologous envelope protein includes the ectodomain of... Agent: Lawrence Sung0- S2iplaw, PLLC

20070104735 - Immune modulator: Use of an immune modulator composition and/or pharmaceutical composition comprising a whole cell of a bacterium from the genera Rhodococcus, Gordonia, Nocardia, Dietzia, Tsukamurella and Nocardioides, for use in the manufacture of a medicament for the treatment of an autoimmune disease or autoimmune disorder, including certain vascular disorders.... Agent: Steptoe & Johnson LLP

20070104736 - Non-toxic mutants of pathogenic gram-negative bacteria: A method is provided for identifying, isolating, and producing htrB mutants of gram-negative bacterial pathogens. The method comprises mutating the htrB gene of a gram-negative bacterial pathogen so that there is a lack of a functional HtrB protein, resulting in a mutant that lacks one or more secondary acyl chains... Agent: Viksnins Harris & Padys Pllp

20070104737 - Recombinant light chains of botulinum neurotoxins and light chain fusion proteins for use in research and clinical therapy: Botulinum neurotoxins, the most potent of all toxins, induce lethal neuromuscular paralysis by inhibiting exocytosis at the neuromuscular junction. The light chains (LC) of these dichain neurotoxins are a new class of zinc-endopeptidases that specifically cleave the synaptosomal proteins, SNAP-25, VAMP, or syntaxin at discrete sites. The present invention relates... Agent: Baker & Botts L.L.P.

20070104739 - Equine protozoal myeloencephalitis vaccine: The present invention provides an immunogenically active component comprising inactivated Sarcocystis neurona cells and/or inactivated Neospora hughesi cells; antigens derived therefrom; DNA derived therefrom; or a mixture; or in combination with other vaccine components thereof. Further provided are vaccine compositions useful for preventing or ameliorating equine protozoal myeloencephalitis infection and... Agent: Wyeth Patent Law Group

20070104738 - Extracellular vesicles from non-pathogenic amoebae useful as vehicle for transferring a molecule of interest to an eukaryotic cell: The invention relates to membrane vesicles from non-pathogenic amoeba, in particular from the amoeba Dictyostelium discoideum, containing a molecule of therapeutic interest, to a method of preparing such vesicles and to the use of said vesicles as a vehicle for transferring the molecule therapeutic interest to an eukaryotic mammalian cell.... Agent: Young & Thompson

20070104745 - Aqueous dispersions of crystalline polymers and uses: Aqueous dispersions of crystalline polymers based on hydrophobic monomers, preferably on a mixture of hydrophobic and hydrophilic monomers which contains a crosslinking monomer, particularly side chain crystalline (SCC) polymers. The dispersions are useful for providing coatings on substrates, particularly on seeds (whose dormancy is thus extended) and on fibrous substrates,... Agent: Sheldon Mak Rose & Anderson PC

20070104741 - Delivery of tetrahydrocannabinol: A self-emulsifying drug delivery system to improve dissolution, stability, and bioavailability of drug compounds of dronabinol or other cannabinoids. The drug compound(s) are dissolved in an oily medium (e.g. triglycerides and/or mixed glycerides and/or free fatty acids containing medium and/or long chain saturated, mono-unsaturated, and/or poly-unsaturated free fatty acids) together... Agent: Townsend & Banta C/o Portfolio Ip

20070104743 - Formulations of fispemifene: s

20070104742 - Novel oral formulations of ospemifene:

20070104744 - Ophthalmic and contact lens solutions containing forms of vitamin b: The present invention relates to improved ophthalmic solutions that employ select B vitamins; pyridoxine and its salts; and thiamine and its salts in order to more effectively preserve solutions and to reduce the degree to which cationic preservatives will deposit on contact lenses. Ophthalmic solutions are here understood to include... Agent: Hiscock & Barclay, LLP

20070104740 - Self-microemulsifying drug delivery systems of a hiv protease inhibitor: The present invention relates to pharmaceutical formulations of (3R,3aS,6aR)-hexahydrofuro[2,3-b]furan-3-yl(1S,2R)-3-[[(4-aminophenyl)sulfonyl](isobutyl) amino]-1-benzyl-2-hydroxypropylcarbamate, salts, esters, polymorphic and pseudopolymorphic forms thereof, which are self-microemulsifying drug delivery systems and comprise as carrier a lipophilic phase, one or more surfactants, a hydrophilic solvent and a nucleation inhibitor.... Agent: Philip S. Johnson Johnson & Johnson

20070104747 - Cosmetic composition comprising at least one anti-dandruff agent and also oxyethylenated sorbitan monolaurate, and cosmetic treatment process using said composition: Disclosed herein is a cosmetic composition comprising, in an aqueous medium, at least one anti-dandruff agent other than 2-pyridone derivatives, and at least one oxyethylenated sorbitan monolaurate comprising from 2 to 25 oxyethylene units. The anti-dandruff agent may be chosen, for example, from zinc pyrithione, salicylic acid, selenium disulphide, and... Agent: Finnegan, Henderson, Farabow, Garrett & Dunner LLP

20070104746 - Methods and compositions for reducing skin damage: The Notch signal transduction pathway has been identified as a target for screening and treatment methods for the prevention and/or reduction of short- and long-term UVB-induced skin damage, e.g., the prevention and/or reduction of UVB-induced wrinkles. The invention thus features screening and treatment methods for prevention or reduction of UVB-induced... Agent: Fish & Richardson PC

20070104748 - Delivery system for continuous release of volatile substances: A delivery system for continuous release of fragrances, repellents, attractants, and the like is disclosed. The substance to be released is comprised in a sheetlike polymer matrix. By virtue of the fact that this polymer matrix is in wound form, the substance to be released can be released from the... Agent: Frommer Lawrence & Haug

20070104750 - Pesticidally active compositions having enhanced activity: The present invention relates to a pesticidally active composition comprising: 1) at least one pesticidally active ingredient having at least one functionality which is reactive with singlet oxygen, and 2) at least one compound which acts as an activity enhancer, which is distinct from the pesticidally active ingredient.... Agent: Dow Agrosciences LLC

20070104749 - Pesticide delivery granule: A pesticide granule is provided that includes a base carrier particle. A liquid pesticide coating is applied to the particle surface, The coating may contain adjuvants. The coating has sufficient tack to adhere a second powdered pesticide to the carrier particle. The usage of tackifying agents to render the particle... Agent: Gifford, Krass, Sprinkle,anderson & Citkowski, P.c

20070104751 - Systemic plant conditioning composition: This invention relates to compositions and methods facilitating availability, uptake and translocation of active ingredients in plants. More specifically, this invention relates to the surprising discovery that the application to the roots, such as administration to the soil surrounding plants, of two or more osmolytes in combination with an active... Agent: Viksnins Harris & Padys Pllp

20070104752 - Aneurysm embolization material and device: The present invention includes a method for treating an aneurysm. The method includes providing a biocompatible polymeric string or hollow tube and transporting the string or hollow tube to the aneurysm. The aneurysm is filled with the string. The string is cut when the aneurysm is substantially filled.... Agent: Schwegman, Lundberg, Woessner & Kluth, P.A.

20070104758 - Biofunctional, antimicrobial coatings for medical devices: The present invention provides compositions and methods for an improved coating for medical devices. Provided is an interfacial biomaterial or biofunctional coating composition comprising at least one binding domain that has bind specificity for a surface material of a medical device, and at least one binding domain that has binding... Agent: Affinergy, Inc.

20070104757 - Latent reactive blood compatible agents: A reagent and related method for use in passivating a biomaterial surface, the reagent including a latent reactive group and a bifunctional aliphatic acid (e.g., fatty acid), in combination with a spacer group linking the latent reactive group to the aliphatic acid in a manner that preserves the desired function... Agent: Intellectual Property Group Fredrikson & Byron, P.A.

20070104753 - Medical device with a coating comprising an active form and an inactive form of therapeutic agent(s): The present invention relates generally to coated medical devices, such as a stent, that has a surface completely or partially covered with a coating that comprises a first region containing an inactive form of a therapeutic agent and a second region containing an active form of a therapeutic agent. The... Agent: Jones Day

20070104754 - Method and system for treatment of eating disorders: The invention comprises a gastric device having an outer region and a gas producing material. The gastric device hydrates within a patient's stomach and the gas producing material expands the device to a greater volume. Accordingly, the volume of the hydrated, expanded gastric devices occupy space in the stomach cavity... Agent: Ralph C. Francis Francis Law Group

20070104755 - Method and system for treatment of eating disorders: The invention comprises a gastric device having a pouch formed from a degradable film. Preferably, the pouch contains a gas producing material. The gastric device hydrates within a patient's stomach and the gas producing material expands the device to a greater volume. Accordingly, the volume of the hydrated, expanded gastric... Agent: Ralph C. Francis Francis Law Group

20070104756 - Obesity controlling method: A method of controlling obesity by injecting bio-compatible bulking material into the pyloric sphincter area of the stomach. The injection of this material bulks the pyloric sphincter, retarding stomach emptying and producing a feeling of satiation in the patient. The method may be supplemental and augmented by inducing flacid paralysis... Agent: Wolf Greenfield & Sacks, PC

20070104759 - Polymeric delivery formulations of leuprolide with improved efficacy: The present invention is directed to a flowable composition that is suitable for use as a controlled release implant. The flowable composition includes a biodegradable thermoplastic polyester that is at least substantially insoluble in aqueous medium or body fluid. The flowable composition also includes a biocompatible polar aprotic solvent. The... Agent: Schwegman, Lundberg, Woessner & Kluth, P.A.

20070104762 - Appetizer supplement to suppress age-related decline in capacity and appetite: A method for administering daily micronutrient requirements (DMRs) comprising vitamins, minerals and essential fatty acids targeted to reduce appetite and/or the risks associated with aging. The DMRs are administered to individuals via food products. In an embodiment of the present invention, the DMRs are offered in the form of a... Agent: Roberts, Mardula & Wertheim, LLC

20070104760 - Enteropathy ameliorating composition: The present invention relates to a composition for preventing, ameliorating or treating a bowel disease, comprising galactomannan and/or arabinogalactan; a liquid food for preventing, ameliorating or treating a bowel disease, characterized in that the liquid food comprises a protein and galactomannan and/or arabinogalactan; and a composition for preventing, ameliorating or... Agent: Birch Stewart Kolasch & Birch

20070104761 - Low radiocarbon nucleotide and amino acid dietary supplements: Methods for significantly lowering the carbon-14 content of DNA and histones in vertebrates, especially humans, to about 10% to about 98% below normal background levels and thereby reduce chromosomal damage using dietary supplements based on low radiocarbon nucleotides, amino acids, and other DNA and histone precursors. Administration of the supplements... Agent: Lerner, David, Littenberg, Krumholz & Mentlik

20070104763 - Composition of fentanyl citrate oral solid transmucosal dosage form, excipient and binding material therefore, and methods of making: A process of preparing a highly uniform oral transmucosal lozenge of fentanyl citrate (a “fentanyl lollipop”) provides uniform distribution of the drug. The content uniformity between the lozenges and uniform distribution of the drug within a lozenge is achieved by dry mixing a micronized drug of a particle size of... Agent: Bradley N. Ruben, PC

20070104765 - Livestock and poultry feed additive composition: A livestock and poultry feed additive composition includes at least one essential oil derived from at least one of an herb and a spice and containing thymol and carvacrol as its main ingredients, at least one organic acid derived from at least one of citric, fumaric, fulvic and humic acid... Agent: Law Offices Of Adam H. Jacobs

20070104764 - Recombinant production of antimicrobial peptides: The invention relates to the use of co-expression of an antimicrobial agent and an enzyme, with a view to improving yield and/or overall production economy. Examples of antimicrobial agents are antimicrobial peptides such as lactoferricins and antimicrobial enzymes such as lysozyme and glucose oxidase, and examples of enzymes are endoglucanase,... Agent: Novozymes North America, Inc.

20070104767 - Compositions and methods for improving integrity of compromised body passageways and cavities: The present invention provides compositions and methods for improving the integrity of body passageways following surgery or injury. Representative examples of therapeutic agents include microtubule stabilizing agents, fibrosis inducers, angiogenic factors, growth factors and cytokines and other factors involved in the wound healing or fibrosis cascade.... Agent: Seed Intellectual Property Law Group PLLC

20070104768 - Devices for the delivery of molecular sieve materials for the formation of blood clots: An apparatus for promoting the clotting of blood comprises a substrate and a zeolite in powder form deposited on the substrate. At least a portion of the substrate is selected from a group consisting of paper, polymer matrix, polyethylene sheet, hydrophilic macromolecules, and cloth. An agent for promoting the clotting... Agent: Michaud-duffy Group LLP

20070104766 - Elastomeric article with antimicrobial coating: A first aspect of the present invention is directed to a surface treatment for elastomeric articles such as medical gloves, comprising a water-based coating formulation and antimicrobial agent(s) embraced therein in an essentially powder-free composition coating. A second aspect of the present invention is directed to a water-based coating formulation... Agent: Morgan & Finnegan, L.L.P.

20070104769 - Bioabsorbable hemostatic gauze: Bioabsorbable, water-soluble hemostatic cellulose based gauze matrix structures are described, including one or more species of chitosan, etherized cellulose, nonionic surfactant, water-soluble polysaccharide hydrocolloid and/or gum. Approximately 85% to 95% deacetylated decrystallized chitosan, present in an amount from about 2% to about 15% by weight, is found to be particularly... Agent: Michaelson & Associates

20070104770 - Methods and compositions for topical wound treatment: Methods for improved treatment of wounds on a patient. Method includes locally administering a healing composition to the skin wound such that the healing of the skin wound is enhanced. The healing composition includes from about 5 mg to about 40 mg lidocaine hydrochloride per gram of the healing composition,... Agent: Dinsmore & Shohl, LLP

20070104772 - Amorolfine patch for the treatment of onychomycosis: A transungual patch/device useful for the treatment of onychomycosis includes: (i) a backing medium; and (ii) an adhesive matrix layer deposited thereon which contains (a) a thus effective amount of amorolfine active agent or derivative thereof essentially uniformly distributed therethrough, dissolved or dispersed in the adhesive, and (b) at least... Agent: Buchanan, Ingersoll & Rooney PC

20070104773 - Skin application medicament, method of applying the same to skin, and method of manufacturing the same: The skin application medicament is used for treating or mitigating various symptoms on the skin, such as pimples, acne, comedo, wrinkles, rough skin, blotches, freckles, or the like. Generally, there is hitherto employed an application sheet comprising a predetermined amount of medicinal substances with other substances applied on unwoven fabric... Agent: Armstrong, Kratz, Quintos, Hanson & Brooks, LLP

20070104771 - Transdermal galantamine delivery system: A transdermal galantamine delivery system to an individual. The system has a high galantamine loading with suitable permeation enhancers to effect therapeutic flux rate. Acrylate polymeric reservoir with the high galantamine and permeation enhancers dissolved therein provides desirable adhesive characteristics and effective transdermal therapeutic properties for multiple-day delivery.... Agent: Philip S. Johnson Johnson & Johnson

20070104775 - Amphoteric liposomes: A serum-stable mixture of lipids capable of encapsulating an active agent to form a liposome, said mixture comprising phosphatidylcholine and phosphatidylethanolamine in a ratio in the range of about 0.5 to about 8. The mixture may also include pH sensitive anionic and cationic amphiphiles, such that the mixture is amphoteric,... Agent: Mintz Levin Cohn Ferris Glovsky & Popeo

20070104776 - Drug having regulatory cell ligand contained in liposome: A liposome containing a regulatory cell ligand such as α-galactosyl ceramide or β-galactosyl ceramide is employed as the active ingredient of a drug for preventing or treating immune diseases etc.... Agent: Fitch, Even, Tabin & Flannery

20070104774 - Method for preparing phytosphingosine liposome composition: The invention relates to a method for preparing phytosphingosine liposome composition having excellent long-term storage stability and the method comprises dispersing phytosphingosine in water, separately dissolving phospholipid in a solvent and mixing the two solutions prepared by the above procedures.... Agent: Dickstein Shapiro LLP

20070104777 - Targeted liposomal drug delivery system: A metal targeting complex which associates with a charged liposomal structure is provided. The metal targeting complex provides the targetability of the liposomal construct to the desired receptor sites of a warm-blooded host for therapy or diagnostic use.... Agent: Drinker Biddle & Reath Attn: Intellectual Property Group

20070104778 - Controlled-release emulsion compositions: The present invention is directed to controlled-release composition containing a solubilized material comprising an active agent and at least one oil-based surfactant capable of solubilizing the active agent, the solubilized material dispersed in a controlled-release particulate matrix.... Agent: Davidson, Davidson & Kappel, LLC

20070104780 - Formulation comprising a drug of low water solubility and method of use thereof: A pharmaceutical composition comprises a drug-carrier system having a small-molecule drug of low water solubility, e.g. N-[4-(3-amino-1H-indazol-4-yl)phenyl]-N′-(2-fluoro-5-methylphenyl)urea (ABT-869), and (+)-1-(5-tert-butyl-1-yl)-3-(1H-indazol-4-yl)-urea (ABT-102), in solution in a substantially non-aqueous carrier that comprises at least one phospholipid and a pharmaceutically acceptable solubilizing agent. The drug-carrier system, when mixed with an aqueous phase, typically... Agent: Robert Deberardine D-377/ap6a-1

20070104781 - Hypocholesteremic preparations containing mixtures of phytostenol(ester)s and conjugated fatty acids, and methods of using the same: A hypocholesteremic preparation containing at least one component (a) selected from the group consisting of phytostenols and phytostenol esters and at least one component (b) selected from conjugated fatty acids having from about 6 to about 24 carbon atoms and glycerides of conjugated fatty acids having from about 6 to... Agent: Cognis Corporation Patent Department

20070104779 - Treatment with omega-3 fatty acids and products thereof: A method for reducing non-HDL cholesterol levels of a subject comprising administering a pharmaceutical composition comprising omega-3 fatty acids to the subject in an amount sufficient to reduce non-HDL cholesterol. The method may include a reduction of the triglyceride levels of the subject and, optionally, an increase in the HDL... Agent: Arent Fox PLLC

20070104784 - Compositions and methods of treatment comprising amoxicillin and potassium clavulante with xanthan: Bacterial infections may be treated using a high dosage regimen of amoxicillin and potassium clavulanate. Preferably, the dosage is provided by a bilayer tablet.... Agent: Glaxosmithkline Corporate Intellectual Property - Uw2220

20070104783 - Double-layered absorbable solid compositions for the topical treatment of oral mucosal disorders: Bioadhesive sticker tablets which are applied directly to vaginal, rectal and/or oral mucosa are described herein. In one embodiment, the sticker tablets are applied directly to ulcers or lesions in the oral cavity. The compositions adhere immediately upon administration, swell over time, and remain adherent to the ulcer or lesion... Agent: Patrea L. Pabst Pabst Patent Group LLP

20070104782 - Modified release tablet formulations with enhanced mechanical properties: A method of formulating a drug in solid dosage form of a specified hardness, the drug containing at least one pharmaceutically active agent that has a pH dependent release profile, at least one non-pH dependent sustained release agent, and an effective amount of Eudragit L100-55.... Agent: Millen, White, Zelano & Branigan, P.C.

20070104785 - Tablets of linezolid form iii and processes for their preparation: The present invention relates to solid oral dosage forms of linezolid polymorphic Form III with reproducible dissolution profile and processes for their preparation. The solid dosage form includes linezolid Form III, one or more of means to reduce the gelling tendency of linezolid form III, and one or more of... Agent: Ranbaxy Inc.

20070104787 - Carboxyalkyl cellulose esters for sustained delivery of pharmaceutically active substances: wherein: R1-R6 are each independently selected from —OH, —OC(O)(alkyl), and —O(CH2)xC(O)OH, and pharmaceutically acceptable salts thereof, wherein x ranges from 1-3, a degree of substitution per anhydroglucose of —OH ranges from 0.1 to 0.7, a degree of substitution per anhydroglucose of —C(O)(alkyl) ranges from 0.1 to 2.7, and a degree... Agent: Finnegan, Henderson, Farabow, Garrett & Dunner LLP

20070104786 - Dosage forms for immediate gastric release of a calcium transport stimulator coupled with delayed gastric release of a bis-phosphonate: The present invention provides a gastric retention dosage form for immediate or uncontrolled release of a vitamin D derivative that stimulates calcium absorption from the intestine, like calcitriol, alphacalcidol and calcifediol, combined with delayed release of a bis-phosphonate calcium resorption inhibitor such as alendronic acid and its pharmaceutically acceptable salts... Agent: Kenyon & Kenyon LLP

20070104788 - Once-daily administration of central nervous system drugs: Delayed onset chronotherapeutic formulations of central nervous system (CNS) drugs are disclosed. The formulations comprise at least one CNS drug or pharmaceutically acceptable salt thereof that exhibits an in vivo elimination half-life of less than about 8 hours, wherein the formulation exhibits at least one in vivo parameter, at steady... Agent: Finnegan, Henderson, Farabow, Garrett & Dunner LLP

20070104789 - Gastro-resistant and ethanol-resistant controlled-release formulations comprising hydromorphone: The invention provides a controlled-release composition comprising hydromorphone or a pharmaceutically acceptable form thereof in association with a gastro-resistant and ethanol-resistant compound and method of use thereof.... Agent: Diehl Servilla LLC

20070104790 - Mesoporous compositions for use in drug delivery: The present invention encompasses novel mesoporous compositions comprising vitamin E and alumina, and methods for their synthesis. The mesoporous compositions of the present invention have applications as drug-delivery vehicles.... Agent: Morgan Lewis & Bockius LLP

20070104791 - Method of preparing a pharmaceutical composition and pharmaceutical compositions obtainable thereby: An aqueous pharmaceutical composition comprising: a) 0.005 to 10% by wt of one or more water-soluble pharmaceutically active ingredients or pharmaceutically acceptable salts thereof; b) from 0.01 to 10% by wt hydroxypropyl methyl cellulose having a viscosity of from 2500 to 5500 cps (mPa·s); and c) a buffer for maintaining... Agent: Gomez International Patent Office, LLC

20070104794 - Enzyme granules: The present application relates to a steam treated pelletized feed composition comprising a granule comprising a core and a coating wherein the core comprises an active compound and the coating comprises a salt.... Agent: Novozymes North America, Inc.

20070104792 - Nanoparticulate tadalafil formulations: The present invention is directed to compositions comprising nanoparticulate tadalafil, or a salt or derivative thereof, having improved bioavailability, faster rates of absorption and a faster onset of therapeutic effect. The nanoparticulate tadalafil particles of the composition are proposed to have an effective average particle size of less than about... Agent: Elan Drug Delivery, Inc. C/o Foley & Lardner LLP

20070104793 - Process for making ceramic, mineral, and metal beads from powder: A method is provided for synthesizing beads using starting ceramic, metal, or mineral powders. Typical size of these round beads can range from about 0.1 mm to about 10 mm based on the processing variables. In the method, a slip is obtained which contains a metal, ceramic, and/or mineral powder... Agent: Ceramatec, Inc.

20070104795 - Multiphase active ingredient formulation: The invention relates to a formulation having a plurality of phases containing active ingredients. Said formulation is characterised in that: it contains a first, innermost, finely distributed phase (I) consisting of active ingredients or an active ingredient solution, preferably some of the phase particles being surrounded by a barrier sheath... Agent: Norris, Mclaughlin & Marcus, P.A.

20070104797 - Use of brown's gas and feeding apparatus of the brown's gas: Provided is a new use of Brown's gas, more particularly, to the use of Brown's gas for the treatment of diseases in mammals and a Brown's gas supply apparatus therefor. It is based on the assumption that the Brown's gas is a medium capable of directly supplying moisture (special form... Agent: J C Patents Inc

20070104796 - Use of xenon with hypothermia for treating neonatal asphyxia: The present invention relates to the use of xenon in the preparation of a medicament for the treatment of neonatal asphyxia in a neonatal subject, wherein said medicament is for use in combination with hypothermia.... Agent: Fay Sharpe LLP

20070104798 - Synergistic antimicrobial preparations containing chlorite and hydrogen peroxide: An anti-microbial preservative for use in ophthalmic and dermatologic products. The preservative includes from about 0.005 wt. % to about 0.20 wt. % chlorite compound and from about 0.005 wt. % to about 0.05 wt. % peroxy compound. Additionally, the preservative does not generate chlorine dioxide within the pH range... Agent: Stetina Brunda Garred & Brucker

20070104799 - Treatment of chronic kidney disease (ckd) subjects using lanthanum compounds: A subject with symptoms of chronic kidney disease (CKD), who does not have end-stage renal disease (ESRD), can be treated by orally administering a pharmaceutical composition as an active ingredient a therapeutically effective amount of a non-toxic lanthanum compound. Administration of a lanthanum compound can prevent the progression of CKD,... Agent: Darby & Darby P.C.

20070104800 - Compositions and methods for cancer treatment: The present invention relates to compositions comprising a vitamin E analog and an arsenic compound for treating hyperproliferative cells disorders such as cancer. The composition of the invention potentiates arsenic toxicity towards cancer cells and can also prevent arsenic-mediated toxicity of non-cancerous cells.... Agent: Venable LLP

20070104801 - Fertility and anti-aging supplement for the fertility health of females and males: A fertility-enhancing supplement contains a balance of compositions and ingredients that will enhance the reproduction system in the female and male to help support conception, while also supporting the anti-aging of the reproductive system, taken in balance to aid in the uptake by the body of certain and particular compositions... Agent: William W. Jones

20070104802 - Method of inhibiting alveolar bone resorption and periodontal membrane loss and composition for internal use to be used therein: Alveolar bone resorption, periodontal membrane loss, and gingival recession can be inhibited by administering 500 mg to 2000 mg per day of calcium, 10 mg to 40 mg per day of soy isoflavone aglycone, and vitamin D3 to persons having a tendency for decreased bone density, postmeopausal women, and periodontal... Agent: Knobbe Martens Olson & Bear LLP

20070104803 - Chinese herbal composition for treating diseases: The present invention relates to a Chinese herbal composition for treating bacterial lipopolysaccharide-induced diseases. The composition is extracted from a mixture of Huang Qui, Huanglian and Dauhuang. The composition is used for treating a lung inflammation and a hypotension.... Agent: Volpe And Koenig, P.C.

20070104804 - Composition for treating cancer cells and preparation method for the same: A composition for treating cancer cells and a preparation method therefor are provided. The novel flavonoid compounds are obtained from natural plants, and more particularly the compounds have a cytotoxicity on cancer cells.... Agent: Trojan Law Offices

20070104806 - Compositions containing cotinus coggygria extract and use thereof in treating hemorrhoids: The present invention relates to a method for treating hemorrhoids by topically administering to tissue in need of such treatment a composition containing cotinus coggygria extract.... Agent: Philip S. Johnson Johnson & Johnson

20070104805 - Compositions of hoodia gordonii and pinolenic acid derivatives: The present invention is directed to compositions containing a pine nut oil and an extract from the genus Hoodia or Trichocaulon and methods of treatment for weight loss.... Agent: Dorsey & Whitney LLP Intellectual Property Department

20070104808 - Compositions and methods for treatment of rhinovirus: Methods for prophylactic and anti-transmissivity uses of an anti-microbial composition are disclosed. The methods comprise the step of administering to a mammal or a bird, an amount of a composition having a first ingredient obtainable from ginger; a second ingredient obtainable from green tea; an optional third ingredient obtainable from... Agent: Knoble, Yoshida & Dunleavy

20070104807 - Compositions and methods for weight-loss and weight-loss maintenance in daytime and nighttime formulation: Compositions and methods for administering a diet supplement to humans are provided for the enhancement of weight loss, suppression of appetite, prevention of muscle protein catabolism, and providing antioxidants in either a daytime or nighttime formulation. Said diet supplement is comprised of at least a source of Catechins and at... Agent: Kenyon & Kenyon LLP

20070104809 - Composition comprising a bacteriocin and an extract from a plant of the labiatae family: The present invention provides a composition comprising (a) an antimicrobial material; and (b) an extract obtained from or obtainable from a plant of the Labiatae family, wherein (a) and (b) are different; wherein the composition contains phenolic diterpenes in an amount of greater than 1.0 wt. %, based on the... Agent: Steptoe & Johnson LLP

20070104810 - Agents for sequestering aging factors and uses thereof: Methods for the prevention or treatment of disorders and complications of disorders resulting from cell damage caused by an aging-related isoform of NADH oxidase (arNOX) are described. The agent for such inhibition comprises processed various Narcissus tazetta extracts, preferably IBR-DORMIN®, both alone and in combination with other inhibition agents, including... Agent: Dorsey & Whitney LLP Intellectual Property Department

20070104811 - Pharmaceutical composition useful for the treatment of prostate cancer: Present invention provides a pharmaceutical composition useful for the treatment of prostate cancer in a subject wherein the said composition comprising the therapeutically effective amount of an extract obtained from any plant parts of Murrya koenigii and Tribulus terrestris.... Agent: Ladas & Parry

20070098632 - Analogs of terpene trilactones from ginkgo biloba and related compounds and uses thereof: wherein R1 is H, OH, a photoactivatable moiety, a fluorescent moiety, or a radioactive moiety; R2 is H, OH, a photoactivatable moiety, a fluorescent moiety, or a radioactive moiety; R3 is H or OH; R4 is H, OH, a photoactivatable moiety, a fluorescent moiety, or a radioactive moiety; and wherein... Agent: Cooper & Dunham, LLP

20070098631 - Diagnostic compounds comprising a scaffold coupled to a signal entity for medical imaging diagnostic: namely Biphenyl; Arylpiperidine; Arylpiperazine; 1,4 dyhydropyridine; Dihydropyrimidone; 1,4 benzodiazepine-2-one; 1,5 benzodiazepine-2-one; 1,4-benzodiazepine-2,5 diones; pyrrolo2,1-c 1,4 benzodiazepines 5,11 diones; 1,4 benzothiazepine-5-ones; 5,11-dihydro-benzo pyrido 3,2b 1,4 diazepine-6-ones Benzopyrane; Chromone; Benzopyranone; Coumarine, pyranocoumarine Benzopiperazinones; Quinazolinone; Quinazolindione; Quinoxalinone Imidazoquinoxaline; indole; Benzimidazole Benzofurane Benzothiophene; SIGNAL is a signal entity for medical imaging diagnostic, and pharmaceutically... Agent: Birch Stewart Kolasch & Birch

20070098634 - Compositions and methods for the diagnosis and treatment of tumor: The present invention is directed to compositions of matter useful for the diagnosis and treatment of tumor in mammals and to methods of using those compositions of matter for the same.... Agent: Genentech, Inc.

20070098633 - Virtual colonoscopy with radiolabeled phospholipid ether analogs: The present invention provides agents and methods for dual modality virtual colonoscopy that gives both anatomical and functional information using hybrid CT/PET scanning. In preferred embodiments, the present invention provides radiolabeled tumor-specific agents and methods for distinguishing benign polyps from malignant tumors. In further embodiments, the present invention provides compositions... Agent: Godfrey & Kahn S.c.

20070098637 - Generation and use of vasculogenic tumors and products derived from same: Tumors can be directed into a vasculogeinc program and used to regenerate tissues in a verterbrate host, identify factors originating from the tumor that are useful for tissue regeneration, and to generate such factors for use in a subject apart from the tumor itself.... Agent: Wolf Greenfield & Sacks, PC

20070098636 - Method of identifying responders to treatment with insulin sensitizers: A patient who is a responder to a therapeutic treatment for insulin resistance or for one or more diseases associated with type 2 diabetes can be identified by the method of measuring the amount of HMW adiponectin and the amount of total adiponectin or LMW adiponectin in the patient's tissue... Agent: Merck And Co., Inc

20070098635 - Secreted polypeptide species associatedwith cardiovascular disorders: The invention discloses human secreted polypeptides that circulate at an increased level in the plasma of patients with cardiovascular disorders. The invention also provides methods of using compositions including the polypeptides, polynucleotides encoding them, and antibodies specific for these polypeptides, for diagnosis, prognosis, and treatment of cardiovascular disorders.... Agent: Novartis Corporate Intellectual Property

20070098639 - Process for the preparation of coated polymer particles: A process for the preparation of coated polymer particles containing superparamagnetic crystals, said process comprising reacting porous, surface-functionalized, superparamagnetic crystal-containing polymer particles of diameter 0.5 to 1.8 μm with at least one polyisocyanate and at least one diol or at least one epoxide.... Agent: Invitrogen Corporation C/o Intellevate

20070098643 - Oligomers of gadolinium chelates, their applicationascontrast products in magnetic resonance imaging and their synthesis intermediates: p

20070098640 - Nanoparticle-based imaging agents for x-ray/computed tomography: The present invention is generally directed to core/shell nanoparticles, wherein such core/shell nanoparticles comprise a nanoparticle core and a nanoshell disposed about the nanoparticle core such that, in the aggregate, they form a core/shell nanoparticle that is operable for use as an imaging agent in X-ray/computed tomography (CT). Typically, such... Agent: General Electric Company Global Research

20070098641 - Nanoparticle-based imaging agents for x-ray/computed tomography: The present invention is generally directed to core/shell nanoparticles, wherein such core/shell nanoparticles comprise a nanoparticle core and a nanoshell disposed about the nanoparticle core such that, in the aggregate, they form a core/shell nanoparticle that is operable for use as an imaging agent in X-ray/computed tomography (CT). Typically, such... Agent: General Electric Company Global Research

20070098642 - Nanoparticle-based imaging agents for x-ray/computed tomography: The present invention is generally directed to core/shell nanoparticles, wherein such core/shell nanoparticles comprise a nanoparticle core and a nanoshell disposed about the nanoparticle core such that, in the aggregate, they form a core/shell nanoparticle that is operable for use as an imaging agent in X-ray/computed tomography (CT). Typically, such... Agent: General Electric Company Global Research

20070098638 - Macrocyclic cyanine and indocyanine bioconjugates provide improved biomedical applications: The sensitivity and specificity of the optical modality can be enhanced by the use of highly absorbing compounds as contrast agents. Novel macrocyclic cyanine and indocyanine bioconjugates that absorb and emit light in the near infrated region of electromagnetic spectrum are disclosed. These compounds are especially useful for endoscopic, localized... Agent: Patrick W. Rasche Armstrong Teasdale LLP

20070098646 - Aerosol propellants comprising unsaturated fluorocarbons: Disclosed herein are propellants comprising fluorocarbons and/or hydrofluorocarbons. Also disclosed are sprayable compositions comprising the propellants.... Agent: E I Du Pont De Nemours And Company Legal Patent Records Center

20070098644 - Delivery of a combination therapy for asthma and chronic obstructive pulmonary disease: A method of delivery of a combination therapy to the pulmonary system that includes providing a nebulizer and a fluid comprising a long-acting corticosteroid, a long-acting beta-agonist, and a long-acting anticholinergic in a pharmaceutically acceptable vehicle, and administering the solution to the patient using the nebulizer. The corticosteroid is budesonide,... Agent: Akerman Senterfitt

20070098645 - Intranasal delivery of compounds that reduce intrancranial pressure: Increasing intranasal lymphatic circulation as a means of decreasing intracranial pressure in traumatic brain injury.... Agent: Philip S. Johnson Johnson & Johnson

20070098647 - Skin care products: The invention relates to a formulation comprising an aqueous emulsion and a propellant gas for a foam skin cream, wherein the emulsion comprises urea and hyaluronic acid, at least one free fatty acid and at least two emulsifiers, wherein the hyaluronic acid has a molecular weight of at least 1×105... Agent: Darby & Darby P.C.

20070098648 - Treating mouth sores caused by dental braces with blobs of hydrophilic gums: A method for treating mouth sores caused by abrasion of orthodontic braces by placing oral patch or blob on the brace or sore to speed healing and relieve pain. The oral patch or blob is placed either on the portion of the brace that comes into contact with the sore... Agent: Graybeal, Jackson, Haley LLP

20070098649 - Method and composition for controlling oral pathogens: A composition and method of controlling oral and other human pathogens is disclosed. The composition and method utilize an antimicrobial or antibiotic and a berberine as active agents to treat mammals, including humans.... Agent: Greenlee Winner And Sullivan P C

20070098651 - Antimicrobial decapeptide oral hygiene treatment: A method for promoting oral hygiene that treats mature biofilms comprises the step of applying the antimicrobial peptide KSL and a surface active agent to the oral environment of applying KSL after mechanical disruption of the biofilm. An antiplaque chewing gum comprising KSL provides a sustained release oral hygiene treatment.... Agent: Office Of The Staff Judge Advocate U.s. Army Medical Research And Materiel Command

20070098650 - Dental formulation: An orally absorbable improved dental formulation is provided. The dental formulation, which reduce the occurrence of oral plaque, reduce gingival inflammation and bleeding, and whiten the user's teeth, may be a toothpaste or a rinse which comprises the following active ingredients: carbamide peroxide, papain, xylitol, and coenzyme Q10 (ubiquinone)... Agent: Sills Cummis Epstein & Gross P.C.

20070098652 - Fluoride-calcium compositions, dental products, and methods for providing dental fluoride: Disclosed are dental compositions and methods. In accordance with one embodiment, a dental composition includes calcium, fluorine, which is generally present in the form of fluoride, and phosphate or another stabilizing anion. The composition is stable as against precipitation of calcium fluoride during transport and storage, but is unstable against... Agent: Banner & Witcoff, Ltd.

20070098653 - Non-aqueous liquid composition having ultraviolet-absorbing capability: The present invention provides a non-aqueous liquid composition from which the coated film on the skin is transparent and slippery, does not cause stickiness and uncomfortable feeling such as creaky feeling and stretch feeling, but causes fresh feeling of use, and keeps the capability of protecting the skin from ultraviolet... Agent: Manelli Denison & Selter

20070098654 - Nail whitening composition: A cosmetic composition for bleaching discolored nails containing at least one hydrogen peroxide generator in an amount sufficient to perform bleaching of discolored nails, at least one film forming polymer and at least one cosmetically acceptable volatile solvent. Also disclosed is a method of bleaching discolored nails involving applying onto... Agent: Lerner, David, Littenberg, Krumholz & Mentlik

20070098655 - Use of diphenylmethane derivatives as tyrosinase inhibitors: c

20070098658 - Cosmetic composition textured with a bis-urea derivative with a liquid fatty phase textured with a bis-urea compound:

20070098656 - Topical skin barriers and methods of evaluation thereof: A topical skin barrier for protecting and promoting healing of skin, and for providing comfort to a patient, comprises a semi-solid hydrocarbon and a water-absorbing compound. The topical skin barrier effectively adheres to skin, affords protection from moisture and waste, and provides transparency in use. Methods of in vitro evaluation... Agent: Walter K. Roloff

20070098657 - Topical skin barriers and methods of evaluation thereof: A topical skin barrier for protecting and promoting healing of skin, and for providing comfort to a patient, comprises a semi-solid hydrocarbon, a water-absorbing compound, and a pain relief agent. The topical skin barrier effectively adheres to skin, affords protection from moisture and waste, provides transparency in use, and is... Agent: Walter K. Roloff

20070098659 - Method for making a cosmetic device having discrete elements: The present invention relates to a method of making a cosmetic device comprising a cosmetic composition and a plurality of discrete elements using a releasably connected matrix of discrete elements.... Agent: Philip S. Johnson Johnson & Johnson

20070098661 - Liquid to powder composition: The invention relates to silicone liquid-to-powder compositions for topical skincare applications. More specifically the invention relates to topical compositions comprising: a cosmetically acceptable powder, a silicone elastomer; a volatile fluid and a nonvolatile silicone fluid. The resulting product can be in the form of a viscous cream, lotion or putty... Agent: Dow Corning Corporation Mail Number C01232

20070098660 - Methods and compositions for epilation: A method of preparing a body surface for epilation is provided. The method includes, prior to said epilation, applying to the body surface a composition that is adapted to leave a powder residue on the body surface. The composition includes a fluid vehicle Compositions of the present invention may include... Agent: Philip S. Johnson Johnson & Johnson

20070098662 - Cosmetic composition promoting oxygen transport into the skin: A cosmetic composition containing from about 1% to about 50% by weight of membrane-forming sphingolipids and/or galactolipids and about 5% to about 50% by weight of a fluorocarbon or fluorocarbon mixture charged with oxygen. Surprisingly, it has been shown that the use of membrane-forming sphingolipids and/or galactolipids as transport vesicles... Agent: Simpson & Simpson, PLLC

20070098663 - Preparation and cosmetic applications of sucrose polyhydroxy lactone conjugates: This invention relates to the preparation of conjugates of sucrose and certain polyhydroxy lactones. Such conjugates have shown surprising and unexpected adhesive properties, which are useful for certain cosmetic applications such as dermabrasion, topical exfoliation, age spot removal, wart removal, and hair removal (depilation).... Agent: Shyam K. Gupta Bioderm Research

20070098664 - Cosmetic application of rod-coil copolymers: The present invention relates to a cosmetic composition containing, in a physiologically acceptable medium, at least one rod-coil type block copolymer comprising at least one “coil” polymeric block structure of variable conformation bonded to at least one “rod” block structure of restricted conformation, the composition being characterized in that said... Agent: Oliff & Berridge, PLC

20070098665 - Effects of skin surface temperature on the epidermal permeability barrier homeostasis: A method for accelerating barrier recovery of skin by activating the TRPV4 and/or by blocking the TRPV1 on epidermal cell is provided.... Agent: Snider & Associates

20070098666 - Citric acid ester: A mixture of citric acid esters of ethoxylated alcohols wherein the residue of the alcohol contains from 12 to 18 carbon atoms ethoxylated with from 5 to 9 ethoxy groups and a ratio by weight of monoester to diester in the mixture of citric acid esters in a range of... Agent: Cognis Corporation Patent Department

20070098667 - Methods and compositions for epilation: A method of preparing a body surface for epilation is provided. The method includes, prior to said epilation, applying to the body surface a composition that is adapted to leave a powder residue on the body surface. The composition includes a fluid vehicle Compositions of the present invention may include... Agent: Philip S. Johnson Johnson & Johnson

20070098671 - Composition and method of treatment for irritated skin: A composition for application to irritated skin including honey, aloe, and a derivative of the mangosteen plant. The composition may also include a thickening agent. Also disclosed is a method of treating skin including the step of applying the composition to the skin.... Agent: Advantia Law Group

20070098670 - Compositions and methods for using juice organic, juice based skin care products: The disclosure herein is directed to organic skin-based products that comprise an excess of 70% organic ingredients. The skin care products described herein are composed of a plurality of juices and other organic materials.... Agent: Baker & Mckenzie LLP Patent Department

20070098669 - Herbal skin formulation: An herbal skin formulation is described which is obtained by mixing naturally occurring Chinese herbs in a cooking vessel, adding sesame oil and continuing coooking until the mixture is browned. The herbs are then removed and beeswax added to the sesame oil until melting occurs. Upon cooling, the resultant is... Agent: Edward M. Fink, Esq.

20070098668 - Use of a lyophilisate of dedifferentiated plant cells for skin depigmentation and/or lightening: The invention relates to the use of at least one lyophilisate of dedifferentiated plant cells in a cosmetic or pharmaceutical composition for skin depigmentation and/or lightening purposes along with a protective regenerative effect. In addition, the invention relates to a topically-applied cosmetic or pharmaceutical composition comprising one such lyophilisate.... Agent: Birch Stewart Kolasch & Birch

20070098673 - Antibacterial deodorizer kit for refrigerator and purifying system using the same: In an embodiment of the present invention, a cold air inlet port of a refrigerating chamber of a refrigerator is provided with an antibacterial deodorizer kit, which is formed by injection-molding deodorizing agent containing antibacterial capsules. The antibacterial capsules are formed by microcapsulizing the antibacterial substance. A cold air discharge... Agent: Birch Stewart Kolasch & Birch

20070098672 - Fogger propellant system for containing and dispersing antimicrobial and air freshening compounds: A fogger propellant system configured to discharge an antimicrobial mixture in order to substantially inhibit growth and reproduction of microbes in the area adjacent to the system. The system further includes a container that has disposed therein a propellant and an antimicrobial compound. The antimicrobial compound is dispersed from the... Agent: Galasso & Associates, Lp

20070098677 - Ophthalmic compositions containing galactomannan polymers and borate: The present invention is directed to ophthalmic compositions containing a gelling amount of a combination of galactomannan polysaccharides and borates. The compositions gel or partially gel upon administration to the eye. The present invention also discloses methods of topical ophthalmic administration of the compositions to the eye.... Agent: Michael C. Mayo, R&d Counsel Alcon Laboratories, Inc.

20070098674 - Compositions and methods for cell killing: A method of generating a change in a cellular process of a target cell is disclosed. The method comprises contacting the target cell with a solid buffer, so as to alter an intracellular pH value in at least a portion of the cell, thereby generating the change in a cellular... Agent: Martin D. Moynihan Prtsi, Ins.

20070098678 - Enteric coated aliphatic amine polymer bile acid sequestrants: Tablets, capsules, sachets, or papers having one or more aliphatic amine polymers allow for the targeted release of the polymers at a specific region of the gastrointestinal tract, especially the small intestine. These tablets, capsules, sachets, or papers are useful in a method for lowering cholesterol in a mammal in... Agent: Hamilton, Brook, Smith & Reynolds, P.C.

20070098679 - Methods and compositions for applying pharmacologic agents to the ear: Methods and materials useful for applying pharmacologic agents to the ear are described. The methods involve delivering a composition that contains at least one viscogenic agent and at least one pharmacologic agent to the epidermal surface of the tympanic membrane via the ear canal. The composition is delivered to the... Agent: Fish & Richardson P.C.

20070098675 - Cross-linked polymer matrices, and methods of making and using same: Functionalized chondroitin sulfate, cross-linked polymer matrices comprising functionalized chondroitin sulfate, and methods of making and using the same are provided. Such polymer matrices may be used for tissue engineering, reconstructing cartilage, and the like. Kits are also provided for detection of cartilage degrading enzymes.... Agent: Bell, Boyd, & Lloyd LLP

20070098676 - Functionally diverse macromolecules and their synthesis: Functionally diverse macromolecules and synthetic routes for obtaining the same are disclosed. In certain embodiments, the synthesis proceeds in a divergent manner. In other embodiments, the routes rely on the differential reactivity of monomeric electrophilic triazine building blocks that display protected or unprotected groups. This diversity permits the facile introduction... Agent: Fulbright & Jaworski L.L.P.

20070098680 - Agent for treating diabetes mellitus: The object of the present invention is to provide a method for treating diabetes which is simple, safe and effective when compared to conventional diabetes treatment. The administration of one or more stem cell-recruiting factors allows a simple and safe repair of disrupted β-cells in pancreatic Langerhans' islets. Thus, the... Agent: Browdy And Neimark, P.l.l.c. 624 Ninth Street, Nw

20070098681 - Apo-2 ligand/trail variants and uses thereof: The disclosure provides Apo-2 ligand variant polypeptides. Methods of making and chemically modifying Apo-2 ligand variant polypeptides are also provided. In addition, formulations of Apo-2 ligand variant polypeptides are provided. In addition, therapeutic methods for using Apo-2 ligand variant polypeptides are provided.... Agent: Genentech, Inc.

20070098682 - Cytokine zalpha11 ligand antibodies: Antibodies that bind to polypeptides and peptides comprising the sequence of zalpha11 Ligand as shown in SEQ ID NO: 2 are described. The antibodies may bind the full length sequence of 162 amino acid residues or a fragment thereof, including a mature polypeptide of 131 amino acid residues and smaller... Agent: Zymogenetics, Inc. Intellectual Property Department

20070098683 - Cytokine zalpha11 ligand antibodies: Antibodies that bind to polypeptides and peptides comprising the sequence of zalpha11 Ligand as shown in SEQ ID NO: 2 are described. The antibodies may bind the full length sequence of 162 amino acid residues or a fragment thereof, including a mature polypeptide of 131 amino acid residues and smaller... Agent: Zymogenetics, Inc. Intellectual Property Department

20070098685 - Methods and kits to treat chronic inflammatory immune diseases by administering a proteasome inhibitor and an interleukin 2 receptor agonist: Methods and kits for treatment of immune diseases with an IL2 receptor agonist and a proteasome inhibitor are provided.... Agent: Sonia K. Guterman Lawson & Weitzen, LLP

20070098684 - Methods of reducing aggregation of il-1ra: Methods of reducing aggregation of an aggregating IL-1ra comprising incubating IL-1ra with at least one accessory molecule are provided. Kits comprising IL-1ra and at least one accessory molecule are also provided. Pharmaceutical compositions comprising IL-1ra and at least one accessory molecule are also provided.... Agent: Finnegan, Henderson, Farabow, Garrett & Dunner LLP

20070098686 - Use of apoptotic cells ex vivo to generate regulatory t cells: The present invention provides a method of generating T cells with regulatory activity by incubating leukocytes with autologous apoptotic peripheral blood mononuclear cells.... Agent: Philip S. Johnson Johnson & Johnson

20070098687 - Pharmaceutical composition containing interferon for the treatment of hpv infections: Disclosed is a liquid pharmaceutical composition containing interferon for peroral administration, and the use thereof in the treatment of infections caused by human papilloma virus (HPV).... Agent: Young & Thompson

20070098688 - Polymer conjugates of interferon beta-1a and uses: An interferon beta polypeptide comprising interferon-beta 1a coupled to a polymer containing a polyalkylene glycol moiety wherein the interferon-beta-1a and the polyalkylene glycol moiety are arranged such that the interferon-beta-1a has an enhanced activity relative to another therapeutic form of interferon beta (interferon-beta-1b) and exhibits no decrease in activity as... Agent: Foley Hoag, LLP Patent Group, World Trade Center West

20070098692 - Materials and methods for treating ocular-related disorders: The present invention is directed to a method of prophylactically or therapeutically treating an animal for at least one ocular-related disorder, e.g., ocular neovascularization or age-related macular degeneration. The method comprises contacting an ocular cell with an expression vector comprising a nucleic acid sequence encoding an inhibitor of angiogenesis and... Agent: Leydig Voit & Mayer, Ltd

20070098689 - Mutant viruses: An herpes simplex virus wherein the herpes simplex virus genome comprises nucleic acid encoding a nitroreductase (NTR) is disclosed. Disclosed herpes simplex viruses are indicated to be useful in the treatment of cancer which may involve gene directed enzyme prodrug therapy.... Agent: Klarquist Sparkman, LLP

20070098691 - Prostate specific antigen oligo-epitope peptide: The invention is a prostate specific antigen oligo-epitope peptide which comprises more than one PSA epitope peptide, which conforms to one or more human HLA class I motifs. The prostate specific antigen oligo-epitope peptide in combination with various HLA-class I molecules or interactions with various T-cell receptors elicits PSA specific... Agent: Office Of Technology Transfer National Institutes Of Health

20070098690 - Truncated cmv promoters and vectors containing same: The present invention relates to nucleic acid molecules comprising certain truncated forms of the human cytomegalovirus (CMV) immediate-early enhancer-promoter, either alone or operably linked to transgenes of interest, including those encoding partially-deleted CFTR proteins. This invention further relates to vectors comprising these nucleic acid molecules and host cells transformed by... Agent: Baker & Botts

20070098704 - Method of repairing tissue of a mammal: Method of treating disease or repairing tissue with compositions comprising mammalian peripheral blood stem cells, preferably CD34+/CD38− cells, and preferably peripheral blood stem cells resulting from TVEMF-expansion.... Agent: Ladas & Parry LLP

20070098701 - Methods for enhancing survival and/or proliferation of neural stem cells and neurite extension enhancers therefor pharmaceutical compostions containing neural stem cells assay methods and screening methods: Problems to be Solved Methods for enhancing survival and/or proliferation of neural stem cells and pharmaceutical compositions containing neural stem cells prepared by such methods, together with methods for assaying factors enhancing survival and/or proliferation of neural stem cells and methods for screening for such factors. Means for Solving the... Agent: Finnegan, Henderson, Farabow, Garrett & Dunner LLP

20070098703 - Methods for using adipose-derived cells for healing of aortic aneurysmal tissue: The present invention encompasses methods and apparatus for minimizing the risks inherent in endovascular grafting for aneurysm repair. The invention includes tracking a delivery means into an aneurismal site and deploying a stent graft in the aneurysmal site along side the delivery means. Next, adipocytes derived from adipose tissue are... Agent: Medtronic Vascular, Inc.IPLegal Department

20070098702 - Recombinant protein polymer vectors for systemic gene delivery: The present invention relates to genetically engineered non-viral vectors for delivering a nucleic acid such as a therapeutic gene to a target cell. The vectors are suitable for systemic administration to an animal. In the simplest embodiment the non-viral vector is a nucleic acid-binding protein-based polymer (NABP) having at least... Agent: Evans & Molinelli, PLLC

20070098700 - Synthetic mammalian retotransposon gene: The invention relates to synthetic transposon and retrotransposon genes that exhibit higher levels of expression relative to natural transposon and retrotransposon genes. The invention further relates to transposons and retrotransposons comprising such synthetic genes.... Agent: Edwards Angell Palmer & Dodge LLP

20070098705 - Probiotic composition comprising at least two lactic acid bacterial strains which are able to clonise the gatrointestonal tracts in combination with having intestinal survival property, intestinal binding property, an infection protection property and fib: In a probiotic composition comprising at least two specific lactic acid bacterial strains, the strains are able to colonize the gastrointestinal tract of humans and animals and have in combination at least two beneficial properties. The properties include an intestinal survival property, an intestinal binding property, an infection protecting property,... Agent: Merchant & Gould PC

20070098694 - Compositions and methods for the evaluation and resuscitation of cadaveric hearts for transplant: The present invention describes devices, solutions, and methods for the ex-vivo assessment, resuscitation, triage, and maintenance of human candidate cadaveric hearts.... Agent: Thomas W. Brown Medlen & Carroll, LLP

20070098696 - Immortalized fibroblasts: Aspects of the invention provide an immortalized fibroblast cell line capable of the growth and maintenance of human embryonic stem cells. An immortalized fibroblast cell line derived from an early stage mouse embryo is provided. Methods of preparing an immortalized fibroblast cell line from an early stage mouse embryo are... Agent: Wolf Greenfield & Sacks, PC

20070098693 - Methods for enhancing engraftment of purified hematopoietic stem cells in allogenic recipients: CD8+/TCR− bone marrow cells facilitate engraftment of hemapoietic stem cells (HSQ in allogeneic recipients without causing graft versus host disease. The present invention identifies the main subpopulation (55-65%) of CD8+/TCR− facilitating cells (FQ as plasmacytoid precursor dendritic cells (p-preDC). The present invention notably demonstrates that FC and p-preDC share many... Agent: Fish & Richardson P.C.

20070098695 - Methods of islet separation during isolation: The present invention relates to methods for improving the viability and recovery of islets that are separated from a donor organ for subsequent transplantation. In a preferred embodiment, the islets are separated from a donor pancreas and transplanted into the liver of a diabetic patient. A protective agent is mixed... Agent: Eric A. Lerner Eckert Seamans Cherin & Mellott, LLC

20070098698 - Pregnancy-induced oligodendrocyte precursor cell proliferation regulated by prolactin: The present invention relates to a method to increase oligodendrocytes and oligodendrocyte precursor cells through administration of prolactin or a prolactin inducing agent.... Agent: Fish & Richardson P.C.

20070098697 - Preventing transfusion related complications in a recipient of a blood transfusion: This invention is directed toward a process for reducing transfusion related complications in a recipient of an allogeneic blood transfusion by adding to the blood to be transfused a photosensitizer comprising riboflavin, irradiating the blood and riboflavin with light, transfusing the irradiated blood into a recipient, and reducing a transfusion... Agent: Gambro, Inc Patent Department

20070098699 - Process for preparing bone marrow stem cells, and composition related thereto: Process for preparing a composition comprising TVEMF-expanded bone marrow stem cells, anti the composition resulting therefrom.... Agent: Ladas & Parry LLP

20070098706 - Nadph oxidase cytosolic cofactor mutant: A purified polypeptide includes an NADPH oxidase cytosolic cofactor polypeptide NOXA1 or P67phox having a C-terminal SH3 domain insertion mutation of at least three consecutive amino acids positioned between PEDL and GIFPK motifs of said SH3 domain so as to reduce activity of the purified polypeptide relative to the wild-type... Agent: Gifford, Krass, Sprinkle,anderson & Citkowski, P.c

20070098707 - Methods and compositions for inhibiting c-met dimerization and activation: The invention provides methods and compositions for modulating the HGF/c-met signaling pathway, in particular by regulating c-met dimerization and/or binding of ligand to c-met using a c-met antagonist that disrupts c-met multimerization.... Agent: Genentech, Inc.

20070098708 - Heparan sulfate glycosaminoglycan lyase and uses thereof: The invention provides recombinant B. thetaiotaomicron HSGAG lyase polypeptides. The invention also provides nucleic acid molecules encoding such polypeptides, recombinant expression vectors containing B. thetaiotaomicron HSGAG lyase nucleic acid molecules, and host cells into which the expression vectors have been introduced. Characterization, diagnostic and therapeutic methods utilizing compositions of the... Agent: Fish & Richardson PC

20070098709 - Methods for treating and preventing diabetic retinopathy: This invention provides a method for treating diabetic retinopathy in a subject afflicted therewith, comprising administering to the subject's eyes a therapeutically effective amount of an agent that modulates the binding between AGE and RAGE in the subject's eyes, wherein the agent is not soluble RAGE or a derivative thereof,... Agent: Cooper & Dunham, LLP

20070098710 - Anxiolytic composition comprising essential oil derived from plants as active ingredients, anxiolytic comprising thereof, and a producing method thereof: The present invention provides a percutaneous anxiolytic of which active ingredient is an essential oil derived from plants, a composition thereof, and a method for producing thereof. The percutaneous anxiolytic comprising Rose Absolute, which is an active ingredient, an essential oil adsorbent, a release water remover, an essential oil adsorption/desorption... Agent: Armstrong, Kratz, Quintos, Hanson & Brooks, LLP

20070098712 - method for making multispecific antibodies having heteromultimeric and common components: The invention relates to a method of preparing heteromultimeric polypeptides such as bispecific antibodies, bispecific immunoadhesins and antibody-immunoadhesin chimeras. The invention also relates to the heteromultimers prepared using the method. Generally, the method provides a multispecific antibody having a common light chain associated with each heteromeric polypeptide having an antibody... Agent: Merchant & Gould PC

20070098711 - Methods of producing stable b-lymphocytes: The invention provides a method of producing a stable lymphocyte culture and methods of producing monoclonal antibodies.... Agent: Mintz, Levin, Cohn, Ferris, Glovsky And Popeo, P.C.

20070098713 - Nanoparticle delivery systems and methods of use thereof: Certain embodiments of the invention relate to the use of small particles in biological systems, including the delivery of biologically active agents. Some embodiments involve using a collection of particles comprising an agent, a surfactant molecule having an HLB value of less than about 6.0 units, and a polymer soluble... Agent: Dardi & Associates, PLLC

20070098715 - Antibodies against the tenascin major antigens: The invention described herein relates to antibodies directed to the antigen Ten-M2 and uses of such antibodies. In particular, there are provided fully human monoclonal antibodies directed to the antigen Ten-M2. Isolated polynucleotide sequences encoding, and amino acid sequences comprising, heavy and light chain immunoglobulin molecules, particularly sequences corresponding to... Agent: Mintz, Levin, Cohn, Ferris, Glovsky & Popeo, P.C.

20070098714 - Preventive agent for vasculitis: To provide a preventive and/or therapeutic agent for vasculitis such as polyarteritis nodosa, the aortitis syndrome, and a vasculitis that is associated with immunological abnormalities, said agent comprising an interleukin-6 (IL-6) antagonist as an active ingredient.... Agent: Foley And Lardner LLP Suite 500

20070098716 - Toll like receptor 3 modulators, methods and uses: Toll Like Receptor 3 (TLR3) modulators, such as antibodies, polynucleotides encoding TLR3 antibodies or fragments thereof, and methods of making and using the foregoing are disclosed.... Agent: Philip S. Johnson Johnson & Johnson

20070098720 - Cd40-binding apc-activating molecules: Disclosed are agonist anti-CD40 molecules, including monoclonal antibodies, which can bind to and stimulate professional and non-professional human antigen-presenting cells (“APCs”), enhance the stimulatory effect of CD40L on CD40 positive cells and/or induce phenotypical maturation of monocyte derived dendritic cells. Several such monoclonal antibodies are provided, and cell lines producing... Agent: Darby & Darby P.C.

20070098719 - Gitr binding molecules and uses therefor: The present invention provides binding molecules that specifically bind to GITR, e.g., human GITR (hGITR), on T cells and dendritic cells. Binding molecules of the invention are characterized by binding to hGITR with high affinity, in the presence of a stimulating agent, e.g., CD3, are agonistic, and abrogate the suppression... Agent: Lahive & Cockfield, LLP

20070098718 - Methods of therapy for b cell-related cancers: Methods of treating a human subject for a cancer characterized by neoplastic B cell growth are provided. The methods comprise administering combination antibody therapy to the subject, where an effective amount of an antagonist anti-CD40 antibody or antigen-binding fragment thereof in combination with an anti-CD20 antibody or antigenbinding fragment thereof... Agent: Alston & Bird LLP

20070098717 - Methods of therapy for solid tumors expressing the cd40 cell-surface antigen: Methods of therapy are provided for treating a subject for a solid tumor that comprises carcinoma cells expressing the CD40 cell-surface antigen. The methods comprise administering a therapeutically effective amount of an antagonist anti-CD40 antibody or antigen-binding fragment thereof to a subject in need thereof. The antagonist anti-CD40 antibody or... Agent: Alston & Bird LLP

20070098721 - Amyloid beta(1-42) oligomers, derivatives thereof and antibodies thereto, methods of preparation thereof and use thereof: The invention relates to neuromodulatory oligomers of the amyloid-β(1-42) protein, a particular production method, by means of which the oligomer can be obtained in a reproducible manner at high yield, the use of the oligomers as diagnostic and therapeutics agents, for the generation of oligomer-specific antibodies and for the discovery... Agent: Wood, Phillips, Katz, Clark & Mortimer

20070098722 - Medicament comprising inhibitors of long pentraxin ptx3: The use of inhibitors of long pentraxin PTX3 for the preparation of a medicament for the prevention and treatment of autoimmune diseases and of degenerative diseases of bone and cartilage is described.... Agent: Nixon & Vanderhye, PC

20070098726 - Methods of making and using antibodies directed to parathyroid hormone: The present invention relates to methods of generating anti-PTH antibodies and antibodies generated by the methods of the invention. The anti-PTH antibodies generated by the methods of the invention specifically bind to an epitope on a whole PTH (1-84) which includes one or more N-terminal amino acid residues of the... Agent: Morrison & Foerster LLP

20070098724 - Methods of treatment using vascular occlusion in combination with one or more therapies: The present invention relates generally to methods and compositions for treating a disease or condition by administering a first therapeutic protocol comprising targeting and delivering solid-phase platelet-dependent vascular occlusion agents, and administering at least one second therapeutic composition or method.... Agent: William J Bundren The Law Office Of William J Bundren

20070098725 - Peptide-based immunization therapy for treatment of atherosclerosis: The present invention relates to antibodies raised against fragments of apolipoprotein B, in particular defined peptides thereof, for immunization or therapeutic treatment of mammals, including humans, against ischemic cardiovascular diseases, using one or more of said antibodies.... Agent: Gauthier & Connors, LLP

20070098723 - Peptide-based passive immunization therapy for treatment of atherosclerosis: The present invention relates to passive immunization for treating or preventing atherosclerosis using an isolated human antibody directed towards at least one oxidized fragment of apolipoprotein B in the manufacture of a pharmaceutical composition for therapeutical or prophylactical treatment of atherosclerosis by means of passive immunization, as well as method... Agent: Gauthier & Connors LLP

20070098727 - Use of cytokine expression to predict skin inflammation; methods of treatment: Provided are methods for diagnosing the propensity of a subject to develop skin inflammation, in particular, psoriasis. Also provided are methods of treatment with antagonists of IL-17, IL-19, and/or IL-23.... Agent: Schering-plough Corporation Patent Department (k-6-1, 1990)

20070098730 - Multiple antigen glycopeptide carbohydrate, vaccine comprising the same and use thereof: A carbohydrate peptide conjugate comprising a carrier comprising a dendrimeric poly-Lysine enabling multipic epitopes to be covalently attached thereto, at least one peptide comprising one T epitope or several identical or different T epitopes, at least one carbohydrate moiety, or a derivative thereof, containing B epitope, provided it is not... Agent: Oblon, Spivak, Mcclelland, Maier & Neustadt, P.C.

20070098728 - Novel compositions and methods in cancer: This invention is in the field of cancer-associated (CA) genes. Specifically it relates to methods for detecting and diagnosing cancer or the likelihood of developing cancer based on the presence or absence of expression of PI3KR1, GNAS, NESP5, JAK1, neurogranin, HIPK1, or Nrf2, or proteins encoded by those genes. The... Agent: Sagres Discovery Inc. Intellectual Property - R440

20070098729 - Novel serpentine transmembrane antigens expressed in human cancers and uses thereof: Described is a novel family of cell surface serpentine transmembrane antigens. Two of the proteins in this family are exclusively or predominantly expressed in the prostate, as well as in prostate cancer, and thus members of this family have been termed “STEAP” (Six Transmembrane Epithelial Antigen of the Prostate). Four... Agent: Heller Ehrman LLP

20070098731 - Treatment of infection due to clostridium difficile: The present invention discloses a Clostridium difficile lactate dehydrogenase comprising the amino acid sequence of SEQ ID NO: 2, or an amino acid sequence exhibiting at least 70, 80, 90, 95, 96, 97, 98, 99, or 99.5% identity with the amino acid sequence of SEQ ID NO: 2. A Clostridium... Agent: Rothwell, Figg, Ernst & Manbeck, P.C.

20070098734 - Ex-vivo priming for generating cytotoxic t lymphocytes specific for non-tumor antigens to treat autoimmune and allergic disease: Cytotoxic T lymphocytes (CTLs) specific for antigenic peptides derived from IgE molecule can be generated in vitro by stimulating resting naive CD8 T cells with IgE peptides presented by artificial antigen presenting cells. The IgE specific CTLs lyse the target cells loaded with IgE peptides in vitro and inhibit antigen... Agent: Woodcock Washburn LLP

20070098732 - Immunologic compounds for prevention, protection, prophylaxis or treatment of immunological disorders, infections and cancer: The present invention relates to the use of PDT-treated cells (whole or fragments thereof) and/or supernatant thereof in the preparation of vaccines for immunoprotection or immunomodulation. More particularly, the use of PDT-treated cells (whole or fragments thereof) and/or supernatant thereof in the preparation of an immunologic compound for prevention, protection,... Agent: Crowell & Moring LLP Intellectual Property Group

20070098733 - In ovo delivery of an immunogen containing implant: The disclosure provides a method for administering an agent to an avian species by in ovo delivery of an implant releasably containing the agent. In one embodiment, the method is particularly advantageous for stimulating an immune response in a bird by in ovo administration of a biocompatible implant releasably containing... Agent: Mueting, Raasch & Gebhardt, P.A.

20070098736 - Injection vehicle for polymer-based formulations: The invention provides injection vehicles suitable for administering particulate suspensions, such as polymer-based formulations, as well as associated pharmaceutical formulations, articles of manufacture, and kits. Other aspects of the invention included methods for producing and administering pharmaceutical formulations. The injection vehicles of the invention are superior to conventional injection vehicles... Agent: Merchant & Gould PC

20070098735 - Methods for the elimination of pathogens and other particulate agents: Disclosed herein are methods of treating infections, wounds, and exposure to particulate agents, comprising administering a heat shock protein (HSP) such as HSP70. The HSP may be uncomplexed to an antigenic peptide. Uncomplexed HSPs have been shown to activate phagocytosis by macrophages, and are thus particularly useful for the rapid... Agent: Cantor Colburn, LLP

20070098737 - Streptococcal streptolysin s vaccines: Provided are streptolysin S (SLS) polypeptides, peptides, and variants thereof, antibodies directed thereto, and isolated nucleic acids encoding such proteins. In one embodiment, a method is provided wherein a synthetic peptide of SLS is used to elicit an immune response specific for SLS in a subject to treat or prevent... Agent: Seed Intellectual Property Law Group PLLC

20070098738 - Msp-3-like family of genes: The present invention relates to the protection against malaria. More particularly, the invention pertains to a novel family of genes encompassing the already known MSP-3 gene, and showing exceptional redundancy of exposed epitopes, hence suggesting that this family of genes plays an important part in the immunogenicity of the parasite.... Agent: Finnegan, Henderson, Farabow, Garrett & Dunner LLP

20070098739 - Vaccine compositions for vaccinating dogs against canine infectious respiratory disease: A vaccine composition for vaccinating dogs comprising any one or more of (a) an agent capable of raising an immune response against Streptococcus equi sub species zooepidemicus in a dog, (b) an agent capable of raising an immune response against Mycoplasma cynos in a dog, and (c) an agent capable... Agent: Knobbe Martens Olson & Bear LLP

20070098740 - Stabilisation of viral microparticles: A micro-particulate dry powder composition comprising a viral particle can be prepared by spray-drying a mixture of the viral particle and a stabilizing carbohydrate using an outlet temperature of no more than 60° C.... Agent: Saliwanchik Lloyd & Saliwanchik A Professional Association

20070098741 - Vectors derived from antibodies for transferring substances into cells: The present invention provides novel polypeptides which can effectively penetrate into cells thereby transporting a substance of interest into the cells.... Agent: Oblon, Spivak, Mcclelland, Maier & Neustadt, P.C.

20070098742 - Canine influenza virus and related compositions and methods of use: The present invention provides an isolated canine influenza virus of subtype H3N8 comprising an HA having SEQ ID NO: 4 or an amino acid sequence that is greater than 99% identical to SEQ ID NO: 4, with the proviso that the amino acids at positions 94 and 233 are identical... Agent: Barnes & Thornburg LLP

20070098743 - Mutant vesicular stomatitis viruses and uses thereof: The present invention provides mutant viruses with a decreased ability to block nuclear transport of mRNA or protein in an infected cell which are attenuated in vivo. The mutant viruses of the present invention may also be capable of triggering the anti-viral systems of normal host cells while remaining sensitive... Agent: Legal Department

20070098745 - Antagonistic properties of reef fish microflora: The present invention provides methods for preventing biofilm formation on a surface. The present invention also relates to anti-biofilm forming agents, to methods of producing and using them, and to anti-fouling coatings produced therefrom.... Agent: Cooley Godward Kronish LLP Attn: Patent Group

20070098744 - Probiotic enterococci for improved immunity: Compositions and methods for modulating immunity and vaccine efficacy in animals are disclosed. The compositions and methods utilize probiotic organisms, specifically probiotic Enterococcus strains, and are particularly applicable to felines.... Agent: Drinker Biddle & Reath Attn: Intellectual Property Group

20070098746 - Multi-layered coating technology for taste masking: Various embodiments of the present invention relate to compositions and methods that have multi-layer coating technology that provide improved taste masking. This technology enables taste masked drug substances to withstand hydration due to saliva in the mouth and aqueous solutions.... Agent: Johnson & Johnson

20070098748 - Stabilized formulations of alpha adrenergic receptor antagonists and the uses thereof: The present invention provides compositions and stable liquid formulations comprising alpha adrenergic receptor antagonists and use thereof for increasing blood flow. In one embodiment, the stable liquid formulations of this invention are useful for reversing the effects of an anesthetic agent, preferably a long-lasting local anesthetic agent administered in conjunction... Agent: Sterne, Kessler, Goldstein & Fox P.l.l.c.

20070098747 - Topical pharmaceutical composition for the treatment of inflammatory dermatoses: Provided is a topical pharmaceutical composition for the treatment of inflammatory dermatoses, including acne vulgaris, together with methods for its use. The composition and methods involve the topical use of an active agent effective in the treatment of inflammatory dermatoses plus a permeation-enhancing base that, in one embodiment, gives the... Agent: Intellectual Property Group Fredrikson & Byron, P.A.

20070098749 - Cosmetic device comprising discrete elements: A cosmetic device comprising a solid or semi-solid cosmetic composition comprising a plurality of discrete elements is provided. The discrete elements each comprise a water soluble core surrounded by an erodible shell. The cosmetic composition may be a cleansing composition. The discrete elements may form a matrix.... Agent: Philip S. Johnson Johnson & Johnson

20070098751 - Method and composition for inhibition of microbial growth in aqueous food transport and process streams: The present invention relates to compositions including peroxyacetic acid and peroxyoctanoic acid and methods for preventing microbial growth in aqueous streams including the step of applying a composition of the invention to the stream. The compositions and methods can control microbial growth in aqueous streams used for transporting or processing... Agent: Merchant & Gould PC

20070098750 - Pesticidal compositions containing isopropyl myristate and analogs of same as a synergist for plant essential oils: Pesticidal compositions containing as a pesticidally acceptable carrier, at least one plant essential oil compound as a pesticidally active ingredient; and isopropyl myristate, isopropyl palmitate or analogs thereof, as a synergist, and methods for using same, are disclosed.... Agent: Nixon & Vanderhye, PC

20070098752 - Quick dissolving carrier granules: A quickly dissolving carrier granule made up of wood fibers, mineral filler, and starch-based or dextrin-based adhesive binder. The wood fibers in these granules are preferably wood fibers ranging from about 10 microns to about 2 mm in length. Typically, at least about 35 weight-% of the fibers are retained... Agent: Birch Stewart Kolasch & Birch

20070098758 - Biologically absorbable coatings for implantable devices and methods for fabricating the same: Coatings for an implantable medical device and a method of fabricating thereof are disclosed, the coatings comprising a biologically degradable, biologically erodable, and/or biologically resorbable ABA or AB block copolymer. A biologically active agent can be conjugated to the block copolymer.... Agent: Squire, Sanders & Dempsey LLP

20070098756 - Bone matrix compositions and methods: An osteoinductive composition, corresponding osteoimplants, and methods for making the osteoinductive composition are disclosed. The osteoinductive composition comprises osteoinductive factors, such as may be extracted from demineralized bone, and a carrier. The osteoinductive composition is prepared by providing demineralized bone, extracting osteoinductive factors from the demineralized bone, and adding the... Agent: Dorsey & Whitney LLP Intellectual Property Department

20070098757 - E-ptfe foil impregnated with an encapsulated bioactive substance: A method of impregnating an e-PTFE (expanded polytetrafluoroethylene) foil with a biologically-active substance.... Agent: Morrison & Foerster, LLP

20070098753 - Local administration of a combination of rapamycin and cilostazol for the treatment of vascular disease: Medical devices, and in particular implantable medical devices, may be coated to minimize or substantially eliminate a biological organism's reaction to the introduction of the medical device to the organism. The medical devices may be coated with any number of biocompatible materials. Therapeutic drugs, agents or compounds may be mixed... Agent: Philip S. Johnson Johnson & Johnson

20070098754 - Method and article to restore function to gi or urinary tract of a patient: Method and article for restoring function to a region of a body selected from the group consisting of a gastrointestinal tract and a urinary tract of a patient. A biological agent is optionally associated with a carrier and inserted into the region of the body. The biological agent is stabilized... Agent: Iplm Group, P.A.

20070098755 - Tissue augmentation devices and methods: Tissue augmentation devices, as well as methods of manufacturing and using the same, are disclosed. In certain embodiments, a tissue augmentation device comprises an elongate tissue penetrating member and an amount of remodelable material, wherein at least a portion of the elongate member is cannulated, and at least a portion... Agent: Woodard, Emhardt, Moriarty, Mcnett & Henry LLP

20070098759 - Method for regenerating cartilage: Disclosed is a method for regenerating articular cartilage in an animal comprising administering a therapeutically effective amount of a non-demineralized particulate articular cartilage having a distribution of particle sizes within the range of from about 60 microns to about 500 microns.... Agent: Leydig Voit & Mayer, Ltd

20070098760 - Method for treating and/or preventing retinal diseases with sustained release corticosteroids: The present invention relates to a method for administering a corticosteroid to a posterior segment of an eye. In the method, a sustained release device is implanted to deliver the corticosteroid to the eye. The aqueous corticosteroid concentration remains less than vitreous corticosteroid concentration during release of the corticosteroid from... Agent: Fish & NeaveIPGroup Ropes & Gray LLP

20070098764 - Colon cleansing compositions and methods: A composition comprising, per litre of aqueous solution, from 30 to 350 g polyethylene glycol, from 3 to 20 g of an ascorbic acid component selected form the group consisting of ascorbic acid, a salt of ascorbic acid, or a mixture thereof, an alkali metal or alkaline earth metal sulphate,... Agent: Leon R. Yankwich Yankwich & Associates, P.C.

20070098762 - Immunemodulating oligosaccharides: The present invention relates to a method for enhancing the immune system and the treatment and/or prevention of immune system related disorders in a mammal, particularly newborns, said method comprising the administration of acid oligosaccharide and neutral oligosaccharide. Food compositions suitable for use in the above method are also provided.... Agent: The Webb Law Firm, P.C.

20070098765 - Method of making and using theaflavin, theaflavin-3-gallate, theaflavin-3'-gallate and theaflavin 3,3'-digallate and mixtures thereof: The present invention discloses methods of making a mixture of theaflavin, theaflavin-3-gallate, theaflavin-3′-gallate and theaflavin 3,3′-digallate, pharmaceutical compositions of the above mixture of theaflavins, diet supplement compositions of the above mixture of theaflavins and methods for using the above mixtures of theaflavin and pharmaceutical compositions thereof to treat or prevent... Agent: Cooley Godward Kronish LLP Attn: Patent Group

20070098761 - Processed fat composition for preventing/ameliorating lifestyle-related diseases: The object of the invention is to provide a composition for prevention and/or amelioration of life-style related disease, and/or a composition for inhibition and/or amelioration of increase in body weight, comprising at least one compound selected from the group consisting of glabrene, glabridin, glabrol, 3′-hydroxy-4′-O-methylglabridin, 4′-O-methylglabridin and hyspaglabridin B as... Agent: Kenyon & Kenyon LLP

20070098763 - Soluble fiber combinations for weight control and improving parameters of cardiovascular health: A food or pharmaceutical agent is provided for treating or offsetting the risks of a disease or disorder such as a cardiovascular disease, a hypercholesterolemia disorder, a low serum high density lipid (HDL)/low density lipid (LDL) ratio, a hypertriglyceridemia disorder, and diabetes includes a pharmaceutical carrier, and a composition including... Agent: David K. Benson

20070098766 - Nonaqueous pressure-sensitive adhesive for medicinal tape preparation for percutaneous absorption, medicinal tape preparation for percutaneous asorption, and process for producing the same: A nonaqueous pressure-sensitive adhesive for a medicinal tape preparation for percutaneous absorption comprising (a) a support, (b) a pressure-sensitive adhesive layer containing a drug and a nonaqueous pressure-sensitive adhesive and (c) a release film laminated in that order, and a medicinal tape preparation for percutaneous absorption comprising the adhesive. The... Agent: Ohlandt, Greeley, Ruggiero & Perle, LLP

20070098767 - Substrate and personal-care appliance for health, hygiene, and/or environmental applications(s); and method of making said substrate and personal-care appliance: Substrates, and personal-care appliances made from such substrates, include an inter-bonded fibrous layer having shaped discontinuities and reinforcing strands attached to said inter-bonded fibrous layer. Pores between the fibers in the inter-bonded fibrous layer are suited to help hold liquid. The shaped discontinuities are suited to help generate suds or... Agent: Kimberly-clark Worldwide, Inc.

20070098768 - Two-sided personal-care appliance for health, hygiene, and/or environmental application(s); and method of making said two-sided personal-care appliance: Disclosed is a two-side personal-care appliance for various applications, including exfoliation of skin. The appliance comprises a first interbonded fibrous layer having three-dimensional contours on both faces of the layer. These contours facilitate exfoliation and/or stimulation and/or gentle abrasion of skin. Furthermore, these contours facilitate contact and attachment to the... Agent: Kimberly-clark Worldwide, Inc.

20070098769 - Systems and methods for treating hot flashes associated with menopause: Kits and systems for treating hot flashes in a menopausal woman include one or more cooling devices suitable to be placed on a woman's skin, at a hot flash origin site, such as a location on the woman's back, for example, between the shoulder blades of the woman when experiencing... Agent: Frank J Uxa

20070098770 - Cosmetic path using method thereof, and cosmetic path package: The present invention provides a cosmetic patch which can contain therein either one of a water soluble vitamin and a fat soluble vitamin, particularly when the vitamin is vitamin C, can contain and retain vitamin C stably while avoiding its deterioration due to oxidation or hydrolysis and not causing deterioration... Agent: Sughrue Mion, PLLC

20070098771 - High enhancer-loading polyacrylate formulation for transdermal applications: A polyacrylate formulation suitable for delivery of drug to through a body surface of an individual. By loading the drug and permeation enhancers at a high concentration into a polyacrylate proadhesive that has inadequate adhesive properties for typical adhesive application on the skin, a formulation with desirable adhesive characteristics and... Agent: Philip S. Johnson Johnson & Johnson

20070098774 - Method of delivering a medication: A needleless microprotrusion method for infusion of a medicament into a patient includes disposing a substrate plurality of microprotrusions onto a patients' palm. A chemodenervating agent is disposed for delivery by the microprotrusions and the substrate supports and conforms the microprotrusions to the patients' palm in order to enable uniform... Agent: Walter A. Hackler

20070098773 - Needleless microprotrusion elastoplast system: A needleless microprotrusion system for infusion of a medicament into a patient includes a plurality of microprotrusions having a length sufficient to penetrate a stratum corneum of the patient. A chemodenervating agent is disposed for delivery by the microprotrusions and a substrate is provided for supporting the microprotrusions and conforming... Agent: Walter A. Hackler

20070098775 - Novel composition for transdermal and/or transmucosal administration of active compounds that ensures adequate therapeutic levels: A pharmaceutical composition in the form of a solution, cream, lotion, spray, ointment, gel, aerosol, tablet, suppository or patch device for transdermal or transmucosal administration of alprazolam to a subject, which includes as a permeation enhancing mixture a fatty component in an amount of 0.1% to 20% by weight which... Agent: Winston & Strawn LLP Patent Department

20070098772 - Transdermal norelgestromin delivery system: A system for transdermal delivery of norelgestromin (NGMN) to an individual. The system has a high NGMN loading with suitable permeation enhancers to effect therapeutic flux rate. Polyacrylate drug reservoir with the NGMN and high loading of one or more of permeation enhancers and NGMN dissolved therein provides desirable adhesive... Agent: Philip S. Johnson Johnson & Johnson

20070098776 - Hla class i a2 tumor associated antigen peptides and vaccine compositions: A composition or vaccine composition comprising at least one peptide that has less than 600 contiguous amino acids having 100% identity to a native sequence of CEA, HER2/neu, MAGE2, MAGE3, or p53, the peptide further comprising at least one epitope selected from Table 6.... Agent: Sterne, Kessler, Goldstein & Fox PLLC

20070098777 - Pharmaceutical or food composition for treatment or prevention of brain edema: Melatonin has an activity of treating or preventing brain edema. Thus, the invention relates to a pharmaceutical composition comprising melatonin as an active ingredient. And, the invention relates to use of melatonin in the preparation of a pharmaceutical composition comprising melatonin as an active ingredient.... Agent: Oblon, Spivak, Mcclelland, Maier & Neustadt, P.C.

20070098778 - Co-formulations or kits of bioactive agents: Provided, among other things, is a formulation or kit comprising: (a) a pharmaceutically effective dosage of one or more a glucose-level-controlling bioactive agents selected from an α-glucodase inhibitor, sulfonylurea, meglitinide, thiazolidinediones, biguanide, insulin, dual PPARα/γ agonist, PPARγ agonist or insulin secretagogue; and (b) a pharmaceutically effective dosage of (i) one... Agent: Roger Glenn Hendricks

20070098784 - Delivery system for biological component: A controlled release delivery system composition and method applied to humans and animals, for oral, anal or vaginal administration of a biological component is disclosed. Preferably, a bacterium is delivered, and more preferably the bacterium is probiotic in nature, however, the biological component is not limited to the bacterium.... Agent: Miller Nash LLP

20070098779 - Films and capsules made from modified carboxymethylcellulose materials: Films and/or capsules for the delivery of and/or coating of active ingredients are provided. Such edible films and/or capsules comprise particular modified carboxymethylcellulose (CMC) materials either alone or in combination with other types of hydrocolloids or biogums. The utilization of such modified CMC products aids in the production of such... Agent: J M Huber Corporation

20070098783 - Hydrophilic vehicle-based dual controlled release matrix system: A hydrophilic vehicle-based dual controlled-release matrix system, suitable for encapsulation in hard or soft capsules, has been developed. The matrix is in the form of a solution or a suspension, which allows for easier formulation of low dose compounds. The matrix includes two rate controlling barriers for the controlled release... Agent: Patrea L. Pabst Pabst Patent Group LLP

20070098780 - Method for preparing a pharmaceutical compound by way of magnetic carbon nanocapsules: A method for preparing a pharmaceutical compound by way of magnetic carbon nanocapsules is disclosed. The method comprises steps of: (a) providing a magnetic carbon nanocapsule with C—(COOH)2 group, and Pt cations, to form a complex; (b) collecting the complex from the magnetic carbon nanocapsule; and (c) removing the Pt... Agent: Bacon & Thomas, PLLC

20070098781 - Modified release compositions for dpp-iv inhibitors: The present invention refers to pharmaceutical composition comprising a DPP-IV inhibitor.... Agent: Hoffmann-la Roche Inc. Patent Law Department

20070098782 - Ramipril formulation: A Ramipril formulation which is suitably stabilised to control the degradation to the active metabolite ramiprilat.... Agent: Sterne, Kessler, Goldstein & Fox P.l.l.c.

20070098785 - Medicant delivery system and device: A medicant delivery system and device containing a pre-measured, multi-symptom relieving medicine dose is provided. In particular, the delivery system relates to highly viscous cold and/or flu relieving medicants conveniently packaged in single doses. The medicant contains a plurality of therapeutic ingredients and is flavor neutral. The viscosity of the... Agent: Snell & Wilmer L.L.P. (main)

20070098786 - Enteric valproic acid: An enteric valproic acid soft gelatin capsule, in which the enteric polymer is a component of the capsule shell rather than a coating, has been developed. The fill material comprises valproic acid or divalproex sodium and, optionally, one or more pharmaceutically acceptable excipients such as corn oil. The capsule shell... Agent: Patrea L. Pabst Pabst Patent Group LLP

20070098787 - Composition for preventing and treating varicose veins of lower extremities: A preventive/therapeutic agent for varicose veins or a composition for the prevention or alleviation of symptoms relevant to varicose veins. The preventive/therapeutic agent for varicose veins or the composition for the prevention or alleviation of symptoms relevant to varicose veins each is characterized by containing eicosapentaenoic acid.... Agent: Birch Stewart Kolasch & Birch

20070098788 - Non-benzodiazepine hypnotic compositions: Pharmaceutical compositions comprising non-benzodiazepine hypnotic drugs or their pharmaceutically acceptable salts, solvates, enantiomers or mixtures and processes for preparing the same. The invention also includes immediate release and extended release pharmaceutical compositions comprising non-benzodiazepine hypnotic drugs, useful for sleep induction and sleep maintenance.... Agent: Dr. Reddy's Laboratories, Inc.

20070098789 - Organoleptically acceptable ibuprofen oral dosage formulations, methods of making and using the same: Organoleptically acceptable solid oral dosage formulations of ibuprofen, and methods of making and using the same, are provided. A feature of the subject formulations is that they include ibuprofen and a masking component. In certain embodiments, the masking component includes one or more of a cooling agent, an organic acid... Agent: Bozicevic, Field & Francis LLP

20070098791 - Controlled release compositions comprising a combination of isosorbide dinitrate and hydralazine hydrochloride: The invention relates to a controlled release composition comprising a combination of isosorbide dinitrate and hydralazine, such as hydralazine hydrochloride, that in operation delivers the drug in a pulsed or multi-modal manner for the treatment of angina, ischaemic heart disease, arterial hypertension and related disease conditions. Preferably, the isosorbide dinitrate... Agent: Synnestvedt & Lechner, LLP

20070098790 - Nutritional supplement for the enhancement of the health of the liver: Compositions, systems, and methods of enhancing the health of the liver are disclosed. The synergistic effect of N-acetylcysteine, glutathione, vitamin C and vitamin E is to counteract the toxic effects of analgesics such as acetaminophen on the liver. Also disclosed is an enteric coating material which may be used with... Agent: Knobbe Martens Olson & Bear LLP

20070098792 - Oxymorphone controlled release formulations: The invention pertains to a method of relieving pain by administering a controlled release pharmaceutical tablet containing oxymorphone which produces a mean minimum blood plasma level 12 to 24 hours after dosing, as well as the tablet producing the sustained pain relief.... Agent: Mayer, Brown, Rowe & Maw LLP

20070098793 - Oxymorphone controlled release formulations: The invention pertains to a method of relieving pain by administering a controlled release pharmaceutical tablet containing oxymorphone which produces a mean minimum blood plasma level 12 to 24 hours after dosing, as well as the tablet producing the sustained pain relief.... Agent: Mayer, Brown, Rowe & Maw LLP

20070098794 - Oxymorphone controlled release formulations: The invention pertains to a method of relieving pain by administering a controlled release pharmaceutical tablet containing oxymorphone which produces a mean minimum blood plasma level 12 to 24 hours after dosing, as well as the tablet producing the sustained pain relief.... Agent: Mayer, Brown, Rowe & Maw LLP

20070098795 - Pharmaceutical formulation: A solid, oral controlled release pharmaceutical dosage form has a water-soluble active ingredient dispersed in a matrix and releases the active ingredient at such a rate upon administration that the median tmax is 2.5 to 6 hours and the ratio of mean Cmax to mean plasma level of the active... Agent: Davidson, Davidson & Kappel, LLC

20070098796 - Controlled release compositions comprising a combination of isosorbide dinitrate and hydralazine hydrochrloride: The invention relates to a controlled release composition comprising a combination of isosorbide dinitrate and hydralazine, such as hydralazine hydrochloride, that in operation delivers the drug in a pulsed or multi-modal manner for the treatment of angina, ischaemic heart disease, arterial hypertension and related disease conditions. Preferably, the isosorbide dinitrate... Agent: Synnestvedt & Lechner LLP Elan Corporation PLC

20070098797 - Modified release composition of at least one form of venlafaxine: The present invention relates to a modified release composition of at least one form of venlafaxine, which is a delayed controlled release composition. The composition comprises a core comprising at least one form of venlafaxine selected from the group consisting of venlafaxine, an active metabolite of venlafaxine, a pharmaceutically acceptable... Agent: Hunton & Williams LLP Intellectual Property Department

20070098798 - Method and article to restore function to a flow control location in a patient: Article and method of restoring function to a flow control location in a patient. A biological agent is inserted into a region near the flow control location. The biological agent is stabilized in the region. The biological agent is a biological agent selected from a group consisting of growth factors,... Agent: Iplm Group, P.A.

20070098799 - Mineralized hydrogels and methods of making and using hydrogels: The present invention provides mineralized hydrogels and methods of making and using mineralized hydrogels, by combining a first mixture including a calcium derivative, a second mixture including a phosphate derivative and a hydrogel to form a calcium phosphate dispersion containing the hydrogel. The hydrogel in the calcium phosphate dispersion are... Agent: Wood, Herron & Evans, LLP (zimmer)

20070098805 - Methods of making and using novel griseofulvin compositions: The present invention is directed to nanoparticulate compositions comprising griseofulvin. The griseofulvin particles of the composition preferably have an effective average particle size of less than about 2 microns.... Agent: Elan Drug Delivery, Inc. C/o Foley & Lardner LLP

20070098802 - Organic nanoparticles and associated methods: Methods of preparing organic nanoparticles are provided. Such methods can include generating a mixture of an organic material, a first liquid, and a second liquid, wherein the organic material is more soluble in the second liquid than in the first liquid. The methods can also include adding a third liquid... Agent: Hewlett Packard Company

20070098801 - Particles shaped as platelets: The present invention relates to polymer particles shaped as platelets and to a process of manufacturing such particles. The particles according to the invention exhibit a faster rate of dissolution in aqueous media than art-known particles.... Agent: Philip S. Johnson Johnson & Johnson

20070098806 - Polymer-based antimicrobial agents, methods of making said agents, and products incorporating said agents: The present invention relates to antimicrobial agents, methods for the production of these agents, and the use of these agents. The antimicrobial agent of the present invention includes a water-soluble polymer and oligodynamic metal ions which interact with counter-ions of the polymer such that the metal ions are bound to... Agent: Gordon & Jacobson, P.C. Suite 407

20070098803 - Small particle compositions and associated methods: Small particle compositions are provided. The particles may have one or more desired features related to particle morphology, topology and crystallographic orientation. The small particle size coupled with such feature(s) can lead to significant property advantages in a variety of different applications including catalytic applications.... Agent: Wolf Greenfield & Sacks, PC

20070098804 - Solid particulate tadalafil having a bimodal particle size distribution: Provided is a solid particulate tadalafil having a bimodal particle size distribution.... Agent: Kenyon & Kenyon LLP

20070098800 - Therapeutic compositions: The present invention provides new formulations of injectable particles (e.g. microspheres) useful for intra-articular (i.a.) injection. The formulations are made of biocompatible polymers that biodegrade to generate NSAIDs, ad are useful for treating inflamed joints, thus providing safe, long-lasting relief of joint pain and swelling. In one embodiment, the present... Agent: Connolly Bove Lodge & Hutz, LLP

20070098807 - Matrices for drug delivery and methods for making and using the same: In one aspect, biocompatible matrices such as sol-gels encapsulating a reaction center may be administered to a subject for conversion of prodrugs into biologically active agents. In certain embodiments, the biocompatible matrices of the present invention are sol-gels. In one embodiment, the enzyme L-amino acid decarboxylase is encapsulated and implanted... Agent: Foley & Lardner LLP

20070098808 - Krill and/or marine extracts for prevention and/or treatment of cardiovascular diseases arthritis, skin cancer diabetes, premenstrual syndrome and transdermal transport: The present invention relates to a method of treatment and/or prevention of cardiovascular disease, rheumatoid arthritis, skin cancer, premenstrual syndrome, diabetes and transdermal transport enhancement. The method comprises the administration of a therapeutically effective amount of krill and/or marine oil to a patient. The present invention also relates to a... Agent: Crowell & Moring LLP Intellectual Property Group

20070098809 - Therapeutic use of lipids extracted from mother of pearl: The invention relates to the use of lipids extracted from the mother of pearl of mother-of-pearl molluscs, as a medicament, in particular in pathologies and traumas relating to a decrease in filaggrin activity and/or an increase in membrane transglutaminase activity. The invention also relates to pharmaceutical compositions containing same.... Agent: Nixon & Vanderhye, PC

20070098811 - High strength biological cement composition and using the same: A hydraulic cement for biomedical applications. The cement sets in-situ, hardening when exposed to water to produce nano-dispersed composite of calcium-silicate-hydrate gel mixed with hydroxyapatite. In comparison with prior cements, the composition provides high biocompatibility, high bioactivity and high biomechanical strength, due to the composite structure of the calcium silicate... Agent: Todd N. Hathaway

20070098810 - Preparation for solid calcium bolus product: A preparation of a solid calcium bolus product for preventing or treating milk fever of dairy animals is described by mixing water with calcium chloride, calcium propionate, calcium carbonate, calcium phosphate, calcium oxide, magnesium oxide, vitamin D or their combination in particle or powder form at a weight ratio of... Agent: Rigel Technology Corporation

20070098812 - Annexin ii and uses thereof: The present invention relates to the field of diagnosis and treatment of neurodegenerative diseases, ischemic events, and central nervous system injury, and provides compositions and methods for alleviation or reduction of the symptoms and signs associated with damaged neuronal tissues whether resulting from tissue trauma, or from chronic or acute... Agent: Cooper & Dunham, LLP

20070098813 - Ophthalmic and contact lens solutions with a peroxide source and a preservative: The present invention relates to an ophthalmic solution including 0.00001 to about 3.0 percent by weight of a peroxide producing agent and 0.1 to 500 parts per million of a preservative.... Agent: Hiscock & Barclay, LLP

20070098814 - Medical device's manufacture and usage in alternative medicine for rehabilitation treatment of chronic diseases: This invention provides information regarding the methods and procedures for manufacturing a new medical device, Health recovery chip kit. It also describes the methods and steps for using this kit to treat the chronic, but non-contagious diseases. The treatment by this kit is safe, more effective, non-invasive and easy to... Agent: Xu, Zhilong

20070098815 - Orally administrable gallium compositions and methods of use: Provided are pharmaceutical gallium compositions that are particularly useful for oral administration. The pharmaceutical compositions include solid, liquid, and paste formulations, which have high oral gallium bioavailability and are suitable for human and veterinary applications. The compositions comprise pharmaceutically acceptable gallium compounds, such as gallium maltolate, gallium 8-quinolinolonate, or gallium... Agent: Mintz, Levin, Cohn, Ferris, Glovsky And Popeo, P.c

20070098816 - Pharmaceutical composition containing histone deacetylase inhibitor: An anticancer drug having a synergistic effect by combined use of a histone acetylase derivative such as N-(2-aminophenyl)-4-[N-(pyridin-3-ylmethoxycarbonyl) amninomethyl]benzamide (MS-275) and another anticancer active substance.... Agent: Millen, White, Zelano & Branigan, P.C.

20070098817 - Biofouling control: A system and method for stabilizing bromine in an industrial water system by monitoring and flexible dosing of chlorine oxidant and halide ion stabilizer residual levels. The system comprises chlorine oxidant, and a halide ion source with a halogen stabilizer.... Agent: William J. Maheras Nalco Company

20070098818 - Ophthalmic and contact lens solutions containing simple saccharides as preservative enhancers: The present invention relates to an ophthalmic solution comprising 0.00001 to 10.0 weight percent of a simple saccharide, at least 0.00001 weight percent of a preservative, and not more than about 0.2 percent by weight chloride. The simple saccharide is chosen from the group consisting of: inositol; mannitol; sorbitol; sucrose;... Agent: Hiscock & Barclay, LLP

20070098819 - Micronutrient supplement with calcium, vitamin d or calcium & vitamin d combination for premenstrual syndrome, postpartum depression, depression and panic attacks: A bolus dose supplement, foodstuff, beverage and beverage concentrate with calcium and vitamin D for the treatment and prevention of PMS, panic attacks, and postpartum depression. The combination of adequate calcium and vitamin D is provided as a multi-vitamin and mineral supplement. The bolus dose is comprised of 2 main... Agent: Gottlieb Rackman & Reisman PC

20070098820 - Compositions containing cis-isomers of a carotenoid compound and process: The present invention relates to a primary composition that includes at least one carotenoid-containing extract, concentrate or oleoresin enriched in cis-isomers of the carotenoid compound, and process of forming the same. It also relates to an oral composition that contains the primary composition in a foodstuff, in a food supplement,... Agent: Bell, Boyd & Lloyd LLP

20070098821 - Method for controlling body weight in estrogen-insufficient women: Disclosed are methods of controlling body weight in estrogen-insufficient women by administering compositions comprising (A) those dried fruit solids that inherently comprise flavonoids, hydroxycinnamic acids, and a fiber component of which at least about 20% by weight is soluble fiber, and (B) a soluble, indigestible oligosaccharide in addition to any... Agent: Ross Products Division Of Abbott Laboratories Department 108140-ds/1

20070098822 - Food compositions and methods: Compositions are provided according to the present invention which include microorganisms and/or products of microorganismal metabolism. Humans and other animals have difficulty gaining nutritional benefit from many highly abundant plant materials, such as cellulose. A traditional means of gaining the benefit of these nutrients has been through the cultivation of... Agent: Julie K. Staple Gifford, Krass, Groh, Sprinkle

20070098824 - Canola extracts containing high levels of phenolic acids: Disclosed in certain embodiments is a canola extract comprising greater than 30% sinapic acid, pharmaceutical compositions thereof, and methods thereof.... Agent: Davidson, Davidson & Kappel, LLC

20070098823 - Maca extract and cosmetic composition containing such an extract: The invention relates to a method for extracting substances from maca, to the obtained extract, to a cosmetic and pharmaceutical composition containing said extract, and to the use thereof as an anti-aging cosmetic agent. The method is characterized by a step involving the use of an enzymatic hydrolysis of proteins.... Agent: Foley And Lardner LLP Suite 500

20070098825 - Compositions containing phaseolus vulgaris extract and alpinia officinarum extract for the prevention and treatment of obesity and type ii diabetes: Disclosed are compositions containing Phaseolus vulgaris extract and Alpinia officinarum extract for the prevention and treatment of obesity and type II diabetes.... Agent: Walter H. Schneider

20070098826 - Use of pinitol or chiroinositol for protecting the liver: Disclosed in this invention is a use of pinitol or chiroinositol for protecting the liver.... Agent: Sughrue Mion, PLLC

20070098827 - In vitro and in vivo anti-inflammatory effects of a sesquiterpene lactone extract from chicory (cichorium intybus l.): A method of preparing a chicory extract enriched with sesquiterpene lactones is provided. The method includes performing an initial extraction chicory in a polar solvent, such as methanol or ethanol, at ambient temperature to form an alcoholic extract. The alcoholic extract is subsequently defatted with a non-polar solvent, preferably hexane... Agent: Mathews, Shepherd, Mckay, & Bruneau, P.A.

20070098828 - Methods and compositions for the prevention and regression of neovascularization: The present invention provides methods and compositions for the prevention and treatment of conditions characterized by neovascularization. Preferably, the present invention is directed to a potent inhibitor of angiogenesis. This inhibitor may be useful for the treatment of ocular diseases by preventing neovascularization. The invention is based, at least in... Agent: Thomas M. Saunders Brown Rudnick Berlack Israels LLP